

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
14 February 2002 (14.02.2002)

PCT

(10) International Publication Number  
WO 02/12294 A2(51) International Patent Classification<sup>7</sup>: C07K 14/315,  
A61K 39/09, C07K 16/12, C12N 5/12, A61K 39/40,  
C12N 15/12, 15/63, A61K 48/00, C12Q 1/68, G01N  
33/53, C07K 14/34Elisabeth [CA/US]; 1041 Murray Hill Lane S., Memphis,  
TN 38120 (US). BOHNSACK, John [US/US]; 760 South  
1200 East, Salt Lake City, UT 84102 (US).

(21) International Application Number: PCT/US01/24795

(74) Agent: DIETZEL, Christine, E.; Klauber & Jackson, 411  
Hackensack Avenue, Hackensack, NJ 07601 (US).

(22) International Filing Date: 8 August 2001 (08.08.2001)

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/634,341 8 August 2000 (08.08.2000) US(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier application:(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG).US 09/634,341 (CON)  
Filed on 8 August 2000 (08.08.2000)**Published:**— without international search report and to be republished  
upon receipt of that reportFor two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.(71) Applicants (for all designated States except US): ST.  
JUDE CHILDREN'S RESEARCH HOSPITAL  
[US/US]; 332 North Lauderdale Street, Memphis, TN  
38105-2794 (US). UNIVERSITY OF UTAH RE-  
SEARCH FOUNDATION [US/US]; 615 Arapeen Drive,  
Suite 10, Salt Lake City, UT 84108 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ADDERSON,



A2

(54) Title: GROUP B STREPTOCOCCUS POLYPEPTIDES NUCLEIC ACIDS AND THERAPEUTIC COMPOSITIONS AND  
VACCINES THEREOF

WO 02/12294

(57) Abstract: This invention provides isolated nucleic acids encoding polypeptides comprising amino acid sequences of streptococcal matrix adhesion (Ema) polypeptides. The invention provides nucleic acids encoding Group B streptococcal Ema polypeptides EmaA, EmaB, EmaC, EmaD and EmaE. The present invention provides isolated polypeptides comprising amino acid sequences of Group B streptococcal polypeptides EmaA, EmaB, EmaC, EmaD and EmaE, including analogs, variants, mutants, derivatives and fragments thereof. Ema homologous polypeptides from additional bacterial species, including *S. pneumoniae*, *S. pyogenes*, *E. faecalis* and *C. diphtheriae* are also provided. Antibodies to the Ema polypeptides and immunogenic fragments thereof are also provided. The present invention relates to the identification and prevention of infections by virulent forms of streptococci. This invention provides pharmaceutical compositions, immunogenic compositions, vaccines, and diagnostic and therapeutic methods of use of the isolated polypeptides, antibodies thereto, and nucleic acids. Assays for compounds which modulate the polypeptides of the present invention for use in therapy are also provided.

**GROUP B STREPTOCOCCUS POLYPEPTIDES NUCLEIC ACIDS AND  
THERAPEUTIC COMPOSITIONS AND VACCINES THEREOF**

5

**GOVERNMENTAL SUPPORT**

The research leading to the present invention was supported, at least in part, by a grant  
from NAID, Grant No.A140918. Accordingly, the Government may have certain  
10 rights in the invention.

**FIELD OF THE INVENTION**

This invention relates generally to extracellular matrix adhesin (Ema) proteins,  
15 antibodies thereto and to vaccines, compositions and therapeutics. The Group B  
streptococcal Ema polypeptides are EmaA, EmaB, EmaC, EmaD and EmaE. The  
invention further relates to Ema polypeptides from various species of bacteria,  
including *S. pneumoniae*, *S. pyogenes*, *E. faecalis* and *C. diphtheriae*. The invention  
also relates to the identification and prevention of infections by streptococci. Isolated  
20 nucleic acids encoding Group B streptococcal Ema polypeptides, particularly EmaA,  
EmaB, EmaC, EmaD and EmaE and to other bacterial Ema homologs are included  
herein. Assays for compounds which modulate the polypeptides of the present  
invention for use in therapy are also provided.

25

**BACKGROUND OF THE INVENTION**

Streptococci are catalase negative gram positive cocci. They may be classified by the  
type of hemolysis exhibited on blood agar, by the serologic detection of carbohydrate  
antigens, or by certain biochemical reactions. Medically important streptococci include  
30 Groups A, B, D, *S. pneumoniae* and the viridans group of streptococci. Lancefield  
type A (GroupA) Streptococcus pyogenes is an important human pathogen - the cause  
of streptococcal pharyngitis, impetigo and more severe infections such as bacteremia

and necrotizing fascitis. The immunologic sequelae of Group A Streptococcal infections are also important health problems - rheumatic carditis is the most common cause of acquired cardiac disease worldwide and post-streptococcal glomerulonephritis is a cause of hypertension and renal dysfunction. Group B Streptococcus agalactiae are

5 the most common cause of serious bacterial infections in newborns, and important pathogens in pregnant women and nonpregnant adults with underlying medical problems such as diabetes and cardiovascular disease. Group D streptococci include the enterococci (*Streptococcus faecalis* and *faecium*) and the "nonenterococcal" Group D streptococci. *Streptococcus pneumoniae* (*pneumococcus*) is not classified by group

10 in the Lancefield system. *Pneumococci* are extremely important human pathogens, the most common cause of bacterial pneumonia, middle ear infections and meningitis beyond the newborn period. The viridans group of streptococci include *S. milleri*, *S. mitis*, *S. sanguis* and others. They cause bacteremia, endocarditis, and dental infections. Enterococci are important causes of urinary tract infections, bacteremia

15 and wound infections (predominantly as nosocomial infections in hospitalized patients), and endocarditis. Over the past decade enterococci have developed resistance to many conventional antibiotics and there are some strains resistant to all known antibiotics.

Group B streptococci (GBS) are the most common cause of serious bacterial disease

20 in neonates, and are important pathogens in pregnant women and adults with underlying illnesses (Baker CJ. (2000) "Group B streptococcal infections" in *Streptococcal infections. Clinical aspects, microbiology, and molecular pathogenesis*. (D. L. Stevens and E. L. Kaplan), New York: Oxford University Press, 222-237). Common manifestations of these infections include bacteremia, pneumonia,

25 meningitis, endocarditis, and osteoarticular infections (Baker CJ. (2000) "Group B streptococcal infections" in *Streptococcal infections. Clinical aspects, microbiology, and molecular pathogenesis*. (D. L. Stevens and E. L. Kaplan), New York: Oxford University Press, 222-237; Blumberg H.M. et al. (1996) *J Infect Dis* 173:365-373).

The incidence of invasive GBS disease is approximately 2.6 in 1000 live births and 7.7

30 in 100,000 in the overall population, with mortality rates that vary from 6 to 30% (Baker CJ. (2000) "Group B streptococcal infections" in *Streptococcal infections*.

*Clinical aspects, microbiology, and molecular pathogenesis.* (D. L. Stevens and E. L. Kaplan), New York: Oxford University Press, 222-237; Blumberg H.M. et al. (1996) *J Infect Dis* 173:365-373). Although much neonatal disease is preventable by administration of prophylactic antibiotics to women in labor, antibiotic prophylaxis

5 programs can be inefficient, suffer from poor compliance, or fail if antibiotic resistance emerges. No effective prophylaxis strategy for adult infections has been established.

During childbirth, GBS can pass from the mother to the newborn. By one estimate, up to 30% of pregnant women carry GBS at least temporarily in the vagina or rectum

10 without symptoms. Infants born to these women become colonized with GBS during delivery (Baker, C.J. and Edwards, M.S. (1995) "Group B Streptococcal Infections" in *Infectious Disease of the Fetus and Newborn Infant* (J.S. Remington and J.O Klein), 980-1054). Aspiration of infected amniotic fluid or vaginal secretions allow GBS to gain access to the lungs. Adhesion to, and invasion of, respiratory epithelium and

15 endothelium appear to be critical factors in early onset neonatal infection. (Baker, C.J. and Edwards, M.S. (1995) "Group B Streptococcal Infections" in *Infectious Disease of the Fetus and Newborn Infant* (J.S. Remington and J.O Klein), 980-1054; Rubens, C.E. et al. (1991) *J Inf Dis* 164:320-330). Subsequent steps in infection, such as blood stream invasion and the establishment of metastatic local infections have not been

20 clarified. The pathogenesis of neonatal infection occurring after the first week of life is also not well understood. Gastrointestinal colonization may be more important than a respiratory focus in late onset neonatal disease (Baker, C.J. and Edwards, M.S. (1995) "Group B Streptococcal Infections" in *Infectious Disease of the Fetus and Newborn Infant* (J.S. Remington and J.O Klein), 980-1054). Considerable evidence suggests that

25 invasion of brain microvascular endothelial cells by GBS is the initial step in the pathogenesis of meningitis. GBS are able to invade human brain microvascular endothelial cells and type III GBS, which are responsible for the majority of meningitis, accomplish this 2-6 times more efficiently than other serotypes (Nizet, V. et al. (1997) *Infect Immun* 65:5074-5081).

Because GBS is widely distributed among the population and is an important pathogen in newborns, pregnant women are commonly tested for GBS at 35-37 weeks of pregnancy. Much of GBS neonatal disease is preventable by administration of prophylactic antibiotics during labor to women who test positive or display known risk

5 factors. However, these antibiotics programs do not prevent all GBS disease. The programs are deficient for a number of reasons. First, the programs can be inefficient. Second, it is difficult to ensure that all healthcare providers and patients comply with the testing and treatment. And finally, if new serotypes or antibiotic resistance emerges, the antibiotic programs may fail altogether. Currently available tests for GBS

10 are inefficient. These tests may provide false negatives. Furthermore, the tests are not specific to virulent strains of GBS. Thus, antibiotic treatment may be given unnecessarily and add to the problem of antibiotic resistance. Although a vaccine would be advantageous, none are yet commercially available.

15 Traditionally, GBS are divided into 9 serotypes according to the immunologic reactivity of the polysaccharide capsule (Baker CJ. (2000) "Group B streptococcal infections" in *Streptococcal infections. Clinical aspects, microbiology, and molecular pathogenesis.* (D. L. Stevens and E. L. Kaplan), New York: Oxford University Press, 222-237; Blumberg H.M. et al. (1996) *J Infect Dis* 173:365-373; Kogan, G. et al.

20 (1996) *J Biol Chem* 271:8786-8790). Serotype III GBS are particularly important in human neonates, causing 60-70% of all infections and almost all meningitis (Baker CJ. (2000) "Group B streptococcal infections" in *Streptococcal infections. Clinical aspects, microbiology, and molecular pathogenesis.* (D. L. Stevens and E. L. Kaplan), New York: Oxford University Press, 222-237). Type III GBS can be subdivided into

25 three groups of related strains based on the analysis of restriction digest patterns (RDPs) produced by digestion of chromosomal DNA with *Hind* III and *Sse*8387. (I. Y. Nagano et al. (1991) *J Med Micro* 35:297-303; S. Takahashi et al. (1998) *J Inf Dis* 177:1116-1119).

30 Over 90% of invasive type III GBS neonatal disease in Tokyo, Japan and in Salt Lake City, Utah is caused by bacteria from one of three RDP types, termed RDP type III-3,

while RDP type III-2 are significantly more likely to be isolated from vagina than from blood or CSF. These results suggest that this genetically-related cluster of type III-3 GBS are more virulent than III-2 strains and could be responsible for the majority of invasive type III disease globally.

5

Preliminary vaccines for GBS used unconjugated purified polysaccharide. GBS poly - and oligosaccharides are poorly immunogenic and fail to elicit significant memory and booster responses. Baker et al immunized 40 pregnant women with purified serotype III capsular polysaccharide (Baker, C.J. et al. (1998) *New Engl J of Med* 339:1180-1185). Overall, only 57% of women with low levels of specific antibody responded to the vaccine. The poor immunogenicity of purified polysaccharide antigen was further demonstrated in a study in which thirty adult volunteers were immunized with a tetravalent vaccine composed of purified polysaccharide from serotypes Ia, Ib, II, and III (Kotloff, K.L. et al. (1996) *Vaccine* 14:446-450). Although safe, this vaccine was only modestly immunogenic, with only 13% of subjects responding to type Ib, 17% to type II, 33% responding to type Ia, and 70% responding to type III polysaccharide. The poor immunogenicity of polysaccharide antigens prompted efforts to develop polysaccharide conjugate vaccines, whereby these poly - or oligosaccharides are conjugated to protein carriers. Ninety percent of healthy adult women immunized with a type III polysaccharide-tetanus toxoid conjugate vaccine responded with a 4-fold rise in antibody concentration, compared to 50% immunized with plain polysaccharide (Kasper, D.L. et al (1996) *J of Clin Invest* 98:2308-2314). A type Ia/Ib polysaccharide-tetanus toxoid conjugate vaccine was similarly more immunogenic in healthy adults than plain polysaccharide (Baker, C.J. et al (1999) *J Infect Dis* 179:142-150).

The disadvantage of polysaccharide-protein conjugate vaccines is that the process of purifying and conjugating polysaccharides is difficult, time-consuming and expensive. A protein antigen which could be cheaply and easily produced would be an improvement.

If one were to make a polysaccharide-protein conjugate vaccine, a GBS-specific carrier protein may be preferable to one of the commonly used carriers such as tetanus or diphtheria toxoids because of the potential problems associated with some of these carrier proteins, particularly variable immunogenicity and the problems associated with

5 repeated vaccination with the same carrier protein. Selection of appropriate carrier proteins is important for the development of polysaccharide-protein vaccine formulations. For example, *Haemophilus influenzae* type b poly- or oligosaccharide conjugated to different protein carriers has variable immunogenicity and elicits antibody with varying avidity (Decker, M.D. et al (1992) *J Pediatrics* **120**:184-189;

10 Schlesinger, Y. (1992) *JAMA* **267**:1489-1494). Repeated immunization with the same carrier protein may also suppress immune responses by competition for specific B cells (epitopic suppression) or other mechanisms. This is of particular concern for the development of GBS vaccines since recently developed poly/oligosaccharide-protein conjugate vaccines against the bacteria *H. influenzae*, *S. pneumoniae*, and *N.*

15 *meningitidis* all utilize a restricted number of carrier proteins (tetanus toxoid, CRM197, diphtheria toxoid), increasing the number of exposures to these carriers an individual is likely to receive. Additionally, using tetanus as a carrier protein offers no specific advantage beyond the improved immunogenicity of the vaccine. A second-generation vaccine containing a GBS-specific carrier protein would enhance

20 immunogenicity and have an advantage in that a GBS-specific immune response would be generated against both the carrier protein and the poly/oligosaccharide.

Therefore, in view of the aforementioned deficiencies attendant with prior art vaccines and methods, it should be apparent that there still exists a need in the art for an

25 effective and immunogenic GBS vaccine. The availability and use of a GBS polypeptide in a conjugate vaccine is desirable. A GBS polypeptide which is present or expressed in all GBS serotypes would have the added advantage of providing broad, general immunity across many GBS serotypes. It would be particularly relevant and useful to provide a streptococcal vaccine or immunogen which is expressed broadly in

30 various streptococcal species, whereby broad or general immunity against multiple and unique groups of streptococci (for instance, Group A, Group B and *S. pneumoniae*),

particularly against distinct virulent and clinically relevant streptococcal bacteria, could thereby be generated.

The citation of references herein shall not be construed as an admission that such is  
5 prior art to the present invention.

#### SUMMARY OF THE INVENTION

In accordance with the present invention, streptococcal polypeptides termed  
10 extracellular matrix adhesins (Ema) are provided which are particularly useful in the identification and prevention of infections by streptococci.

In its broadest aspect, the present invention encompasses isolated polypeptides comprising an amino acid sequence of a streptococcal polypeptide selected from the  
15 group of EmaA, EmaB, EmaC, EmaD and EmaE. The isolated peptides, including combinations of one or more thereof, are suitable for use in immunizing animals and humans against bacterial infection, particularly streptococci.

The present invention is directed to an isolated streptococcal EmaA polypeptide which  
20 comprises the amino acid sequence set out in SEQ ID NO: 2, and analogs, variants and immunogenic fragments thereof.

The present invention is directed to an isolated streptococcal EmaB polypeptide which comprises the amino acid sequence set out in SEQ ID NO: 4, and analogs, variants and  
25 immunogenic fragments thereof.

The present invention is directed to an isolated streptococcal EmaC polypeptide which comprises the amino acid sequence set out in SEQ ID NO: 6, and analogs, variants and immunogenic fragments thereof.

The present invention is directed to an isolated streptococcal EmaD polypeptide which comprises the amino acid sequence set out in SEQ ID NO: 8, and analogs, variants and immunogenic fragments thereof.

5 The present invention is directed to an isolated streptococcal EmaE polypeptide which comprises the amino acid sequence set out in SEQ ID NO: 10, and analogs, variants and immunogenic fragments thereof.

10 The present invention also provides Ema polypeptide homologs from distinct bacterial species, particularly including distinct streptococcal species, more particularly including Group B streptococcus, Group A streptococcus (particularly *S. pyogenes*) and *S. pneumoniae*. The present invention also provides Ema polypeptides from additional distinct bacterial species, particularly including *Enterococcus faecalis* and *Corynebacterium diphtheriae*. Nucleic acids encoding Ema polypeptide homologs from 15 distinct bacterial species are also provided.

20 The present invention thus provides an isolated streptococcal Ema polypeptide comprising the amino acid sequence set out in SEQ ID NO:23. An isolated nucleic acid which encodes the streptococcal polypeptide set out in SEQ ID NO:23 is further provided.

25 The invention thus further provides an isolated streptococcal Ema polypeptide comprising the amino acid sequence set out in SEQ ID NO:26. An isolated nucleic acid which encodes the streptococcal polypeptide set out in SEQ ID NO:26 is further provided.

30 The present invention further provides an isolated streptococcal Ema polypeptide comprising the amino acid sequence set out in SEQ ID NO:37. An isolated nucleic acid which encodes the streptococcal polypeptide set out in SEQ ID NO:37 is further provided.

An enterococcal Ema polypeptide is further provided comprising the amino acid sequence set out in SEQ ID NO:29. An isolated isolated nucleic acid which encodes the enterococcal polypeptide set out in SEQ ID NO:29 is also provided.

5 The invention provides an isolated *Corynebacterium* Ema polypeptide comprising the amino acid sequence set out in SEQ ID NO: 32. Also provided is an isolated nucleic acid which encodes the *Corynebacterium* polypeptide set out in SEQ ID NO: 32.

10 The invention provides an isolated bacterial polypeptide comprising the amino acid sequence TLLTCTPYMINS/THRLLVVR/KG (SEQ ID NO: 34), wherein the polypeptide is not isolated from *Actinomyces*.

The invention further provides an isolated streptococcal polypeptide comprising the amino acid sequence TLLTCTPYMINS/THRLLVVR/KG (SEQ ID NO: 34).

15 Also provided is an isolated bacterial polypeptide comprising the amino acid sequence TLVTCTPYGINTHRLLVTA (SEQ ID NO: 35).

The present invention includes an isolated bacterial polypeptide comprising the amino acid sequence TLVTCTPYGVNTKRLLVRG (SEQ ID NO: 36). An isolated streptococcal polypeptide comprising the amino acid sequence TLVTCTPYGVNTKRLLVRG (SEQ ID NO: 36) is also provided.

25 The invention further includes an isolated polypeptide having the amino acid sequence selected from the group of TLLTCTPYMINS/THRLLVVR/KG (SEQ ID NO: 34), TLVTCTPYGINTHRLLVTA (SEQ ID NO: 35), and TLVTCTPYGVNTKRLLVRG (SEQ ID NO: 36).

30 The present invention contemplates the use of the polypeptides of the present invention in diagnostic tests and methods for determining and/or monitoring of streptococcal infection. Thus, the present invention provides an isolated Ema polypeptide,

particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, labeled with a detectable label.

In the instance where a radioactive label, such as the isotopes  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{36}\text{Cl}$ ,  
5  $^{51}\text{Cr}$ ,  $^{57}\text{Co}$ ,  $^{58}\text{Co}$ ,  $^{59}\text{Fe}$ ,  $^{90}\text{Y}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ , and  $^{186}\text{Re}$  are used, known currently available counting procedures may be utilized. In the instance where the label is an enzyme, detection may be accomplished by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques known in the art.

10

The present invention extends to an immunogenic Ema polypeptide, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, or a fragment thereof. The present invention also extends to immunogenic Ema polypeptides wherein such polypeptides comprise a combination of at least one immunogenic Ema 15 polypeptide, selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, or immunogenic polypeptide fragment thereof, and a GBS polypeptide selected from the group of Spb1, Spb2, C protein alpha antigen, Rib, Lmb, C5a-ase, or immunogenic fragments thereof.

20 In a further aspect, the present invention extends to vaccines based on the Ema proteins described herein. The present invention provides a vaccine comprising one or more streptococcal polypeptides selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable adjuvant. The present invention provides a vaccine comprising one or more streptococcal polypeptides selected from 25 the group of the polypeptide of SEQ ID NO: 23, 26, and 37, and a pharmaceutically acceptable adjuvant.

The present invention further provides a streptococcal vaccine comprising one or more Group B streptococcal polypeptides selected from the group of EmaA, EmaB, EmaC, 30 EmaD and EmaE, further comprising one or more additional streptococcal antigens. The present invention further provides a GBS vaccine comprising one or more Group

B streptococcal polypeptides selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, further comprising one or more additional GBS antigens. In a particular embodiment, the GBS antigen is selected from the group of the polypeptide Spb1 or an immunogenic fragment thereof, the polypeptide Spb2 or an immunogenic fragment thereof, C protein alpha antigen or an immunogenic fragment thereof, Rib or an immunogenic fragment thereof Lmb or an immunogenic fragment thereof, C5a-ase or an immunogenic fragment thereof and Group B streptococcal polysaccharides or oligosaccharides.

5

10 In another aspect, the invention is directed to a vaccine for protection of an animal subject from infection with streptococci comprising an immunogenic amount of one or more Ema polypeptide EmaA, EmaB, EmaC, EmaD or EmaE, or a derivative or fragment thereof. Such a vaccine may contain the protein conjugated covalently to a GBS bacterial polysaccharide or oligosaccharide or polysaccharide or oligosaccharide 15 from one or more GBS serotypes.

20

In a still further aspect, the present invention provides an immunogenic composition comprising one or more streptococcal polypeptides selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable adjuvant.

25

The present invention further provides an immunogenic composition comprising one or more Group B streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, further comprising one or more antigens selected from the group of the polypeptide Spb1 or an immunogenic fragment thereof, the polypeptide Spb2 or an immunogenic fragment thereof, C protein alpha antigen or an immunogenic fragment thereof, Rib or an immunogenic fragment thereof Lmb or an immunogenic fragment thereof, C5a-ase or an immunogenic fragment thereof, and Group B streptococcal polysaccharides or oligosaccharides.

30

The invention further provides pharmaceutical compositions, vaccines, and diagnostic and therapeutic methods of use thereof.

The invention provides pharmaceutical compositions comprising a bacterial Ema polypeptide and a pharmaceutically acceptable carrier. The invention provides pharmaceutical compositions comprising a streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, the polypeptide of SEQ ID NO:23, 5 the polypeptide of SEQ ID NO: 26, the polypeptide of SEQ ID NO:37, and a pharmaceutically acceptable carrier. The invention provides pharmaceutical compositions comprising a streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable carrier. The present invention further provides pharmaceutical compositions comprising one or 10 more GBS Ema polypeptide, or a fragment thereof, in combination with one or more of GBS polypeptide Spb1, Spb2, C protein alpha antigen, Rib, Lmb, C5a-ase, a Group B streptococcal polysaccharide or oligosaccharide vaccine, and an anti-streptococcal vaccine.

15 In a still further aspect, the present invention provides a purified antibody to a streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. In a still further aspect, the present invention provides a purified antibody to a streptococcal polypeptide selected from the group of the polypeptide of SEQ ID NO:23, the polypeptide of SEQ ID NO: 26, and the polypeptide of SEQ ID NO:37.

20 Antibodies against the isolated polypeptides of the present invention include naturally raised and recombinantly prepared antibodies. These may include both polyclonal and monoclonal antibodies prepared by known genetic techniques, as well as bi-specific (chimeric) antibodies, and antibodies including other functionalities suiting them for 25 diagnostic use. Such antibodies can be used in immunoassays to diagnose infection with a particular strain or species of bacteria. The antibodies can also be used for passive immunization to treat an infection with streptococcal bacteria including Group B streptococcus, Group A streptococcus, and *S. pneumoniae*. These antibodies may also be suitable for modulating bacterial adherence and/or invasion including but not 30 limited to acting as competitive agents.

The present invention provides a monoclonal antibody to a streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. The invention thereby extends to an immortal cell line that produces a monoclonal antibody to a streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and

5 EmaE.

An antibody to a streptococcal Ema polypeptide EmaA, EmaB, EmaC, EmaD or EmaE labeled with a detectable label is further provided. In particular embodiments, the label may be selected from the group consisting of an enzyme, a chemical which

10 fluoresces, and a radioactive element.

The present invention provides a pharmaceutical composition comprising one or more antibodies to a streptococcal protein selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable carrier. The invention further

15 provides a pharmaceutical composition comprising a combination of at least two antibodies to Group B streptococcal proteins and a pharmaceutically acceptable carrier, wherein at least one antibody to a protein selected from the group of EmaA, EmaB, EmaC, EmaD, and EmaE is combined with at least one antibody to a protein selected from the group of Spb1, Spb2, Rib, Lmb, C5a-ase and a C protein alpha

20 antigen..

The present invention also relates to isolated nucleic acids, such as recombinant DNA molecules or cloned genes, or degenerate variants thereof, mutants, analogs, or fragments thereof, which encode the isolated polypeptide of the present invention or

25 which competitively inhibit the activity of the polypeptide. The present invention further relates to isolated nucleic acids, such as recombinant DNA molecules or cloned genes, or degenerate variants thereof, mutants, analogs, or fragments thereof, which encode a bacterial Ema polypeptide. The present invention further relates to isolated nucleic acids, such as recombinant DNA molecules or cloned genes, or degenerate

30 variants thereof, mutants, analogs, or fragments thereof, which encode a streptococcal Ema polypeptide. The present invention further relates to isolated nucleic acids, such

as recombinant DNA molecules or cloned genes, or degenerate variants thereof, mutants, analogs, or fragments thereof, which encode a streptococcal Ema polypeptide, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. Preferably, the isolated nucleic acid, which includes degenerates, variants, 5 mutants, analogs, or fragments thereof, has a sequence as set forth in SEQ ID NOS: 1, 3, 5, 7 or 9. In a further embodiment of the invention, the DNA sequence of the recombinant DNA molecule or cloned gene may be operatively linked to an expression control sequence which may be introduced into an appropriate host. The invention accordingly extends to unicellular hosts transformed with the cloned gene or 10 recombinant DNA molecule comprising a DNA sequence encoding an Ema protein, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and more particularly, the DNA sequences or fragments thereof determined from the sequences set forth above.

15 In a particular embodiment, the nucleic acid encoding the EmaA polypeptide has the sequence selected from the group comprising SEQ ID NO:1; a sequence that hybridizes to SEQ ID NO:1 under moderate stringency hybridization conditions; DNA sequences capable of encoding the amino acid sequence encoded by SEQ ID NO:1 or a sequence that hybridizes to SEQ ID NO:1 under moderate stringency hybridization 20 conditions; degenerate variants thereof, alleles thereof, and hybridizable fragments thereof. In a particular embodiment, the nucleic acid encoding the EmaA polypeptide has the sequence selected from the group comprising SEQ ID NO:1; a sequence complementary to SEQ ID NO:1; or a homologous sequence which is substantially similar to SEQ ID NO:1. In a further embodiment, the nucleic acid has the sequence 25 consisting of SEQ ID NO:1.

In a particular embodiment, the nucleic acid encoding the EmaB polypeptide has the sequence selected from the group comprising SEQ ID NO:3; a sequence that hybridizes to SEQ ID NO:3 under moderate stringency hybridization conditions; DNA 30 sequences capable of encoding the amino acid sequence encoded by SEQ ID NO:3 or a sequence that hybridizes to SEQ ID NO:3 under moderate stringency hybridization

conditions; degenerate variants thereof; alleles thereof; and hybridizable fragments thereof. In a particular embodiment, the nucleic acid encoding the EmaB polypeptide has the sequence selected from the group comprising SEQ ID NO:3; a sequence complementary to SEQ ID NO:3; or a homologous sequence which is substantially

5 similar to SEQ ID NO:3. In a further embodiment, the nucleic acid has the sequence consisting of SEQ ID NO:3.

In a particular embodiment, the nucleic acid encoding the EmaC polypeptide has the sequence selected from the group comprising SEQ ID NO:5; a sequence that

10 hybridizes to SEQ ID NO:5 under moderate stringency hybridization conditions; DNA sequences capable of encoding the amino acid sequence encoded by SEQ ID NO:5 or a sequence that hybridizes to SEQ ID NO:5 under moderate stringency hybridization conditions; degenerate variants thereof; alleles thereof; and hybridizable fragments thereof. In a particular embodiment, the nucleic acid encoding the EmaC polypeptide  
15 has the sequence selected from the group comprising SEQ ID NO:5; a sequence complementary to SEQ ID NO:5; or a homologous sequence which is substantially similar to SEQ ID NO:5. In a further embodiment, the nucleic acid has the sequence consisting of SEQ ID NO:5.

20 In a particular embodiment, the nucleic acid encoding the EmaD polypeptide has the sequence selected from the group comprising SEQ ID NO:7; a sequence that hybridizes to SEQ ID NO:7 under moderate stringency hybridization conditions; DNA sequences capable of encoding the amino acid sequence encoded by SEQ ID NO:7 or a sequence that hybridizes to SEQ ID NO:7 under moderate stringency hybridization  
25 conditions; degenerate variants thereof; alleles thereof; and hybridizable fragments thereof. In a particular embodiment, the nucleic acid encoding the EmaD polypeptide has the sequence selected from the group comprising SEQ ID NO:7; a sequence complementary to SEQ ID NO:7; or a homologous sequence which is substantially similar to SEQ ID NO:7. In a further embodiment, the nucleic acid has the sequence  
30 consisting of SEQ ID NO:7.

In a particular embodiment, the nucleic acid encoding the EmaE polypeptide has the sequence selected from the group comprising SEQ ID NO:9; a sequence that hybridizes to SEQ ID NO:9 under moderate stringency hybridization conditions; DNA sequences capable of encoding the amino acid sequence encoded by SEQ ID NO:9 or

5 a sequence that hybridizes to SEQ ID NO:9 under moderate stringency hybridization conditions; degenerate variants thereof; alleles thereof; and hybridizable fragments thereof. In a particular embodiment, the nucleic acid encoding the EmaE polypeptide has the sequence selected from the group comprising SEQ ID NO:9; a sequence complementary to SEQ ID NO:9; or a homologous sequence which is substantially

10 similar to SEQ ID NO:9. In a further embodiment, the nucleic acid has the sequence consisting of SEQ ID NO:9.

In a further embodiment, the nucleic acid encoding the bacterial Ema polypeptide comprises the sequence selected from the group comprising SEQ ID NO: 24, 27, 30  
15 and 33. In a further embodiment, the nucleic acid encoding the bacterial Ema polypeptide has the sequence selected from the group comprising SEQ ID NO: 24, 27, 30 and 33.

A nucleic acid capable of encoding a streptococcal polypeptide EmaA, EmaB, EmaC,  
20 EmaD or EmaE which is a recombinant DNA molecule is further provided. Such a recombinant DNA molecule wherein the DNA molecule is operatively linked to an expression control sequence is also provided herein.

The present invention relates to nucleic acid vaccines or DNA vaccines comprising  
25 nucleic acids encoding immunogenic streptococcal Ema polypeptides, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. The present invention relates to nucleic acid vaccines or DNA vaccines comprising nucleic acids encoding one or more immunogenic Ema polypeptide or a fragment thereof or any combination of one or more Ema polypeptide EmaA, EmaB, EmaC, EmaD or EmaE  
30 with at least one other polypeptide, particularly a GBS polypeptide, more particularly wherein said other GBS polypeptide is selected from the group of Spb1, Spb2, C

protein alpha antigen, Rib, Lmb, C5a-ase, and immunogenic polypeptide fragments thereof.

The invention further relates to a vaccine for protection of an animal subject from

5 infection with a streptococcal bacterium comprising a vector containing a gene encoding an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE operatively associated with a promoter capable of directing expression of the gene in the subject. The present invention further provides a nucleic acid vaccine comprising a recombinant DNA molecule capable of encoding a GBS

10 polypeptide EmaA, EmaB, EmaC, EmaD or EmaE.

The invention further relates to a vaccine for protection of an animal subject from infection with a Group B streptococcal bacterium comprising a vector containing a gene encoding an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE operatively associated with a promoter capable of directing expression of the gene in the subject. The present invention further provides a nucleic acid vaccine comprising a recombinant DNA molecule capable of encoding a GBS polypeptide EmaA, EmaB, EmaC, EmaD or EmaE.

20 The present invention provides a vector which comprises the nucleic acid capable of encoding encoding an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE and a promoter. The present invention provides a vector which comprises the nucleic acid of any of SEQ ID NO: 1, 3, 5, 7 or 9 and a promoter. The invention contemplates a vector wherein the promoter comprises a

25 bacterial, yeast, insect or mammalian promoter. The invention contemplates a vector wherein the vector is a plasmid, cosmid, yeast artificial chromosome (YAC), bacteriophage or eukaryotic viral DNA.

The present invention further provides a host vector system for the production of a

30 polypeptide which comprises the vector capable of encoding an Ema polypeptide, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE in a

suitable host cell. A host vector system is provided wherein the suitable host cell comprises a prokaryotic or eukaryotic cell. A unicellular host transformed with a recombinant DNA molecule or vector capable of encoding encoding an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE is thereby provided.

The present invention includes methods for determining and monitoring infection by streptococci by detecting the presence of a streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. In a particular such method, the streptococcal Ema polypeptide is measured by:

- a. contacting a sample in which the presence or activity of a Streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE is suspected with an antibody to the said streptococcal polypeptide under conditions that allow binding of the streptococcal polypeptide to the antibody to occur; and
- b. detecting whether binding has occurred between the streptococcal polypeptide from the sample and the antibody;

wherein the detection of binding indicates the presence or activity of the streptococcal polypeptide in the sample.

The present invention includes methods for determining and monitoring infection by streptococci by detecting the presence of a streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. In a particular such method, the streptococcal Ema polypeptide is measured by:

- a. contacting a sample in which the presence or activity of a Streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE is suspected with an antibody to the said streptococcal polypeptide under conditions that allow binding of the streptococcal polypeptide to the antibody to occur; and

- b. detecting whether binding has occurred between the streptococcal polypeptide from the sample and the antibody;

wherein the detection of binding indicates the presence or activity of the

5 streptococcal polypeptide in the sample.

The present invention includes methods for determining and monitoring infection by Group B streptococci by detecting the presence of a Group B streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. In a

10 particular such method, the streptococcal Ema polypeptide is measured by:

- a. contacting a sample in which the presence or activity of a Group B streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE is suspected with an antibody to the said Group B streptococcal polypeptide under conditions that allow binding of the Group B streptococcal polypeptide to the antibody to occur; and
- b. detecting whether binding has occurred between the Group B streptococcal polypeptide from the sample and the antibody;

wherein the detection of binding indicates the presence or activity of the Group B streptococcal polypeptide in the sample.

The present invention further provides a method for detecting the presence of a

25 bacterium having a gene encoding a streptococcal polypeptide selected from the group of *emaA*, *emaB*, *emaC*, *emaD* and *emaE*, comprising:

- a. contacting a sample in which the presence or activity of the bacterium is suspected with an oligonucleotide which hybridizes to a streptococcal polypeptide gene selected from the group of *emaA*, *emaB*, *emaC*, *emaD* and *emaE*, under conditions that allow specific hybridization of the oligonucleotide to the gene to occur; and

- b. detecting whether hybridization has occurred between the oligonucleotide and the gene;

wherein the detection of hybridization indicates that presence or activity of the  
5 bacterium in the sample.

The invention includes an assay system for screening of potential compounds effective to modulate the activity of a streptococcal protein EmaA, EmaB, EmaC, EmaD or EmaE of the present invention. In one instance, the test compound, or an extract  
10 containing the compound, could be administered to a cellular sample expressing the particular Ema protein to determine the compound's effect upon the activity of the protein by comparison with a control. In a further instance the test compound, or an extract containing the compound, could be administered to a cellular sample expressing the Ema protein to determine the compound's effect upon the activity of  
15 the protein, and thereby on adherence of said cellular sample to host cells, by comparison with a control.

It is still a further object of the present invention to provide a method for the prevention or treatment of mammals to control the amount or activity of streptococci,  
20 so as to treat or prevent the adverse consequences of invasive, spontaneous, or idiopathic pathological states.

It is still a further object of the present invention to provide a method for the prevention or treatment of mammals to control the amount or activity of Group B streptococci, so as to treat or prevent the adverse consequences of invasive,  
25 spontaneous, or idiopathic pathological states.

The invention provides a method for preventing infection with a bacterium that expresses a streptococcal Ema polypeptide comprising administering an immunogenically effective dose of a vaccine comprising an Ema polypeptide selected  
30 from the group of EmaA, EmaB, EmaC, EmaD and EmaE to a subject.

The invention further provides a method for preventing infection with a bacterium that expresses a Group B streptococcal Ema polypeptide comprising administering an immunogenically effective dose of a vaccine comprising an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE to a subject.

5

The present invention is directed to a method for treating infection with a bacterium that expresses a streptococcal Ema polypeptide comprising administering a therapeutically effective dose of a pharmaceutical composition comprising an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable carrier to a subject.

The invention further provides a method for treating infection with a bacterium that expresses a streptococcal Ema polypeptide comprising administering a therapeutically effective dose of a pharmaceutical composition comprising an antibody to an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable carrier to a subject.

In a further aspect, the invention provides a method of inducing an immune response in a subject which has been exposed to or infected with a streptococcal bacterium comprising administering to the subject an amount of the pharmaceutical composition comprising an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable carrier, thereby inducing an immune response.

25 The invention still further provides a method for preventing infection by a streptococcal bacterium in a subject comprising administering to the subject an amount of a pharmaceutical composition comprising an antibody to an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE and a pharmaceutically acceptable carrier or diluent, thereby preventing infection by a  
30 streptococcal bacterium.

In a further aspect, the invention provides a method of inducing an immune response in a subject which has been exposed to or infected with a Group B streptococcal bacterium comprising administering to the subject an amount of the pharmaceutical composition comprising an Ema polypeptide selected from the group of EmaA, EmaB, 5 EmaC, EmaD and EmaE, and a pharmaceutically acceptable carrier, thereby inducing an immune response.

The invention still further provides a method for preventing infection by a Group B streptococcal bacterium in a subject comprising administering to the subject an amount 10 of a pharmaceutical composition comprising an antibody to an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE and a pharmaceutically acceptable carrier or diluent, thereby preventing infection by a streptococcal bacterium.

15 The invention further provides an *ema* mutant bacteria which is non-adherent and/or non-invasive to cells, particularly which is mutated in one or more genes selected from the group of *emaA*, *emaB*, *emaC*, *emaD* and *emaE*. Particularly, such *ema* mutant is a streptococcal bacteria. More particularly, such *ema* mutant is a Group B streptococcal bacteria. Such non-adherent and/or non-invasive *ema* mutant bacteria 20 can further be utilized in expressing other immunogenic or therapeutic proteins for the purposes of eliciting immune responses to any such other proteins in the context of vaccines and in other forms of therapy.

Other objects and advantages will become apparent to those skilled in the art from a 25 review of the following description which proceeds with reference to the following illustrative drawings.

#### BRIEF DESCRIPTION OF THE DRAWINGS

30 **FIGURE 1** depicts the restriction digest pattern (RDP) type III-3 specific probes. Dot blot hybridization of probe DY1-1 with genomic DNA isolated from type III

GBS. 10 ug of genomic DNA from each of 62 type III GBS strains was transferred to nylon membrane. Radiolabeled probe DY1-1 hybridized with DNA from all III-3 strains (rows A-D) including the original type III-3 strain (well E-1). The probe failed to hybridize with DNA from III-2 strains (F1- F10, G1-7) including the original strain 5 used in the subtraction hybridization (well E 10) and III-1 strains (wells H1-3; cf. Figure 3). The same pattern of hybridization was observed using probe DY1-11.

**FIGURE 2** depicts the nucleic acid and predicted amino acid sequence of *emaA*.

10 **FIGURE 3** depicts the nucleic acid and predicted amino acid sequence of *emaB*.

**FIGURE 4** depicts the nucleic acid and predicted amino acid sequence of *emaC*.

**FIGURE 5** depicts the nucleic acid and predicted amino acid sequence of *emaD*.

15

**FIGURE 6 A-D** depicts the nucleic acid and predicted amino acid sequence of *emaE*.

#### DETAILED DESCRIPTION

20 The present invention provides novel Group B streptococcal Ema polypeptides and their Ema homologs in distinct bacterial species, including distinct streptococcal species. The present invention relates to novel streptococcal Ema polypeptides, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and fragments thereof. Nucleic acids encoding Ema polypeptides, and diagnostic and 25 therapeutic compositions and methods based thereon for identification and prevention of infections by virulent forms of streptococci are provided. In particular, the present invention includes Group B streptococcal Ema polypeptides. The invention further includes polypeptide homologs of the GBS Ema polypeptides, particularly streptococcal homologs, more particularly Ema homologs of *S. pneumoniae* and *S. 30 pyogenes*. Bacterial Ema polypeptide homologs in *E. faecalis* and *C. diphtheriae* are also provided.

*Polypeptides*

The present invention is directed to an isolated polypeptide comprising an amino acid sequence of a bacterial Ema polypeptide. Bacterial Ema polypeptides are provided from streptococcus, enterococcus and corynebacterium. The present invention is particularly directed to an isolated polypeptide comprising an amino acid sequence of a streptococcal Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. The present invention is particularly directed to an isolated polypeptide comprising an amino acid sequence of a Group streptococcal Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. Additional *S. pneumoniae* and *S. pyogenes* Ema polypeptides are included in the invention. *E. faecalis* and *C. diphtheriae* Ema polypeptides are also included in the invention.

15 The polypeptides of the present invention are suitable for use in immunizing animals broadly against streptococcal infection. The polypeptides of the present invention are suitable for use in immunizing animals broadly against Group B, Group A, and *S. pneumoniae* streptococcal infection. The polypeptides of the present invention are suitable for use in immunizing animals against Group B streptococci. These polypeptide or peptide fragments thereof, when formulated with an appropriate adjuvant, are used in vaccines for protection against streptococci, particularly Group B streptococci, and against other bacteria with cross-reactive proteins.

25 GBS proteins with streptococcal homologs outside of Group B have been previously identified (Lachenauer CS and Madoff LC (1997) *Adv Exp Med Biol.* **418**:615-8; Brady L.J. et al (1991) *Infect Immun* **59**(12):4425-35; Stahlhammer-Carlemalm M. et al (2000) *J Infect Dis* **182**(1):142-129). Stahlhammer-Carlemalm et al have demonstrated cross-protection between Group A and Group B streptococci due to cross-reacting surface proteins (Stahlhammer-Carlemalm M. et al (2000) *J Infect Dis* **182**(1):142-129). The R28 protein of group A streptococcus (GAS) and the Rib

protein of group B streptococcus (GBS) are surface molecules that elicit protective immunity to experimental infection. These proteins are members of the same family and cross-react immunologically. In spite of extensive amino acid residue identity, the cross-reactivity between R28 and Rib was found to be limited, as shown by analysis

- 5 with highly purified proteins and specific antisera. Nevertheless, immunization of mice with purified R28 conferred protection against lethal infection with Rib-expressing GBS strains, and immunization with Rib conferred protection against R28-expressing GAS. Thus, R28 and Rib elicited cross-protective immunity.
- 10 The present invention is directed to an isolated streptococcal EmaA polypeptide which comprises the amino acid sequence set out in SEQ ID NO: 2, and analogs, variants and immunogenic fragments thereof.

The present invention is directed to an isolated streptococcal EmaB polypeptide which

- 15 comprises the amino acid sequence set out in SEQ ID NO: 4, and analogs, variants and immunogenic fragments thereof.

The present invention is directed to an isolated streptococcal EmaC polypeptide which comprises the amino acid sequence set out in SEQ ID NO: 6, and analogs, variants

- 20 and immunogenic fragments thereof.

The present invention is directed to an isolated streptococcal EmaD polypeptide which comprises the amino acid sequence set out in SEQ ID NO: 8, and analogs, variants and immunogenic fragments thereof.

- 25 The identity or location of one or more amino acid residues may be changed or modified to include variants such as, for example, deletions containing less than all of the residues specified for the protein, substitutions wherein one or more residues specified are replaced by other residues and additions wherein one or more amino acid
- 30 residues are added to a terminal or medial portion of the polypeptide. These molecules include: the incorporation of codons "preferred" for expression by selected

non-mammalian hosts; the provision of sites for cleavage by restriction endonuclease enzymes; and the provision of additional initial, terminal or intermediate DNA sequences that facilitate construction of readily expressed vectors.

5 The present invention is directed to an isolated Group B streptococcal EmaE polypeptide which comprises the amino acid sequence set out in SEQ ID NO: 10, and analogs, variants and immunogenic fragments thereof.

The present invention thus provides an isolated streptococcal Ema polypeptide  
10 comprising the amino acid sequence set out in SEQ ID NO:23. An isolated nucleic acid which encodes the streptococcal polypeptide set out in SEQ ID NO:23 is further provided.

The invention thus further provides an isolated streptococcal Ema polypeptide  
15 comprising the amino acid sequence set out in SEQ ID NO:26. An isolated nucleic acid which encodes the streptococcal polypeptide set out in SEQ ID NO:26 is further provided.

The present invention further provides an isolated streptococcal Ema polypeptide  
20 comprising the amino acid sequence set out in SEQ ID NO:37. An isolated nucleic acid which encodes the streptococcal polypeptide set out in SEQ ID NO:37 is further provided.

An enterococcal Ema polypeptide is further provided comprising the amino acid  
25 sequence set out in SEQ ID NO:29. An isolated isolated nucleic acid which encodes the enterococcal polypeptide set out in SEQ ID NO:29 is also provided.

The invention provides an isolated *Corynebacterium* Ema polypeptide comprising the amino acid sequence set out in SEQ ID NO: 32. Also provided is an isolated nucleic  
30 acid which encodes the *Corynebacterium* polypeptide set out in SEQ ID NO: 32.

The invention provides an isolated bacterial polypeptide comprising the amino acid sequence TLLTCTPYMINS/THRLLVR/KG (SEQ ID NO: 34), wherein the polypeptide is not isolated from *Actinomyces*.

5 The invention further provides an isolated streptococcal polypeptide comprising the amino acid sequence TLLTCTPYMINS/THRLLVR/KG (SEQ ID NO: 34).

Also provided is an isolated bacterial polypeptide comprising the amino acid sequence TLVTCTPYGINTHRLLVTA (SEQ ID NO: 35).

10 The present invention includes an isolated bacterial polypeptide comprising the amino acid sequence TLVTCTPYGVNTKRLLVRG (SEQ ID NO: 36). An isolated streptococcal polypeptide comprising the amino acid sequence TLVTCTPYGVNTKRLLVRG (SEQ ID NO: 36) is also provided.

15 The invention further includes an isolated polypeptide having the amino acid sequence selected from the group of TLLTCTPYMINS/THRLLVR/KG (SEQ ID NO: 34), TLVTCTPYGINTHRLLVTA (SEQ ID NO: 35), and TLVTCTPYGVNTKRLLVRG (SEQ ID NO: 36).

20 The present invention contemplates the use of the streptococcal polypeptides of the present invention in diagnostic tests and methods for determining and/or monitoring of streptococcal infection. Thus, the present invention provides an isolated GBS Ema polypeptide, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and  
25 EmaE, labeled with a detectable label.

In the instance where a radioactive label, such as the isotopes  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{36}\text{Cl}$ ,  $^{51}\text{Cr}$ ,  $^{57}\text{Co}$ ,  $^{58}\text{Co}$ ,  $^{59}\text{Fe}$ ,  $^{90}\text{Y}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ , and  $^{186}\text{Re}$  are used, known currently available counting procedures may be utilized. In the instance where the label is an enzyme,

30 detection may be accomplished by any of the presently utilized colorimetric,

spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques known in the art.

The present invention extends to an immunogenic bacterial Ema polypeptide. The

5 present invention extends to an immunogenic streptococcal Ema polypeptide, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, or a fragment thereof. The present invention also extends to immunogenic GBS Ema polypeptides wherein such polypeptides comprise a combination of at least one immunogenic GBS Ema polypeptide, selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, or immunogenic polypeptide fragment thereof and GBS polypeptide

10 Spb1, Spb2, C protein alpha antigen, Rib or immunogenic fragments thereof.

As defined herein, "adhesion" means noncovalent binding of a bacteria to a human cell or secretion that is stable enough to withstand washing.

15 The term "extracellular matrix adhesin", "Ema", "ema" and any variants not specifically listed, may be used herein interchangeably, and as used throughout the present application and claims refer to proteinaceous material including single or multiple proteins, and extends to those proteins having the amino acid sequence data described

20 herein and particularly identified by (SEQ ID NOS: 2, 4, 6, 8, 10, 23, 26, 29, 32 and 37), and the profile of activities set forth herein and in the Claims. In particular the Ema proteins provided herein include EmaA, EmaB, EmaC, EmaD and EmaE. The Ema proteins include bacterial Ema homologs. Bacterial Ema homologs include those from streptococcal species and other bacterial species. Accordingly, proteins and

25 polypeptides displaying substantially equivalent or altered activity are likewise contemplated. These modifications may be deliberate, for example, such as modifications obtained through site-directed mutagenesis, or may be accidental, such as those obtained through mutations in hosts that are producers of one or more Ema polypeptide. Also, the term "extracellular matrix adhesin (Ema)" is intended to include

30 within its scope proteins specifically recited herein as well as all substantially homologous analogs and allelic variations.

This invention provides an isolated immunogenic polypeptide comprising an amino acid sequence of a bacterial Ema polypeptide. This invention provides an isolated immunogenic polypeptide comprising an amino acid sequence of a streptococcal Ema polypeptide, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. It is contemplated by this invention that the immunogenic polypeptide has the amino acid sequence set forth in any of SEQ ID NOS: 2, 4, 6, 8, 10, 23, 26, 29, 32 and 37, including immunogenic fragments, mutants, variants, analogs, or derivatives, thereof.

10 This invention is directed to analogs of the polypeptide which comprise the amino acid sequence as set forth above. The analog polypeptide may have an N-terminal methionine or a polyhistidine optionally attached to the N or COOH terminus of the polypeptide which comprise the amino acid sequence.

15 In another embodiment, this invention contemplates peptide fragments of the polypeptide which result from proteolytic digestion products of the polypeptide. In another embodiment, the derivative of the polypeptide has one or more chemical moieties attached thereto. In another embodiment the chemical moiety is a water soluble polymer. In another embodiment the chemical moiety is polyethylene glycol.

20 In another embodiment the chemical moiety is mon-, di-, tri- or tetrapegylated. In another embodiment the chemical moiety is N-terminal monopegylated.

Attachment of polyethylene glycol (PEG) to compounds is particularly useful because PEG has very low toxicity in mammals (Carpenter et al., 1971). For example, a PEG 25 adduct of adenosine deaminase was approved in the United States for use in humans for the treatment of severe combined immunodeficiency syndrome. A second advantage afforded by the conjugation of PEG is that of effectively reducing the immunogenicity and antigenicity of heterologous compounds. For example, a PEG adduct of a human protein might be useful for the treatment of disease in other 30 mammalian species without the risk of triggering a severe immune response. The compound of the present invention may be delivered in a microencapsulation device

so as to reduce or prevent an host immune response against the compound or against cells which may produce the compound. The compound of the present invention may also be delivered microencapsulated in a membrane, such as a liposome.

5 Numerous activated forms of PEG suitable for direct reaction with proteins have been described. Useful PEG reagents for reaction with protein amino groups include active esters of carboxylic acid or carbonate derivatives, particularly those in which the leaving groups are N-hydroxysuccinimide, p-nitrophenol, imidazole or 1-hydroxy-2-nitrobenzene-4-sulfonate. PEG derivatives containing maleimido or haloacetyl groups

10 are useful reagents for the modification of protein free sulphydryl groups. Likewise, PEG reagents containing amino hydrazine or hydrazide groups are useful for reaction with aldehydes generated by periodate oxidation of carbohydrate groups in proteins.

In one embodiment, the amino acid residues of the polypeptide described herein are

15 preferred to be in the "L" isomeric form. In another embodiment, the residues in the "D" isomeric form can be substituted for any L-amino acid residue, as long as the desired functional property of lectin activity is retained by the polypeptide. NH<sub>2</sub> refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxy terminus of a polypeptide.

20 Abbreviations used herein are in keeping with standard polypeptide nomenclature, *J. Biol. Chem.*, 243:3552-59 (1969).

It should be noted that all amino-acid residue sequences are represented herein by

25 formulae whose left and right orientation is in the conventional direction of amino-terminus to carboxy-terminus. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or more amino-acid residues.

Synthetic polypeptide, prepared using the well known techniques of solid phase, liquid

30 phase, or peptide condensation techniques, or any combination thereof, can include natural and unnatural amino acids. Amino acids used for peptide synthesis may be

standard Boc (N<sup>α</sup>-amino protected N<sup>α</sup>-t-butyloxycarbonyl) amino acid resin with the standard deprotecting, neutralization, coupling and wash protocols of the original solid phase procedure of Merrifield (1963, *J. Am. Chem. Soc.* 85:2149-2154), or the base-labile N<sup>α</sup>-amino protected 9-fluorenylmethoxycarbonyl (Fmoc) amino acids first 5 described by Carpino and Han (1972, *J. Org. Chem.* 37:3403-3409). Thus, polypeptide of the invention may comprise D-amino acids, a combination of D- and L-amino acids, and various "designer" amino acids (e.g., β-methyl amino acids, C<sup>α</sup>-methyl amino acids, and N<sup>α</sup>-methyl amino acids, etc.) to convey special properties. Synthetic amino acids include ornithine for lysine, fluorophenylalanine for 10 phenylalanine, and norleucine for leucine or isoleucine. Additionally, by assigning specific amino acids at specific coupling steps, α-helices, β turns, β sheets, γ-turns, and cyclic peptides can be generated.

In one aspect of the invention, the peptides may comprise a special amino acid at the 15 C-terminus which incorporates either a CO<sub>2</sub>H or CONH<sub>2</sub> side chain to simulate a free glycine or a glycine-amide group. Another way to consider this special residue would be as a D or L amino acid analog with a side chain consisting of the linker or bond to the bead. In one embodiment, the pseudo-free C-terminal residue may be of the D or the L optical configuration; in another embodiment, a racemic mixture of D and L- 20 isomers may be used.

In an additional embodiment, pyroglutamate may be included as the N-terminal residue of the peptide. Although pyroglutamate is not amenable to sequence by Edman degradation, by limiting substitution to only 50% of the peptides on a given bead with 25 N-terminal pyroglutamate, there will remain enough non-pyroglutamate peptide on the bead for sequencing. One of ordinary skill would readily recognize that this technique could be used for sequencing of any peptide that incorporates a residue resistant to Edman degradation at the N-terminus. Other methods to characterize individual peptides that demonstrate desired activity are described in detail *infra*. Specific 30 activity of a peptide that comprises a blocked N-terminal group, e.g., pyroglutamate, when the particular N-terminal group is present in 50% of the peptides, would readily

be demonstrated by comparing activity of a completely (100%) blocked peptide with a non-blocked (0%) peptide.

In addition, the present invention envisions preparing peptides that have more well defined structural properties, and the use of peptidomimetics, and peptidomimetic bonds, such as ester bonds, to prepare peptides with novel properties. In another embodiment, a peptide may be generated that incorporates a reduced peptide bond, i.e.,  $R_1-CH_2-NH-R_2$ , where  $R_1$  and  $R_2$  are amino acid residues or sequences. A reduced peptide bond may be introduced as a dipeptide subunit. Such a molecule would be resistant to peptide bond hydrolysis, e.g., protease activity. Such peptides would provide ligands with unique function and activity, such as extended half-lives *in vivo* due to resistance to metabolic breakdown, or protease activity. Furthermore, it is well known that in certain systems constrained peptides show enhanced functional activity (Hruby, 1982, *Life Sciences* 31:189-199; Hruby et al., 1990, *Biochem J.* 268:249-262); the present invention provides a method to produce a constrained peptide that incorporates random sequences at all other positions.

A constrained, cyclic or rigidized peptide may be prepared synthetically, provided that in at least two positions in the sequence of the peptide an amino acid or amino acid analog is inserted that provides a chemical functional group capable of cross-linking to constrain, cyclise or rigidize the peptide after treatment to form the cross-link. Cyclization will be favored when a turn-inducing amino acid is incorporated. Examples of amino acids capable of cross-linking a peptide are cysteine to form disulfide, aspartic acid to form a lactone or a lactase, and a chelator such as  $\gamma$ -carboxyl-glutamic acid (Gla) (Bachem) to chelate a transition metal and form a cross-link. Protected  $\gamma$ -carboxyl glutamic acid may be prepared by modifying the synthesis described by Zee-Cheng and Olson (1980, *Biophys. Biochem. Res. Commun.* 94:1128-1132). A peptide in which the peptide sequence comprises at least two amino acids capable of cross-linking may be treated, e.g., by oxidation of cysteine residues to form a disulfide or addition of a metal ion to form a chelate, so as to cross-link the peptide and form a constrained, cyclic or rigidized peptide.

The present invention provides strategies to systematically prepare cross-links. For example, if four cysteine residues are incorporated in the peptide sequence, different protecting groups may be used (Hiskey, 1981, in *The Peptides: Analysis, Synthesis, 5 Biology*, Vol. 3, Gross and Meienhofer, eds., Academic Press: New York, pp. 137-167; Ponsanti et al., 1990, *Tetrahedron* 46:8255-8266). The first pair of cysteine may be deprotected and oxidized, then the second set may be deprotected and oxidized. In this way a defined set of disulfide cross-links may be formed. Alternatively, a pair of cysteine and a pair of collating amino acid analogs may be incorporated so that the 10 cross-links are of a different chemical nature.

The following non-classical amino acids may be incorporated in the peptide in order to introduce particular conformational motifs: 1,2,3,4-tetrahydroisoquinoline-3-carboxylate (Kazmierski et al., 1991, *J. Am. Chem. Soc.* 113:2275-2283); (2S,3S)-15 methyl-phenylalanine, (2S,3R)-methyl-phenylalanine, (2R,3S)-methyl-phenylalanine and (2R,3R)-methyl-phenylalanine (Kazmierski and Hruby, 1991, *Tetrahedron Lett.*); 2-aminotetrahydronaphthalene-2-carboxylic acid (Landis, 1989, Ph.D. Thesis, University of Arizona); hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate (Miyake et al., 1989, *J. Takeda Res. Labs.* 43:53-76);  $\beta$ -carboline (D and L) (Kazmierski, 20 1988, Ph.D. Thesis, University of Arizona); HIC (histidine isoquinoline carboxylic acid) (Zechel et al., 1991, *Int. J. Pep. Protein Res.* 43); and HIC (histidine cyclic urea) (Dharanipragada).

The following amino acid analogs and peptidomimetics may be incorporated into a 25 peptide to induce or favor specific secondary structures: LL-Acp (LL-3-amino-2-propenidone-6-carboxylic acid), a  $\beta$ -turn inducing dipeptide analog (Kemp et al., 1985, *J. Org. Chem.* 50:5834-5838);  $\beta$ -sheet inducing analogs (Kemp et al., 1988, *Tetrahedron Lett.* 29:5081-5082);  $\beta$ -turn inducing analogs (Kemp et al., 1988, *Tetrahedron Lett.* 29:5057-5060);  $\alpha$ -helix inducing analogs (Kemp et al., 1988, 30 *Tetrahedron Lett.* 29:4935-4938);  $\gamma$ -turn inducing analogs (Kemp et al., 1989, *J. Org. Chem.* 54:109:115); and analogs provided by the following references: Nagai and

Sato, 1985, *Tetrahedron Lett.* 26:647-650; DiMaio et al., 1989, *J. Chem. Soc. Perkin Trans.* p. 1687; also a Gly-Ala turn analog (Kahn et al., 1989, *Tetrahedron Lett.* 30:2317); amide bond isostere (Jones et al., 1988, *Tetrahedron Lett.* 29:3853-3856); tretrazol (Zabrocki et al., 1988, *J. Am. Chem. Soc.* 110:5875-5880); DTC (Samanen et al., 1990, *Int. J. Protein Pep. Res.* 35:501:509); and analogs taught in Olson et al., 1990, *J. Am. Chem. Sci.* 112:323-333 and Garvey et al., 1990, *J. Org. Chem.* 56:436. Conformationally restricted mimetics of beta turns and beta bulges, and peptides containing them, are described in U.S. Patent No. 5,440,013, issued August 8, 1995 to Kahn.

10

The present invention further provides for modification or derivatization of the polypeptide or peptide of the invention. Modifications of peptides are well known to one of ordinary skill, and include phosphorylation, carboxymethylation, and acylation. Modifications may be effected by chemical or enzymatic means. In another aspect, 15 glycosylated or fatty acylated peptide derivatives may be prepared. Preparation of glycosylated or fatty acylated peptides is well known in the art. Fatty acyl peptide derivatives may also be prepared. For example, and not by way of limitation, a free amino group (N-terminal or lysyl) may be acylated, e.g., myristoylated. In another embodiment an amino acid comprising an aliphatic side chain of the structure - 20  $(CH_2)_nCH_3$  may be incorporated in the peptide. This and other peptide-fatty acid conjugates suitable for use in the present invention are disclosed in U.K. Patent GB-8809162.4, International Patent Application PCT/AU89/00166, and reference 5, *supra*.

25 *Chemical Moieties For Derivatization.* Chemical moieties suitable for derivatization may be selected from among water soluble polymers. The polymer selected should be water soluble so that the component to which it is attached does not precipitate in an aqueous environment, such as a physiological environment. Preferably, for therapeutic use of the end-product preparation, the polymer will be pharmaceutically acceptable.

30 One skilled in the art will be able to select the desired polymer based on such considerations as whether the polymer/component conjugate will be used

therapeutically, and if so, the desired dosage, circulation time, resistance to proteolysis, and other considerations. For the present component or components, these may be ascertained using the assays provided herein.

- 5 The water soluble polymer may be selected from the group consisting of, for example, polyethylene glycol, copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or
- 10 poly(n-vinyl pyrrolidone)polyethylene glycol, propylene glycol homopolymers, prolypropylene oxide/ethylene oxide co- polymers, polyoxyethylated polyols and polyvinyl alcohol. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water.
- 15 The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between about 2kDa and about 100kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired
- 20 therapeutic profile (*e.g.*, the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog).

The number of polymer molecules so attached may vary, and one skilled in the art will

- 25 be able to ascertain the effect on function. One may mono-derivative, or may provide for a di-, tri-, tetra- or some combination of derivatization, with the same or different chemical moieties (*e.g.*, polymers, such as different weights of polyethylene glycols). The proportion of polymer molecules to component or components molecules will vary, as will their concentrations in the reaction mixture. In general, the optimum ratio
- 30 (in terms of efficiency of reaction in that there is no excess unreacted component or components and polymer) will be determined by factors such as the desired degree of

derivatization (*e.g.*, mono, di-, tri-, etc.), the molecular weight of the polymer selected, whether the polymer is branched or unbranched, and the reaction conditions.

The polyethylene glycol molecules (or other chemical moieties) should be attached to

5 the component or components with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those skilled in the art, *e.g.*, EP 0 401 384 herein incorporated by reference (coupling PEG to G-CSF), *see also* Malik *et al.*, 1992, *Exp. Hematol.* 20:1028-1035 (reporting pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may

10 be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated polyethylene glycol molecule may be bound. The amino acid residues having a free amino group include lysine residues and the – terminal amino acid residues; those having a free carboxyl group include aspartic acid residues glutamic acid residues and

15 the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecule(s). Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, *e.g.*, Sambrook et al, "Molecular Cloning: A Laboratory Manual" (1989); "Current Protocols in Molecular Biology" Volumes I-III [Ausubel, R. M., ed. (1994)]; "Cell Biology: A Laboratory Handbook" Volumes I-III [J. E. Celis, ed. (1994)]; "Current Protocols in Immunology" Volumes I-III [Coligan, J. E., ed. (1994)]; "Oligonucleotide Synthesis" (M.J. Gait ed. 1984); "Nucleic Acid Hybridization" [B.D. Hames & S.J. Higgins eds. 25 (1985)]; "Transcription And Translation" [B.D. Hames & S.J. Higgins, eds. (1984)];

30

"Animal Cell Culture" [R.I. Freshney, ed. (1986)]; "Immobilized Cells And Enzymes" [IRL Press, (1986)]; B. Perbal, "A Practical Guide To Molecular Cloning" (1984).

Mutations can be made in a nucleic acid encoding the polypeptide of the present

5 invention such that a particular codon is changed to a codon which codes for a different amino acid. Such a mutation is generally made by making the fewest nucleotide changes possible. A substitution mutation of this sort can be made to change an amino acid in the resulting protein in a non-conservative manner (i.e., by changing the codon from an amino acid belonging to a grouping of amino acids having

10 a particular size or characteristic to an amino acid belonging to another grouping) or in a conservative manner (i.e., by changing the codon from an amino acid belonging to a grouping of amino acids having a particular size or characteristic to an amino acid belonging to the same grouping). Such a conservative change generally leads to less change in the structure and function of the resulting protein. A non-conservative

15 change is more likely to alter the structure, activity or function of the resulting protein.

The present invention should be considered to include sequences containing conservative changes which do not significantly alter the activity or binding characteristics of the resulting protein. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid

20 belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. Amino acids containing aromatic ring structures are phenylalanine, tryptophan, and tyrosine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include

25 arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Such alterations will not be expected to affect apparent molecular weight as determined by polyacrylamide gel electrophoresis, or isoelectric point.

30 Particularly preferred substitutions are:

- Lys for Arg and vice versa such that a positive charge may be maintained;

- Glu for Asp and vice versa such that a negative charge may be maintained;
- Ser for Thr such that a free -OH can be maintained; and
- Gln for Asn such that a free NH<sub>2</sub> can be maintained.

5 Synthetic DNA sequences allow convenient construction of genes which will express analogs or "muteins". A general method for site-specific incorporation of unnatural amino acids into proteins is described in Noren, et al. *Science*, **244**:182-188 (April 1989). This method may be used to create analogs with unnatural amino acids.

10 This invention provides an isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of a streptococcal Ema polypeptide. This invention provides an isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of a streptococcal Ema polypeptide. This invention provides an isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of a Group B

15 streptococcal Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. This invention provides an isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of a Group B streptococcal Ema protein selected from the group of Ema proteins EmA, EmB, EmC, EmD and EmE as set forth in FIGURES 2-6. The invention provides an isolated nucleic acid

20 encoding a polypeptide comprising an amino acid sequence of a bacterial Ema polypeptide selected from the group of SEQ ID NO: 23, 26, 29, 32 and 37. In particular embodiments the nucleic acid is set forth in any of SEQ ID NOS: 1, 3, 5, 7, 9, 24, 27, 30, and 33, including fragments, mutants, variants, analogs, or derivatives, thereof. The nucleic acid is DNA, cDNA, genomic DNA, RNA. Further, the isolated

25 nucleic acid may be operatively linked to a promoter of RNA transcription.

The present invention also relates to isolated nucleic acids, such as recombinant DNA molecules or cloned genes, or degenerate variants thereof, mutants, analogs, or fragments thereof, which encode the isolated polypeptide or which competitively

30 inhibit the activity of the polypeptide. The present invention further relates to isolated nucleic acids, such as recombinant DNA molecules or cloned genes, or degenerate

variants thereof, mutants, analogs, or fragments thereof, which encode a GBS Ema polypeptide, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. Preferably, the isolated nucleic acid, which includes degenerates, variants, mutants, analogs, or fragments thereof, has a sequence as set forth in SEQ ID NOS: 1, 5 3, 5, 7 or 9. In a further embodiment of the invention, the DNA sequence of the recombinant DNA molecule or cloned gene may be operatively linked to an expression control sequence which may be introduced into an appropriate host. The invention accordingly extends to unicellular hosts transformed with the cloned gene or recombinant DNA molecule comprising a DNA sequence encoding an Ema protein, 10 particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and more particularly, the DNA sequences or fragments thereof determined from the sequences set forth above.

In a particular embodiment, the nucleic acid encoding the EmaA polypeptide has the 15 sequence selected from the group comprising SEQ ID NO:1; a sequence that hybridizes to SEQ ID NO:1 under moderate stringency hybridization conditions; DNA sequences capable of encoding the amino acid sequence encoded by SEQ ID NO:1 or a sequence that hybridizes to SEQ ID NO:1 under moderate stringency hybridization conditions; degenerate variants thereof; alleles thereof; and hybridizable fragments thereof. In a particular embodiment, the nucleic acid encoding the EmaA polypeptide 20 has the sequence selected from the group comprising SEQ ID NO:1; a sequence complementary to SEQ ID NO:1; or a homologous sequence which is substantially similar to SEQ ID NO:1. In a further embodiment, the nucleic acid has the sequence consisting of SEQ ID NO:1.

25 In a particular embodiment, the nucleic acid encoding the EmaB polypeptide has the sequence selected from the group comprising SEQ ID NO:3; a sequence that hybridizes to SEQ ID NO:3 under moderate stringency hybridization conditions; DNA sequences capable of encoding the amino acid sequence encoded by SEQ ID NO:3 or 30 a sequence that hybridizes to SEQ ID NO:3 under moderate stringency hybridization conditions; degenerate variants thereof; alleles thereof; and hybridizable fragments thereof. In a particular embodiment, the nucleic acid encoding the EmaB polypeptide has the sequence selected from the group comprising SEQ ID NO:3; a sequence

complementary to SEQ ID NO:3; or a homologous sequence which is substantially similar to SEQ ID NO:3. In a further embodiment, the nucleic acid has the sequence consisting of SEQ ID NO:3.

- 5 In a particular embodiment, the nucleic acid encoding the EmaC polypeptide has the sequence selected from the group comprising SEQ ID NO:5; a sequence that hybridizes to SEQ ID NO:5 under moderate stringency hybridization conditions; DNA sequences capable of encoding the amino acid sequence encoded by SEQ ID NO:5 or a sequence that hybridizes to SEQ ID NO:5 under moderate stringency hybridization
- 10 conditions; degenerate variants thereof; alleles thereof; and hybridizable fragments thereof. In a particular embodiment, the nucleic acid encoding the EmaC polypeptide has the sequence selected from the group comprising SEQ ID NO:5; a sequence complementary to SEQ ID NO:5; or a homologous sequence which is substantially similar to SEQ ID NO:5. In a further embodiment, the nucleic acid has the sequence
- 15 consisting of SEQ ID NO:5.

In a particular embodiment, the nucleic acid encoding the EmaD polypeptide has the sequence selected from the group comprising SEQ ID NO:7; a sequence that hybridizes to SEQ ID NO:7 under moderate stringency hybridization conditions; DNA

- 20 sequences capable of encoding the amino acid sequence encoded by SEQ ID NO:7 or a sequence that hybridizes to SEQ ID NO:7 under moderate stringency hybridization conditions; degenerate variants thereof; alleles thereof; and hybridizable fragments thereof. In a particular embodiment, the nucleic acid encoding the EmaD polypeptide has the sequence selected from the group comprising SEQ ID NO:7; a sequence
- 25 complementary to SEQ ID NO:7; or a homologous sequence which is substantially similar to SEQ ID NO:7. In a further embodiment, the nucleic acid has the sequence consisting of SEQ ID NO:7.

In a particular embodiment, the nucleic acid encoding the EmaE polypeptide has the

- 30 sequence selected from the group comprising SEQ ID NO:9; a sequence that hybridizes to SEQ ID NO:9 under moderate stringency hybridization conditions; DNA sequences capable of encoding the amino acid sequence encoded by SEQ ID NO:9 or a sequence that hybridizes to SEQ ID NO:9 under moderate stringency hybridization

conditions; degenerate variants thereof; alleles thereof; and hybridizable fragments thereof. In a particular embodiment, the nucleic acid encoding the EmaE polypeptide has the sequence selected from the group comprising SEQ ID NO:9; a sequence complementary to SEQ ID NO:9; or a homologous sequence which is substantially similar to SEQ ID NO:9. In a further embodiment, the nucleic acid has the sequence consisting of SEQ ID NO:9.

A nucleic acid capable of encoding a GBS polypeptide EmaA, EmaB, EmaC, EmaD or EmaE which is a recombinant DNA molecule is further provided. Such a recombinant DNA molecule wherein the DNA molecule is operatively linked to an expression control sequence is also provided herein.

The present invention relates to nucleic acid vaccines or DNA vaccines comprising nucleic acids encoding immunogenic bacterial Ema polypeptides, particularly immunogenic streptococcal Ema polypeptides. The present invention relates to nucleic acid vaccines or DNA vaccines comprising nucleic acids encoding immunogenic GBS Ema polypeptides, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. The present invention relates to nucleic acid vaccines or DNA vaccines comprising nucleic acids encoding one or more immunogenic GBS Ema polypeptide or a fragment thereof or any combination of one or more Ema polypeptide EmaA, EmaB, EmaC, EmaD or EmaE with at least one other GBS polypeptide, particularly wherein said other GBS polypeptide is selected from the group of Spb1, Spb2, C protein alpha antigen, Rib and immunogenic polypeptide fragments thereof.

The invention further relates to a vaccine for protection of an animal subject from infection with a streptococcal bacterium comprising a vector containing a gene encoding an Ema polypeptide, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, operatively associated with a promoter capable of directing expression of the gene in the subject. The invention further relates to a vaccine for protection of an animal subject from infection with a Group B streptococcal bacterium comprising a vector containing a gene encoding an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE operatively associated with a promoter capable of directing expression of the gene in the subject. The present

invention further provides a nucleic acid vaccine comprising a recombinant DNA molecule capable of encoding a GBS polypeptide EmaA, EmaB, EmaC, EmaD or EmaE.

- 5 The present invention provides a vector which comprises the nucleic acid capable of encoding encoding a bacterial Ema polypeptide, particularly a streptococcal Ema polypeptide. The present invention provides a vector which comprises the nucleic acid capable of encoding encoding an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE and a promoter. The present invention provides a
- 10 vector which comprises the nucleic acid of any of SEQ ID NO: 1, 3, 5, 7, 9, 24, 27, 30, and 33, and a promoter. The invention contemplates a vector wherein the promoter comprises a bacterial, yeast, insect or mammalian promoter. The invention contemplates a vector wherein the vector is a plasmid, cosmid, yeast artificial chromosome (YAC), bacteriophage or eukaryotic viral DNA.

15 The present invention further provides a host vector system for the production of a polypeptide which comprises the vector capable of encoding encoding an Ema polypeptide, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, in a suitable host cell. A host vector system is provided wherein the suitable

- 20 host cell comprises a prokaryotic or eukaryotic cell. A unicellular host transformed with a recombinant DNA molecule or vector capable of encoding encoding an Ema polypeptide, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, is thereby provided.

25 A "vector" is a replicon, such as plasmid, phage or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment.

A "DNA" or "DNA molecule" refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in its either single stranded form, or a double-stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, *inter alia*, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes. In discussing the

structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA).

5

An "origin of replication" refers to those DNA sequences that participate in DNA synthesis.

A DNA "coding sequence" is a double-stranded DNA sequence which is transcribed and translated into a polypeptide *in vivo* when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., 10 mammalian) DNA, and even synthetic DNA sequences. A polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence in the case of eukaryotic mRNA.

Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that 20 provide for the expression of a coding sequence in a host cell.

A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence 25 will be found a transcription initiation site (conveniently defined by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Eukaryotic promoters will often, but not always, contain "TATA" boxes and "CAT" boxes. Prokaryotic promoters contain Shine-Dalgarno sequences in addition to the -10 and -35 consensus sequences.

An "expression control sequence" is a DNA sequence that controls and regulates the transcription and translation of another DNA sequence. A coding sequence is "under the control" of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then translated into 5 the protein encoded by the coding sequence.

A "signal sequence" can be included before the coding sequence. This sequence encodes a signal peptide, N-terminal to the polypeptide, that communicates to the host cell to direct the polypeptide to the cell surface or secrete the polypeptide into the 10 media, and this signal peptide is clipped off by the host cell before the protein leaves the cell. Signal sequences can be found associated with a variety of proteins native to prokaryotes and eukaryotes.

The term "oligonucleotide," as used herein in referring to the probe of the present 15 invention, is defined as a molecule comprised of two or more ribonucleotides, preferably more than three. Its exact size will depend upon many factors which, in turn, depend upon the ultimate function and use of the oligonucleotide.

The term "primer" as used herein refers to an oligonucleotide, whether occurring 20 naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product, which is complementary to a nucleic acid strand, is induced, i.e., in the presence of nucleotides and an inducing agent such as a DNA polymerase and at a suitable temperature and pH. The primer may be either 25 single-stranded or double-stranded and must be sufficiently long to prime the synthesis of the desired extension product in the presence of the inducing agent. The exact length of the primer will depend upon many factors, including temperature, source of primer and use of the method. For example, for diagnostic applications, depending on the complexity of the target sequence, the oligonucleotide primer typically contains 30 15-25 or more nucleotides, although it may contain fewer nucleotides.

The primers herein are selected to be "substantially" complementary to different strands of a particular target DNA sequence. This means that the primers must be

sufficiently complementary to hybridize with their respective strands. Therefore, the primer sequence need not reflect the exact sequence of the template. For example, a non-complementary nucleotide fragment may be attached to the 5' end of the primer, with the remainder of the primer sequence being complementary to the strand.

5    Alternatively, non-complementary bases or longer sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementarity with the sequence of the strand to hybridize therewith and thereby form the template for the synthesis of the extension product.

10   As used herein, the terms "restriction endonucleases" and "restriction enzymes" refer to bacterial enzymes, each of which cut double-stranded DNA at or near a specific nucleotide sequence.

A cell has been "transformed" by exogenous or heterologous DNA when such DNA

15   has been introduced inside the cell. The transforming DNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell. In prokaryotes, yeast, and mammalian cells for example, the transforming DNA may be maintained on an episomal element such as a plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming DNA has

20   become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transforming DNA. A "clone" is a population of cells derived from a single cell or common ancestor by mitosis. A "cell line" is a clone of a primary cell

25   that is capable of stable growth *in vitro* for many generations.

Two DNA sequences are "substantially homologous" when at least about 75% (preferably at least about 80%, and most preferably at least about 90 or 95%) of the nucleotides match over the defined length of the DNA sequences. Sequences that are

30   substantially homologous can be identified by comparing the sequences using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system. Defining

appropriate hybridization conditions is within the skill of the art. See, e.g., Maniatis et al., *supra*; DNA Cloning, Vols. I & II, *supra*; Nucleic Acid Hybridization, *supra*.

A DNA sequence is "operatively linked" to an expression control sequence when the 5 expression control sequence controls and regulates the transcription and translation of that DNA sequence. The term "operatively linked" includes having an appropriate start signal (e.g., ATG) in front of the DNA sequence to be expressed and maintaining the correct reading frame to permit expression of the DNA sequence under the control of the expression control sequence and production of the desired product encoded by 10 the DNA sequence. If a gene that one desires to insert into a recombinant DNA molecule does not contain an appropriate start signal, such a start signal can be inserted in front of the gene.

The term "standard hybridization conditions" refers to salt and temperature conditions 15 substantially equivalent to 5 x SSC and 65°C for both hybridization and wash. However, one skilled in the art will appreciate that such "standard hybridization conditions" are dependent on particular conditions including the concentration of sodium and magnesium in the buffer, nucleotide sequence length and concentration, percent mismatch, percent formamide, and the like. Also important in the 20 determination of "standard hybridization conditions" is whether the two sequences hybridizing are RNA-RNA, DNA-DNA or RNA-DNA. Such standard hybridization conditions are easily determined by one skilled in the art according to well known formulae, wherein hybridization is typically 10-20°C below the predicted or determined  $T_m$  with washes of higher stringency, if desired.

25

It should be appreciated that also within the scope of the present invention are DNA sequences encoding an Ema polypeptide EmaA, EmaB, EmaC, EmaD or EmaE which code for an Ema polypeptide having the same amino acid sequence as any of SEQ ID NOS:2, 4, 6, 8 or 10, but which are degenerate to any of SEQ ID NOS:1, 3, 5, 7 or 9. 30 By "degenerate to" is meant that a different three-letter codon is used to specify a particular amino acid. It is well known in the art that the following codons can be used interchangeably to code for each specific amino acid:

	Phenylalanine (Phe or F)	UUU or UUC
	Leucine (Leu or L)	UUA or UUG or CUU or CUC or CUA or CUG
	Isoleucine (Ile or I)	AUU or AUC or AUA
	Methionine (Met or M)	AUG
5	Valine (Val or V)	GUU or GUC or GUA or GUG
	Serine (Ser or S)	UCU or UCC or UCA or UCG or AGU or AGC
	Proline (Pro or P)	CCU or CCC or CCA or CCG
	Threonine (Thr or T)	ACU or ACC or ACA or ACG
	Alanine (Ala or A)	GCU or GCG or GCA or GCG
10	Tyrosine (Tyr or Y)	UAU or UAC
	Histidine (His or H)	CAU or CAC
	Glutamine (Gln or Q)	CAA or CAG
	Asparagine (Asn or N)	AAU or AAC
	Lysine (Lys or K)	AAA or AAG
15	Aspartic Acid (Asp or D)	GAU or GAC
	Glutamic Acid (Glu or E)	GAA or GAG
	Cysteine (Cys or C)	UGU or UGC
	Arginine (Arg or R)	CGU or CGC or CGA or CGG or AGA or AGG
	Glycine (Gly or G)	GGU or GGC or GGA or GGG
20	Tryptophan (Trp or W)	UGG
	Termination codon	UAA (ochre) or UAG (amber) or UGA (opal)

It should be understood that the codons specified above are for RNA sequences. The corresponding codons for DNA have a T substituted for U.

25

Mutations can be made in SEQ ID NOS: 1, 3, 5, 7 or 9 such that a particular codon is changed to a codon which codes for a different amino acid. Such a mutation is generally made by making the fewest nucleotide changes possible. A substitution mutation of this sort can be made to change an amino acid in the resulting protein in a non-conservative manner (i.e., by changing the codon from an amino acid belonging to a grouping of amino acids having a particular size or characteristic to an amino acid belonging to another grouping) or in a conservative manner (i.e., by changing the codon from an amino acid belonging to a grouping of amino acids having a particular

size or characteristic to an amino acid belonging to the same grouping). Such a conservative change generally leads to less change in the structure and function of the resulting protein. A non-conservative change is more likely to alter the structure, activity or function of the resulting protein. The present invention should be

5 considered to include sequences containing conservative changes which do not significantly alter the activity or binding characteristics of the resulting protein.

Two amino acid sequences are "substantially homologous" when at least about 70% of the amino acid residues (preferably at least about 80%, and most preferably at least 10 about 90 or 95%) are identical, or represent conservative substitutions.

A "heterologous" region of the DNA construct is an identifiable segment of DNA within a larger DNA molecule that is not found in association with the larger molecule in nature. Thus, when the heterologous region encodes a mammalian gene, the gene 15 will usually be flanked by DNA that does not flank the mammalian genomic DNA in the genome of the source organism. Another example of a heterologous coding sequence is a construct where the coding sequence itself is not found in nature (e.g., a cDNA where the genomic coding sequence contains introns, or synthetic sequences having codons different than the native gene). Allelic variations or naturally-occurring 20 mutational events do not give rise to a heterologous region of DNA as defined herein.

A DNA sequence is "operatively linked" to an expression control sequence when the expression control sequence controls and regulates the transcription and translation of that DNA sequence. The term "operatively linked" includes having an appropriate 25 start signal (e.g., ATG) in front of the DNA sequence to be expressed and maintaining the correct reading frame to permit expression of the DNA sequence under the control of the expression control sequence and production of the desired product encoded by the DNA sequence. If a gene that one desires to insert into a recombinant DNA molecule does not contain an appropriate start signal, such a start signal can be 30 inserted in front of the gene.

Further this invention also provides a vector which comprises the above-described nucleic acid molecule. The promoter may be, or is identical to, a bacterial, yeast,

insect or mammalian promoter. Further, the vector may be a plasmid, cosmid, yeast artificial chromosome (YAC), bacteriophage or eukaryotic viral DNA. Other numerous vector backbones known in the art as useful for expressing protein may be employed. Such vectors include, but are not limited to: adenovirus, simian virus 40

5 (SV40), cytomegalovirus (CMV), mouse mammary tumor virus (MMTV), Moloney murine leukemia virus, DNA delivery systems, i.e. liposomes, and expression plasmid delivery systems. Such vectors may be obtained commercially or assembled from the sequences described by methods well-known in the art.

10 This invention also provides a host vector system for the production of a polypeptide which comprises the vector of a suitable host cell. A wide variety of unicellular host cells are also useful in expressing the DNA sequences of this invention. These hosts may include well known eukaryotic and prokaryotic hosts, such as strains of *E. coli*, *Pseudomonas*, *Bacillus*, *Streptomyces*, fungi such as yeasts, and animal cells, such as

15 CHO, RL1, B-W and L-M cells, African Green Monkey kidney cells (e.g., COS 1, COS 7, BSC1, BSC40, and BMT10), insect cells (e.g., Sf9), and human cells and plant cells in tissue culture.

A wide variety of host/expression vector combinations may be employed in expressing

20 the DNA sequences of this invention. Useful expression vectors, for example, may consist of segments of chromosomal, non-chromosomal and synthetic DNA sequences. Suitable vectors include derivatives of SV40 and known bacterial plasmids, e.g., *E. coli* plasmids col El, pCR1, pBR322, pMB9 and their derivatives, plasmids such as RP4; phage DNAs, e.g., the numerous derivatives of phage  $\lambda$ , M13

25 and filamentous single stranded phage DNA; yeast plasmids such as the  $2\mu$  plasmid or derivatives thereof; vectors useful in eukaryotic cells, such as vectors useful in insect or mammalian cells; vectors derived from combinations of plasmids and phage DNAs, such as plasmids that have been modified to employ phage DNA or other expression control sequences; and the like.

30 Any of a wide variety of expression control sequences -- sequences that control the expression of a DNA sequence operatively linked to it -- may be used in these vectors to express the DNA sequences of this invention. Such useful expression control

sequences include, for example, the early or late promoters of SV40, CMV, vaccinia, polyoma or adenovirus, the *lac* system, the *trp* system, the *TAC* system, the *TRC* system, the *LTR* system, the major operator and promoter regions of phage  $\lambda$ , the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase or

5 other glycolytic enzymes, the promoters of acid phosphatase (e.g., Pho5), the promoters of the yeast  $\alpha$ -mating factors, and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof.

10 It will be understood that not all vectors, expression control sequences and hosts will function equally well to express the DNA sequences of this invention. Neither will all hosts function equally well with the same expression system. However, one skilled in the art will be able to select the proper vectors, expression control sequences, and hosts without undue experimentation to accomplish the desired expression without

15 departing from the scope of this invention. For example, in selecting a vector, the host must be considered because the vector must function in it. The vector's copy number, the ability to control that copy number, and the expression of any other proteins encoded by the vector, such as antibiotic markers, will also be considered.

20 In selecting an expression control sequence, a variety of factors will normally be considered. These include, for example, the relative strength of the system, its controllability, and its compatibility with the particular DNA sequence or gene to be expressed, particularly as regards potential secondary structures. Suitable unicellular hosts will be selected by consideration of, e.g., their compatibility with the chosen

25 vector, their secretion characteristics, their ability to fold proteins correctly, and their fermentation requirements, as well as the toxicity to the host of the product encoded by the DNA sequences to be expressed, and the ease of purification of the expression products.

30 This invention further provides a method of producing a polypeptide which comprises growing the above-described host vector system under suitable conditions permitting the production of the polypeptide and recovering the polypeptide so produced.

As used herein, "pg" means picogram, "ng" means nanogram, "ug" or " $\mu$ g" mean microgram, "mg" means milligram, "ul" or " $\mu$ l" mean microliter, "ml" means milliliter, "l" means liter.

5 The present invention extends to the preparation of antisense oligonucleotides and ribozymes that may be used to interfere with the expression of one or more Ema protein at the translational level. This approach utilizes antisense nucleic acid and ribozymes to block translation of a specific mRNA, either by masking that mRNA with an antisense nucleic acid or cleaving it with a ribozyme.

10

Antisense nucleic acids are DNA or RNA molecules that are complementary to at least a portion of a specific mRNA molecule. (See Weintraub, 1990; Marcus-Sekura, 1988.) In the cell, they hybridize to that mRNA, forming a double stranded molecule. The cell does not translate an mRNA in this double-stranded form. Therefore, antisense 15 nucleic acids interfere with the expression of mRNA into protein. Oligomers of about fifteen nucleotides and molecules that hybridize to the AUG initiation codon will be particularly efficient, since they are easy to synthesize and are likely to pose fewer problems than larger molecules when introducing them into Ema-producing cells. Antisense methods have been used to inhibit the expression of many genes *in vitro* 20 (Marcus-Sekura, 1988; Hambor et al., 1988).

Ribozymes are RNA molecules possessing the ability to specifically cleave other single stranded RNA molecules in a manner somewhat analogous to DNA restriction endonucleases. Ribozymes were discovered from the observation that certain mRNAs 25 have the ability to excise their own introns. By modifying the nucleotide sequence of these RNAs, researchers have been able to engineer molecules that recognize specific nucleotide sequences in an RNA molecule and cleave it (Cech, 1988.). Because they are sequence-specific, only mRNAs with particular sequences are inactivated.

30 Investigators have identified two types of ribozymes, *Tetrahymena*-type and "hammerhead"-type. (Hasselhoff and Gerlach, 1988) *Tetrahymena*-type ribozymes recognize four-base sequences, while "hammerhead"-type recognize eleven- to eighteen-base sequences. The longer the recognition sequence, the more likely it is to

occur exclusively in the target mRNA species. Therefore, hammerhead-type ribozymes are preferable to *Tetrahymena*-type ribozymes for inactivating a specific mRNA species, and eighteen base recognition sequences are preferable to shorter recognition sequences.

5

*Antibodies*

This invention further provides an antibody capable of specifically recognizing or binding to the isolated Ema polypeptide of the present invention. The antibody may be 10 a monoclonal or polyclonal antibody. Further, the antibody may be labeled with a detectable marker that is either a radioactive, calorimetric, fluorescent, or a luminescent marker. The labeled antibody may be a polyclonal or monoclonal antibody. In one embodiment, the labeled antibody is a purified labeled antibody. Methods of labeling antibodies are well known in the art.

15

In a further aspect, the present invention provides a purified antibody to a bacterial Ema polypeptide, particularly a streptococcal Ema polypeptide. In a still further aspect, the present invention provides a purified antibody to a Group B streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE.

20

Antibodies against the isolated polypeptides of the present invention include naturally raised and recombinantly prepared antibodies. These may include both polyclonal and monoclonal antibodies prepared by known genetic techniques, as well as bi-specific (chimeric) antibodies, and antibodies including other functionalities suiting them for 25 diagnostic use. Such antibodies can be used in immunoassays to diagnose infection with a particular strain or species of bacteria. The antibodies can also be used for passive immunization to treat an infection with Group B streptococcal bacteria. These antibodies may also be suitable for modulating bacterial adherence and/or invasion including but not limited to acting as competitive agents.

30

The present invention provides a monoclonal antibody to a Group B streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. The invention thereby extends to an immortal cell line that produces a monoclonal antibody

to a Group B streptococcal poypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE.

An antibody to an Ema polypeptide, particularly selected from EmaA, EmaB, EmaC.

5 EmaD or EmaE, labeled with a detectable label is further provided. In particular embodiments, the label may selected from the group consisting of an enzyme, a chemical which fluoresces, and a radioactive element.

The term "antibody" includes, by way of example, both naturally occurring and non-

10 naturally occurring antibodies. Specifically, the term "antibody" includes polyclonal and monoclonal antibodies, and fragments thereof. Furthermore, the term "antibody" includes chimeric antibodies and wholly synthetic antibodies, and fragments thereof. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library.

15

An "antibody" is any immunoglobulin, including antibodies and fragments thereof, that binds a specific epitope. The term encompasses polyclonal, monoclonal, and chimeric antibodies, the last mentioned described in further detail in U.S. Patent Nos. 4,816,397 and 4,816,567.

20

An "antibody combining site" is that structural portion of an antibody molecule comprised of heavy and light chain variable and hypervariable regions that specifically binds antigen.

25

The phrase "antibody molecule" in its various grammatical forms as used herein contemplates both an intact immunoglobulin molecule and an immunologically active portion of an immunoglobulin molecule.

30

Exemplary antibody molecules are intact immunoglobulin molecules, substantially intact immunoglobulin molecules and those portions of an immunoglobulin molecule that contains the paratope, including those portions known in the art as Fab, Fab', F(ab')<sub>2</sub> and F(v), which portions are preferred for use in the therapeutic methods described herein.

Fab and F(ab')<sub>2</sub> portions of antibody molecules are prepared by the proteolytic reaction of papain and pepsin, respectively, on substantially intact antibody molecules by methods that are well-known. See for example, U.S. Patent No. 4,342,566 to Theofilopolous et al. Fab' antibody molecule portions are also well-known and are

5 produced from F(ab')<sub>2</sub> portions followed by reduction of the disulfide bonds linking the two heavy chain portions as with mercaptoethanol, and followed by alkylation of the resulting protein mercaptan with a reagent such as iodoacetamide. An antibody containing intact antibody molecules is preferred herein.

10 The phrase "monoclonal antibody" in its various grammatical forms refers to an antibody having only one species of antibody combining site capable of immunoreacting with a particular antigen. A monoclonal antibody thus typically displays a single binding affinity for any antigen with which it immunoreacts. A monoclonal antibody may therefore contain an antibody molecule having a plurality of

15 antibody combining sites, each immunospecific for a different antigen; e.g., a bispecific (chimeric) monoclonal antibody.

Various procedures known in the art may be used for the production of polyclonal antibodies to polypeptide or derivatives or analogs thereof (see, e.g., *Antibodies -- A Laboratory Manual*, Harlow and Lane, eds., Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York, 1988). For the production of antibody, various host animals can be immunized by injection with the Group B streptococcal Ema polypeptide, an immunogenic fragment thereof, or a derivative (e.g., fragment or fusion protein) thereof, including but not limited to rabbits, mice, rats, sheep, goats, etc. In one embodiment, the polypeptide can be conjugated to an immunogenic carrier, e.g., bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH). Various adjuvant may be used to increase the immunological response, depending on the host species.

30 For preparation of monoclonal antibodies, or fragment, analog, or derivative thereof, any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used (see, e.g., *Antibodies -- A Laboratory Manual*, Harlow and Lane, eds., Cold Spring Harbor Laboratory Press: Cold Spring Harbor,

New York, 1988). These include but are not limited to the hybridoma technique originally developed by Kohler and Milstein (1975, *Nature* 256:495-497), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, *Immunology Today* 4:72), and the EBV-hybridoma technique to produce human 5 monoclonal antibodies (Cole et al., 1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96). Monoclonal antibodies can be produced in germ-free animals utilizing recent technology (PCT/US90/02545). Human antibodies may be used and can be obtained by using human hybridomas (Cote et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:2026-2030) or by transforming human B cells with EBV 10 virus *in vitro* (Cole et al., 1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, pp. 77-96). In fact, according to the invention, techniques developed for the production of "chimeric antibodies" (Morrison et al., 1984, *J. Bacteriol.* 159:870; Neuberger et al., 1984, *Nature* 312:604-608; Takeda et al., 1985, *Nature* 314:452-454) by splicing the genes from a mouse antibody molecule specific for a polypeptide 15 together with genes from a human antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention. Such human or humanized chimeric antibodies are preferred for use in therapy of human infections or diseases, since the human or humanized antibodies are much less likely than xenogenic antibodies to induce an immune response, in particular an allergic response, 20 themselves. An additional embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries (Huse et al., 1989, *Science* 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for the polypeptide, or its derivatives, or analogs.

25 Antibody fragments which contain the idiotype of the antibody molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')<sub>2</sub> fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragment, and the Fab fragments which can be 30 generated by treating the antibody molecule with papain and a reducing agent.

In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, e.g., radioimmunoassay, ELISA

(enzyme-linked immunosorbant assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, *in situ* immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (*e.g.*, gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

Antibodies can be labeled for detection *in vitro*, *e.g.*, with labels such as enzymes, fluorophores, chromophores, radioisotopes, dyes, colloidal gold, latex particles, and chemiluminescent agents. Alternatively, the antibodies can be labeled for detection *in vivo*, *e.g.*, with radioisotopes (preferably technetium or iodine); magnetic resonance shift reagents (such as gadolinium and manganese); or radio-opaque reagents.

The labels most commonly employed for these studies are radioactive elements, enzymes, chemicals which fluoresce when exposed to ultraviolet light, and others. A number of fluorescent materials are known and can be utilized as labels. These include, for example, fluorescein, rhodamine, auramine, Texas Red, AMCA blue and Lucifer Yellow. A particular detecting material is anti-rabbit antibody prepared in goats and conjugated with fluorescein through an isothiocyanate. The polypeptide can also be labeled with a radioactive element or with an enzyme. The radioactive label can be detected by any of the currently available counting procedures. The preferred isotope may be selected from  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{36}\text{Cl}$ ,  $^{51}\text{Cr}$ ,  $^{57}\text{Co}$ ,  $^{58}\text{Co}$ ,  $^{59}\text{Fe}$ ,  $^{90}\text{Y}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ , and  $^{186}\text{Re}$ .

Enzyme labels are likewise useful, and can be detected by any of the presently utilized calorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques. The enzyme is conjugated to the selected particle by reaction with bridging molecules such as carbodiimides, diisocyanates, glutaraldehyde and the

like. Many enzymes which can be used in these procedures are known and can be utilized. The preferred are peroxidase,  $\beta$ -glucuronidase,  $\beta$ -D-glucosidase,  $\beta$ -D-galactosidase, urease, glucose oxidase plus peroxidase and alkaline phosphatase. U.S. Patent Nos. 3,654,090; 3,850,752; and 4,016,043 are referred to by way of 5 example for their disclosure of alternate labeling material and methods.

#### Diagnostic Applications

10 The present invention also relates to a variety of diagnostic applications, including methods for identifying or monitoring streptococcal infections. The present invention also relates to a variety of diagnostic applications, including methods for identifying or monitoring Group B streptococcal infections. The present invention further relates to diagnostic applications or methods utilizing the polypeptides of the present invention, 15 immunogenically recognized fragments thereof, or antibodies thereto. Such methods include the analysis and evaluation of agents, analogs or compounds which modulate the activity of the Ema polypeptides. The Ema polypeptides may also be utilized in diagnostic methods and assays for monitoring and determining immunological response and antibody response upon streptococcal infection or vaccination.

20 As described in detail above, antibody(ies) to the Ema polypeptides or fragments thereof can be produced and isolated by standard methods including the well known hybridoma techniques. For convenience, the antibody(ies) to the Ema polypeptides will be referred to herein as  $Ab_1$  and antibody(ies) raised in another species as  $Ab_2$ .

25 The presence of streptococci in cells can be ascertained by the usual immunological procedures applicable to such determinations. A number of useful procedures are known. Procedures which are especially useful utilize either the Ema polypeptides labeled with a detectable label, antibody against the Ema polypeptides labeled with a 30 detectable label, or secondary antibody labeled with a detectable label.

The procedures and their application are all familiar to those skilled in the art and accordingly may be utilized within the scope of the present invention. The

"competitive" procedure, is described in U.S. Patent Nos. 3,654,090 and 3,850,752.

The "sandwich" procedure, is described in U.S. Patent Nos. RE 31,006 and 4,016,043.

Still other procedures are known such as the "double antibody," or "DASP" procedure.

5

In each instance, the Ema polypeptides forms complexes with one or more antibody(ies) or binding partners and one member of the complex is labeled with a detectable label. The fact that a complex has formed and, if desired, the amount thereof, can be determined by known methods applicable to the detection of labels.

10

In a further embodiment of this invention, commercial test kits suitable for use by a medical specialist may be prepared to determine the presence or absence of streptococci, particularly of streptococci expressing one or more Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. In as much as the 15 *ema* locus, as described herein, is found in the genomic DNA of many, if not all, serotypes of Group B streptococci, it is a useful general marker for Group B streptococci. In as much as Ema homologs exist in other species of streptococci, including Group A and *S. pneumoniae*, it is a useful general marker for streptococci. Therefore, commercial test kits for determining the presence or absence of 20 streptococci, and thereby determining whether an individual is infected with streptococci are contemplated and provided by this invention. Therefore, commercial test kits for determining the presence or absence of Group B streptococci, and thereby determining whether an individual is infected with Group B streptococci are contemplated and provided by this invention.

25

The present invention includes methods for determining and monitoring infection by streptococci by detecting the presence of a streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. In a particular such method, the streptococcal Ema polypeptide is measured by:

30

- a. contacting a sample in which the presence or activity of a Streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE is suspected with an antibody to the said streptococcal

polypeptide under conditions that allow binding of the streptococcal polypeptide to the antibody to occur; and

- b. detecting whether binding has occurred between the streptococcal polypeptide from the sample and the antibody;

5 wherein the detection of binding indicates the presence or activity of the streptococcal polypeptide in the sample.

The present invention includes methods for determining and monitoring infection by Group B streptococci by detecting the presence of a Group B streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. In a particular such method, the streptococcal Ema polypeptide is measured by:

- a. contacting a sample in which the presence or activity of a Group B Streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE is suspected with an antibody to the said Group B streptococcal polypeptide under conditions that allow binding of the Group B streptococcal polypeptide to the antibody to occur; and
- b. detecting whether binding has occurred between the Group B streptococcal polypeptide from the sample and the antibody;

20 wherein the detection of binding indicates the presence or activity of the a Group B streptococcal polypeptide in the sample.

The present invention further provides a method for detecting the presence of a bacterium having a gene encoding a Group B polypeptide selected from the group of *emaA*, *emaB*, *emaC*, *emaD* and *emaE*, comprising:

- a. contacting a sample in which the presence or activity of the bacterium is suspected with an oligonucleotide which hybridizes to a Group B streptococcal polypeptide gene selected from the group of *emaA*, *emaB*, *emaC*, *emaD* and *emaE*, under conditions that allow specific hybridization of the oligonucleotide to the gene to occur; and
- b. detecting whether hybridization has occurred between the oligonucleotide and the gene;

wherein the detection of hybridization indicates that presence or activity of the bacterium in the sample.

The invention includes an assay system for screening of potential compounds effective 5 to modulate the activity of a bacterial Ema protein of the present invention. In one instance, the test compound, or an extract containing the compound, could be administered to a cellular sample expressing the particular Ema protein to determine the compound's effect upon the activity of the protein by comparison with a control. In a further instance the test compound, or an extract containing the compound, could 10 be administered to a cellular sample expressing the Ema protein to determine the compound's effect upon the activity of the protein, and thereby on adherence of said cellular sample to host cells, by comparison with a control.

Accordingly, a test kit may be prepared for the demonstration of the presence of Ema 15 polypeptide or Ema activity in cells, comprising:

(a) a predetermined amount of at least one labeled immunochemically reactive component obtained by the direct or indirect attachment of the Ema polypeptide or a specific binding partner thereto, to a detectable label;  
(b) other reagents; and  
20 (c) directions for use of said kit.

More specifically, the diagnostic test kit may comprise:

(a) a known amount of the Ema polypeptide as described above (or a binding partner) generally bound to a solid phase to form an immunosorbent, or in the 25 alternative, bound to a suitable tag, or plural such end products, etc. (or their binding partners) one of each;

(b) if necessary, other reagents; and  
(c) directions for use of said test kit.

30 In a further variation, the test kit may be prepared and used for the purposes stated above, which operates according to a predetermined protocol (e.g. "competitive," "sandwich," "double antibody," etc.), and comprises:

- (a) a labeled component which has been obtained by coupling the Ema polypeptide to a detectable label;
- (b) one or more additional immunochemical reagents of which at least one reagent is a ligand or an immobilized ligand, which ligand is selected from the group consisting of:
  - (i) a ligand capable of binding with the labeled component (a);
  - (ii) a ligand capable of binding with a binding partner of the labeled component (a);
  - (iii) a ligand capable of binding with at least one of the component(s) to be determined; and
  - (iv) a ligand capable of binding with at least one of the binding partners of at least one of the component(s) to be determined; and
- (c) directions for the performance of a protocol for the detection and/or determination of one or more components of an immunochemical reaction between the Ema polypeptide and a specific binding partner thereto.

In accordance with the above, an assay system for screening potential drugs effective to modulate the activity of the Ema polypeptide may be prepared. The Ema polypeptide may be introduced into a test system, and the prospective drug may also be introduced into the resulting cell culture, and the culture thereafter examined to observe any changes in the Ema polypeptide activity of the cells, due either to the addition of the prospective drug alone, or due to the effect of added quantities of the known Ema polypeptide.

25

#### Therapeutic Applications

The therapeutic possibilities that are raised by the existence of the Group B streptococcal Ema polypeptides EmaA, EmaB, EmaC, EmaD and EmaE derive from the fact that the Ema polypeptides of the present invention are found generally in various serotypes of Group B streptococci. In addition, broader therapeutic possibilities that are raised by the existence of Ema homologous polypeptides in various distinct species of streptococci, including *S. pneumoniae* and *S. pyogenes*. In addition Ema homologous polypeptides have been identified in *E. faecalis* and *C.*

*diphtheriae*. Of particular relevance to their suitability in vaccine and immunological therapy is that the Ema A, EmaB, and EmaC polypeptides possess N-terminal sequences consistent with a signal peptide, indicating secretion from the bacterial cell and at least partial extracellular localization. In addition, the EmaA, EmaB, EmaC, 5 EmaD and EmaE polypeptides demonstrate homology to distinct bacterial proteins involved in or implicated in bacterial adhesion and invasion. Thus, the Ema polypeptides are anticipated to be involved in or required for streptococcal adhesion to and/or invasion of cells, critical for bacterial survival and virulence in the human host.

10

*Modulators of Extracellular Matrix Adhesin Protein*

Thus, in instances where it is desired to reduce or inhibit the effects resulting from the extracellular matrix adhesin protein Ema of the present invention, an appropriate inhibitor of one or more of the Ema proteins, particularly EmaA, EmaB, EmaC, EmaD 15 and EmaE could be introduced to block the activity of one or more Ema protein.

The present invention contemplates screens for a modulator of an Ema polypeptide, in particular modulating adhesion or invasion facilitated by EmaA, EmaB, EmaC, EmaD or EmaE. In one such embodiment, an expression vector containing the Ema 20 polypeptide of the present invention, or a derivative or analog thereof, is placed into a cell in the presence of at least one agent suspected of exhibiting Ema polypeptide modulator activity. The cell is preferably a bacterial cell, most preferably a streptococcal cell, or a bacterial host cell. The amount of adhesion or binding activity is determined and any such agent is identified as a modulator when the amount of 25 adhesion or binding activity in the presence of such agent is different than in its absence. The vectors may be introduced by any of the methods described above. In a related embodiment the GBS Ema polypeptide is expressed in streptococci and the step of determining the amount of adhesion or binding activity is performed by determining the amount of binding to bacterial host cells cells *in vitro*.

30

When the amount of adhesion or binding activity in the presence of the modulator is greater than in its absence, the modulator is identified as an agonist or activator of the Ema polypeptide, whereas when the amount of adhesion binding activity in the

presence of the modulator is less than in its absence, the modulator is identified as an antagonist or inhibitor of the Ema polypeptide. As any person having skill in the art would recognize, such determinations as these and those below could require some form of statistical analysis, which is well within the skill in the art.

5

Natural effectors found in cells expressing Ema polypeptide can be fractionated and tested using standard effector assays as exemplified herein, for example. Thus an agent that is identified can be a naturally occurring adhesion or binding modulator. Alternatively, natural products libraries can be screened using the assays of the present 10 invention for screening such agents.,

Another approach uses recombinant bacteriophage to produce large libraries. Using the "phage method" [Scott and Smith, 1990, *Science* 249:386-390 (1990); Cwirla, et al., *Proc. Natl. Acad. Sci.*, 87:6378-6382 (1990); Devlin et al., *Science*, 249:404-406 15 (1990)], very large libraries can be constructed ( $10^6$ - $10^8$  chemical entities). Yet another approach uses primarily chemical methods, of which the Geysen method [Geysen et al., *Molecular Immunology* 23:709-715 (1986); Geysen et al. *J. Immunologic Method* 102:259-274 (1987)] and the method of Fodor et al. [*Science* 251:767-773 (1991)] are examples. Furka et al. [*14th International Congress of 20 Biochemistry, Volume 5*, Abstract FR:013 (1988); Furka, *Int. J. Peptide Protein Res.* 37:487-493 (1991)], Houghton [U.S. Patent No. 4,631,211, issued December 1986] and Rutter et al. [U.S. Patent No. 5,010,175, issued April 23, 1991] describe methods to produce a mixture of peptides that can be tested.

25 In another aspect, synthetic libraries [Needels et al., *Proc. Natl. Acad. Sci. USA* 90:10700-4 (1993); Ohlmeyer et al., *Proc. Natl. Acad. Sci. USA* 90:10922-10926 (1993); Lam et al., International Patent Publication No. WO 92/00252; Kocis et al., International Patent Publication No. WO 9428028, each of which is incorporated herein by reference in its entirety], and the like can be used to screen for such an agent.

30

This invention provides antagonist or blocking agents which include but are not limited to: peptide fragments, mimetic, a nucleic acid molecule, a ribozyme, a polypeptide, a small molecule, a carbohydrate molecule, a monosaccharide, an oligosaccharide or an

antibody. Also, agents which competitively block or inhibit streptococcal bacterium are contemplated by this invention. This invention provides an agent which comprises an inorganic compound, a nucleic acid molecule, an oligonucleotide, an organic compound, a peptide, a peptidomimetic compound, or a protein which inhibits the 5 polypeptide.

### *Vaccines*

10 In a further aspect, the present invention extends to vaccines based on the Ema proteins described herein. The present invention provides a vaccine comprising one or more Group B streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable adjuvant. The present invention provides a vaccine comprising one or more bacterial Ema polypeptide 15 selected from the group of polypeptides comprising the amino acid sequence set out in any of SEQ ID NO: 23, 26, 29, 32 and 37, and a pharmaceutically acceptable adjuvant.

The present invention further provides a vaccine comprising one or more Group B 20 streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, further comprising one or more additional GBS antigen. The present invention further provides a vaccine comprising one or more Group B streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, further comprising one or more antigens selected from the group of the polypeptide 25 Spb1 or an immunogenic fragment thereof, the polypeptide Spb2 or an immunogenic fragment thereof, C protein alpha antigen or an immunogenic fragment thereof, Rib or an immunogenic fragment thereof, Lmb or an immunogenic fragment thereof, C5a-ase or an immunogenic fragment thereof, and Group B streptococcal polysaccharides or oligosaccharides.

30

In another aspect, the invention is directed to a vaccine for protection of an animal subject from infection with streptococci comprising an immunogenic amount of one or more streptococcal Ema polypeptide, or a derivative or fragment thereof. The Ema

polypeptide may be particularly selected from the group of EmaA, EmaB, EmaC, EmaD or EmaE, or a derivative or fragment thereof. In a further aspect, the invention is directed to a vaccine for protection of an animal subject from infection with streptococci comprising an immunogenic amount of one or more Ema polypeptide

5 EmaA, EmaB, EmaC, EmaD or EmaE, or a derivative or fragment thereof. In a further aspect, the invention is directed to a vaccine for protection of an animal subject from infection with GBS comprising an immunogenic amount of one or more Ema polypeptide EmaA, EmaB, EmaC, EmaD or EmaE, or a derivative or fragment thereof. Such a vaccine may contain the protein conjugated covalently to a

10 streptococcal or GBS bacterial polysaccharide or oligosaccharide or polysaccharide or oligosaccharide from one or more streptococcal or GBS serotypes.

This invention provides a vaccine which comprises a polypeptide bacterial Ema protein and a pharmaceutically acceptable adjuvant or carrier. In particular, a vaccine

15 is provided which comprises one or more Ema polypeptides selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE. This invention provides a vaccine which comprises a combination of at least one bacterial Ema protein selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE and at least one other Group B streptococcal protein particularly Spb1 and/or Spb2 and/or C protein alpha antigen,

20 and a pharmaceutically acceptable adjuvant or carrier. The Ema polypeptide may comprise an amino acid sequence of a Ema protein EmaA, EmaB, EmaC, EmaD, EmaE as set forth in FIGURES 2-6 and SEQ ID NOS: 2, 4, 6, 8 and 10.

This invention further provides a vaccine comprising an isolated nucleic acid encoding

25 a bacterial Ema polypeptide and a pharmaceutically acceptable adjuvant or carrier. This invention further provides a vaccine comprising an isolated nucleic acid encoding a streptococcal Ema polypeptide and a pharmaceutically acceptable adjuvant or carrier. This invention further provides a vaccine comprising an isolated nucleic acid encoding a GBS Ema polypeptide and a pharmaceutically acceptable adjuvant or carrier. This invention further provides a vaccine comprising isolated nucleic acid

30 encoding one or more GBS Ema polypeptide, particularly selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE and a pharmaceutically acceptable adjuvant

or carrier. The nucleic acid may comprise a nucleic acid sequence of a GBS Ema polypeptide as set forth in any of SEQ ID NOS:1, 3, 5, 7, or 9.

Active immunity against streptococci can be induced by immunization (vaccination) 5 with an immunogenic amount of the polypeptide, or peptide derivative or fragment thereof, and an adjuvant, wherein the polypeptide, or antigenic derivative or fragment thereof, is the antigenic component of the vaccine. The polypeptide, or antigenic derivative or fragment thereof, may be one antigenic component, in the presence of other antigenic components in a vaccine. For instance, the polypeptide of the present 10 invention may be combined with other known streptococcal polypeptides or poly/oligosaccharides, or immunogenic fragments thereof, including for instance GBS capsular polysaccharide, Spb1, Spb2, C protein alpha antigen, Rib, Lmb, and C5a-ase in a multi-component vaccine. Such multi-component vaccine may be utilized to enhance immune response, even in cases where the polypeptide of the present 15 invention elicits a response on its own. The polypeptide of the present invention may also be combined with existing vaccines, whole bacterial or capsule-based vaccines, alone or in combination with other GBS polypeptides, particularly Spb1 and/or Spb2 and/or C protein alpha antigen and/or Rib to enhance such existing vaccines.

20 The term "adjuvant" refers to a compound or mixture that enhances the immune response to an antigen. An adjuvant can serve as a tissue depot that slowly releases the antigen and also as a lymphoid system activator that non-specifically enhances the immune response (Hood et al., *Immunology, Second Ed.*, 1984, Benjamin/Cummings: Menlo Park, California, p. 384). Often, a primary challenge with an antigen alone, in 25 the absence of an adjuvant, will fail to elicit a humoral or cellular immune response. Adjuvant include, but are not limited to, complete Freund's adjuvant, incomplete Freund's adjuvant, saponin, mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil or hydrocarbon emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially 30 useful human adjuvant such as BCG (*bacille Calmette-Guerin*) and *Corynebacterium parvum*. Preferably, the adjuvant is pharmaceutically acceptable.

The invention further provides a vaccine which comprises a non-adherent, non-virulent mutant, including but not limited to the *ema*<sup>-</sup> mutants herein described and contemplated. Medaglini et al (Medaglini *et al* (1995) *Proc Natl Acad Sci USA* 92:6868-6872) and Oggioni and Pozzi (Oggioni, M.R. and Pozzi, G. (1996) *Gene* 169:85-90) have previously described the use of *Streptococcus gordonii*, a commensal bacterium of the human oral cavity, as live vaccine delivery vehicles and for heterologous gene expression. Such *ema*<sup>-</sup> mutant can therefore be utilized as a vehicle for expression of immunogenic proteins for the purposes of eliciting an immune response to such other proteins in the context of vaccines. Active immunity against Group B streptococci, can be induced by immunization (vaccination) with an immunogenic amount of the *ema*<sup>-</sup> vehicle expressing an immunogenic protein. Also contemplated by the present invention is the use of any such *ema*<sup>-</sup> mutant in expressing a therapeutic protein in the host in the context of other forms of therapy.

15 The polypeptide of the present invention, or fragments thereof, can be prepared in an admixture with an adjuvant to prepare a vaccine. Preferably, the polypeptide or peptide derivative or fragment thereof, used as the antigenic component of the vaccine is an antigen common to all or many serotypes of GBS bacteria, or common to closely related species of bacteria, for instance *Streptococcus*.

20 Vectors containing the nucleic acid-based vaccine of the invention can be introduced into the desired host by methods known in the art, *e.g.*, transfection, electroporation, micro injection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, lipofection (lysosome fusion), use of a gene gun, or a DNA vector transporter (see, *e.g.*, Wu *et al.*, 1992, *J. Biol. Chem.* 267:963-967; Wu and Wu, 1988, *J. Biol. Chem.* 263:14621-14624; Hartmut *et al.*, Canadian Patent Application No. 2,012,311, filed March 15, 1990).

30 The modes of administration of the vaccine or compositions of the present invention may comprise the use of any suitable means and/or methods for delivering the vaccine or composition to the host animal whereby they are immunostimulatively effective. Delivery modes may include, without limitation, parenteral administration methods, such as paracancerally, transmucosally, transdermally, intramuscularly, intravenously,

intradermally, subcutaneously, intraperitoneally, intraventricularly, intracranially and intratumorally. Preferably, since the desired result of vaccination is to elucidate an immune response to the antigen, and thereby to the pathogenic organism, administration directly, or by targeting or choice of a viral vector, indirectly, to

5 lymphoid tissues, *e.g.*, lymph nodes or spleen, is desirable. Since immune cells are continually replicating, they are ideal target for retroviral vector-based nucleic acid vaccines, since retroviruses require replicating cells. These vaccines and compositions can be used to immunize mammals, for example, by the intramuscular or parenteral routes, or by delivery to mucosal surfaces using microparticles, capsules, liposomes

10 and targeting molecules, such as toxins and antibodies. The vaccines and immunogenic compositions may be administered to mucosal surfaces by, for example, the nasal or oral (intragastric) routes. Alternatively, other modes of administration including suppositories may be desirable. For suppositories, binders and carriers may include, for example, polyalkylene glycols and triglycerides. Oral formulations may

15 include normally employed incipients, such as pharmaceutical grades of saccharine, cellulose and magnesium carbonate.

These compositions may take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 1 to 95% of the

20 immunogenic compositions of the present invention. The immunogenic compositions are administered in a manner compatible with the dosage formulation, and in such amount as to be therapeutically effective, protective and immunogenic. The quantity to be administered depends on the subject to the immunized, including, for example, the capacity of the subject's immune system to synthesize antibodies, and if needed, to

25 produce a cell-mediated, humoral or antibody-mediated immune response. Precise amounts of antigen and immunogenic composition to be administered depend on the judgement of the practitioner. However, suitable dosage ranges are readily determinable by those skilled in the art and may be of the order of micrograms to milligrams. Suitable regimes for initial administration and booster doses are also

30 variable, but may include an initial administration followed by subsequent administrations. The dosage of the vaccine may also depend on the route of administration and will vary according to the size of the host.

Passive immunity can be conferred to an animal subject suspected of suffering an infection with streptococci by administering antiserum, polyclonal antibodies, or a neutralizing monoclonal antibody against one or more Ema polypeptide of the invention to the patient. A combination of antibodies directed against one or more

5 Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, in combination with one or more of antibodies against Spb1, Spb2, Rib and C protein alpha antigen is also contemplated by the present invention. Although passive immunity does not confer long term protection, it can be a valuable tool for the treatment of a bacterial infection in a subject who has not been vaccinated. Passive

10 immunity is particularly important for the treatment of antibiotic resistant strains of bacteria, since no other therapy may be available. Preferably, the antibodies administered for passive immune therapy are autologous antibodies. For example, if the subject is a human, preferably the antibodies are of human origin or have been "humanized," in order to minimize the possibility of an immune response against the

15 antibodies. The active or passive vaccines of the invention can be used to protect an animal subject from infection by streptococcus, particularly Group B streptococcus.

Vaccines for GBS have been previously generated and tested. Preliminary vaccines used unconjugated purified polysaccharide. GBS polysaccharides and oligosaccharides are poorly immunogenic and fail to elicit significant memory and booster responses.

20 Baker et al immunized 40 pregnant women with purified serotype III capsular polysaccharide (Baker, C.J. et al. (1998) *New Engl J of Med* 319:1180-1185). Overall, only 57% of women with low levels of specific antibody responded to the the vaccine. The poor immunogenicity of purified polysaccharide antigen was further

25 demonstrated in a study in which thirty adult volunteers were immunized with a tetravalent vaccine composed of purified polysaccharide from serotypes Ia, Ib, II, and III (Kotloff, K.L. et al. (1996) *Vaccine* 14:446-450). Although safe, this vaccine was only modestly immunogenic, with only 13% of subjects responding to type Ib, 17% to type II, 33% responding to type Ia, and 70% responding to type III polysaccharide.

30 The poor immunogenicity of polysaccharide antigens prompted efforts to develop polysaccharide conjugate vaccines, whereby these polysaccharides or oligosaccharides are conjugated to protein carriers. Ninety percent of healthy adult women immunized with a type III polysaccharide-tetanus toxoid conjugate vaccine responded with a

4-fold rise in antibody concentration, compared to 50% immunized with plain polysaccharide (Kasper, D.L. et al (1996) *J of Clin Invest* **98**:2308-2314). A type Ia/Ib polysaccharide-tetanus toxoid conjugate vaccine was similarly more immunogenic in healthy adults than plain polysaccharide (Baker, C.J. et al (1999) *J Infect Dis* **179**:142-150).

The general method for the conjugation of polysaccharide is described in Wessels et al (Wessels, M.R. et al (1990) *J. Clin Investigation* **86**: 1428-1433). Prior to coupling with tetanus toxoid, aldehyde groups are introduced on the polysaccharide by 10 controlled periodate oxidation, resulting in the conversion of a portion of the sialic acid residues of the polysaccharide to residues of the 8-carbon analogue of sialic acid, 5-acetamido-3,5-dideoxy-D-galactosyloctulosonic acid. Tetanus toxoid is conjugated to the polysaccharide by reductive amination using free aldehyde groups present on the partially oxidized sialic acid residues. The preparation and conjugation of 15 oligosaccharides is described in Paoletti et al (Paoletti, L.C. et al (1990) *J. Biol Chem* **265**: 18278-18283). Purified capsular polysaccharide is depolymerized by enzymatic digestion using endo-beta-galactosidase produced by *Citrobacter freundii*. Following digestion, oligosaccharides are fractionated by gel filtration chromatography. Tetanus toxoid was covalently coupled via a synthetic spacer molecule to the reducing end of 20 the oligosaccharide by reductive amination.

Methods and vaccines comprising GBS conjugate vaccines, comprising capsular polysaccharide and protein are provided and described in U.S. Patent 5, 993,825, 5,843,461, 5,795,580, 5,302,386 and 4,356,263, which are incorporated herein by 25 reference in their entirety. These conjugate vaccines include polysaccharide-tetanus toxoid conjugate vaccines.

One polypeptide proposed to be utilized in a GBS vaccine is the repetitive GBS C protein alpha antigen, which contains up to nine tandemly repeated units of 82 30 amino acids (Michel, J.K. et al (1992) *PNAS USA* **89**: 10060-10064). The polypeptide, methods and vaccines thereof, including polysaccharide-conjugate vaccines generated therewith, are provided and described in U.S. Patent 5,968,521, 5,908,629, 5,858,362, 5,847,081, 5,843,461, 5,843,444, 5,820,860, and 5,648,241,

which are herein incorporated by reference in their entirety. Antibodies generated against C protein alpha antigen with a large numbers of repeats protect against infection, but GBS are able to change the structure of the protein by deleting one or more of the repeat regions and escape detection by these antibodies (Madoff, L.C. et al (1996) *PNAS USA* **93**: 4131-4136). This effect could theoretically be prevented by immunization with a protein with a lower number of repeat units, but the immunogenicity of the C protein alpha antigen is inversely related to the number of repeats - 65% of mice responded to immunization with the 9-repeat protein, but only 11% to a 1-repeat protein (Gravekamp, C. et al (1997) *Infect Immunity* **65**: 5216-5221). This is a disadvantage with any protein with a repetitive structure - it is common for bacteria to be able to alter or reassort these genes to alter the proteins exposed on their surface.

Typical doses for a vaccine composed of a protein antigen are in the range of 2.5-50 ug of total protein per dose. Typical doses for a polysaccharide-protein conjugate vaccine are 7.5-25 ug of polysaccharide and 1.25-250 ug of carrier protein. These types of vaccines are almost always given intramuscularly. Dosing schedules of a vaccine can be readily determined by the skilled artisan, particularly by comparison of similar vaccines, including other GBS vaccines. If used as a universal vaccine, a GBS vaccine would be integrated into the routine immunization schedule. Most similar vaccines require a primary series of immunizations (usually 2 or 3 doses at 2 month intervals beginning at 1 or 2 months of age) and a single booster at 12-18 months of age. A smaller number of doses or a single dose may be adequate in older children (over a year of age). For immunization of pregnant women, an exemplary immunization schedule would be a single dose given in the second or early third trimester. For immunization of non-pregnant adults, a single dose would probably be used. The requirement for subsequent booster doses in adults is difficult to predict - this would be based on the immunogenicity of the vaccine and ongoing surveillance of vaccine efficacy.

In a further aspect, the present invention provides an immunogenic composition comprising one or more bacterial Ema polypeptides. In a still further aspect, the present invention provides an immunogenic composition comprising one of more streptococcal Ema polypeptides. In a particular aspect, the present invention provides

5 an immunogenic composition comprising one of more Group B streptococcal polypeptides selected from the group of EmaA, EmaB, EmaC, EmaD, EmaE and a fragment thereof, and a pharmaceutically acceptable adjuvant. Immunogenic compositions may comprise a combination of one or more Group B Ema polypeptide, or an immunogenic polypeptide fragment thereof, with one or more additional GBS

10 polypeptide or GBS capsular polysaccharide or oligosaccharide.

The present invention further provides an immunogenic composition comprising one or more Group B streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, further comprising one or more antigens selected from the

15 group of the polypeptide Spb1 or an immunogenic fragment thereof, the polypeptide Spb2 or an immunogenic fragment thereof, C protein alpha antigen or an immunogenic fragment thereof, Rib or an immunogenic fragment thereof, and Group B streptococcal polysaccharides or oligosaccharides.

20

*Pharmaceutical Compositions*

The invention provides pharmaceutical compositions comprising a bacterial Ema polypeptide, particularly a streptococcal Ema polypeptide, and a pharmaceutically acceptable carrier. The invention provides pharmaceutical compositions comprising a

25 Group B streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable carrier. The present invention further provides pharmaceutical compositions comprising one or more GBS Ema polypeptide, or a fragment thereof, in combination with one or more of GBS polypeptide Spb1, Spb2, C protein alpha antigen, Rib, a Group B streptococcal

30 polysaccharide or oligosaccharide vaccine, and an anti-streptococcal vaccine.

Such pharmaceutical composition for preventing streptococcal attachment to mucosal surface may include antibody to Ema polypeptide EmaA, EmaB, EmaC, EmaD or

EmaE or any combination of antibodies to one or more such Ema polypeptide. In addition, any such composition may further include antibody to GBS polypeptides Spb1, Spb2, C protein alpha antigen, or Rib. Blocking adherence using such antibody blocks the initial step in infection thereby reducing colonization. This in turn decreases 5 person to person transmission and prevents development of symptomatic disease.

The present invention provides a pharmaceutical composition comprising an antibody to a Group B streptococcal protein selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable carrier. The invention further 10 provides a pharmaceutical composition comprising a combination of at least two antibodies to Group B streptococcal proteins and a pharmaceutically acceptable carrier, wherein at least one antibody to a protein selected from the group of EmaA, EmaB, EmaC, EmaD, EmaE, is combined with at least one antibody to a protein selected from the group of Spb1, Spb2, Rib, and C protein alpha antigen.

15

It is still a further object of the present invention to provide a method for the prevention or treatment of mammals to control the amount or activity of streptococci, so as to treat or prevent the adverse consequences of invasive, spontaneous, or idiopathic pathological states.

20

It is still a further object of the present invention to provide a method for the prevention or treatment of mammals to control the amount or activity of Group B streptococci, so as to treat or prevent the adverse consequences of invasive, spontaneous, or idiopathic pathological states.

25

The invention provides a method for preventing infection with a bacterium that expresses a streptococcal Ema polypeptide comprising administering an immunogenically effective dose of a vaccine comprising an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE to a subject.

30

The invention further provides a method for preventing infection with a bacterium that expresses a Group B streptococcal Ema polypeptide comprising administering an

immunogenically effective dose of a vaccine comprising an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE to a subject.

The present invention is directed to a method for treating infection with a bacterium

5 that expresses a Group B streptococcal Ema polypeptide comprising administering a therapeutically effective dose of a pharmaceutical composition comprising an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable carrier to a subject.

10 The invention further provides a method for treating infection with a bacterium that expresses a Group B streptococcal Ema polypeptide comprising administering a therapeutically effective dose of a pharmaceutical composition comprising an antibody to an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable carrier to a subject.

15 In a further aspect, the invention provides a method of inducing an immune response in a subject which has been exposed to or infected with a Group B streptococcal bacterium comprising administering to the subject an amount of the pharmaceutical composition comprising an Ema polypeptide selected from the group of EmaA, EmaB,

20 EmaC, EmaD and EmaE, and a pharmaceutically acceptable carrier, thereby inducing an immune response.

The invention still further provides a method for preventing infection by a streptococcal bacterium in a subject comprising administering to the subject an amount

25 of a pharmaceutical composition comprising an antibody to an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE and a pharmaceutically acceptable carrier or diluent, thereby preventing infection by a streptococcal bacterium.

30 The invention further provides an *ema* mutant bacteria which is non-adherent and/or non-invasive to cells and which is mutated in one or more genes selected from the group of *emaA*, *emaB*, *emaC*, *emaD* and *emaE*. Particularly, such *ema* mutant is a Group B streptococcal bacteria. Such non-adherent and/or non-invasive *ema* mutant

bacteria can further be utilized in expressing other immunogenic or therapeutic proteins for the purposes of eliciting immune responses to any such other proteins in the context of vaccines and in other forms of therapy.

- 5 This invention provides a method of inhibiting colonization of host cells in a subject which has been exposed to or infected with a streptococcal bacterium comprising administering to the subject an amount of a pharmaceutical composition comprising an Ema polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, thereby inducing an immune response. The therapeutic peptide that blocks
- 10 colonization is delivered by the respiratory mucosal. The pharmaceutical composition comprises the polypeptide selected from the group of SEQ ID NO: 2, 4, 6, 8 and 10.

As used herein, "pharmaceutical composition" could mean therapeutically effective amounts of polypeptide products or antibodies of the invention together with suitable diluents, preservatives, solubilizers, emulsifiers, adjuvant and/or carriers useful in therapy against bacterial infection or in inducing an immune response. A "therapeutically effective amount" as used herein refers to that amount which provides a therapeutic effect for a given condition and administration regimen. Such compositions are liquids or lyophilized or otherwise dried formulations and include diluents of various buffer content (e.g., Tris-HCl., acetate, phosphate), pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts), solubilizing agents (e.g., glycerol, polyethylene glycerol), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimerosal, benzyl alcohol, parabens), bulking substances or tonicity modifiers (e.g., lactose, mannitol), covalent attachment of polymers such as polyethylene glycol to the protein, complexation with metal ions, or incorporation of the material into or onto particulate preparations of polymeric compounds such as polylactic acid, polglycolic acid, hydrogels, etc, or onto liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts, or spheroplasts. Such compositions will influence the physical state, solubility, stability, rate of in vivo release, and rate of in vivo clearance of the polypeptides of the present invention. The choice of compositions will depend on the physical and chemical properties of the polypeptide. Controlled or sustained release compositions include

formulation in lipophilic depots (e.g., fatty acids, waxes, oils). Also comprehended by the invention are particulate compositions coated with polymers (e.g., poloxamers or poloxamines) and the polypeptides of the present invention coupled to antibodies directed against tissue-specific receptors, ligands or antigens or coupled to ligands of tissue-specific receptors. Other embodiments of the compositions of the invention incorporate particulate forms, protective coatings, protease inhibitors or permeation enhancers for various routes of administration, including parenteral, pulmonary, nasal and oral.

10 Further, as used herein "pharmaceutically acceptable carrier" are well known to those skilled in the art and include, but are not limited to, 0.01-0.1M and preferably 0.05M phosphate buffer or 0.8% saline. Additionally, such pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol,

15 vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte

20 replenishers such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, collating agents, inert gases and the like.

The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human.

The phrase "therapeutically effective amount" is used herein to mean an amount sufficient to prevent, and preferably reduce by at least about 30 percent, more preferably by at least 50 percent, most preferably by at least 90 percent, a clinically significant infection by streptococcal bacterium. Alternatively, in the case of a vaccine or immunogenic composition, a therapeutically effective amount is used herein to

mean an amount sufficient and suitable to elicit an immune response and antibody response in an individual, and particularly to provide a response sufficient to prevent, and preferably reduce by at least about 30 percent, more preferably by at least 50 percent, most preferably by at least 90 percent, a clinically significant infection by

5      streptococcal bacterium.

Controlled or sustained release compositions include formulation in lipophilic depots (e.g. fatty acids, waxes, oils). Also comprehended by the invention are particulate compositions coated with polymers (e.g. poloxamers or poloxamines) and the

10     compound coupled to antibodies directed against tissue-specific receptors, ligands or antigens or coupled to ligands of tissue-specific receptors. Other embodiments of the compositions of the invention incorporate particulate forms protective coatings, protease inhibitors or permeation enhancers for various routes of administration, including parenteral, pulmonary, nasal and oral.

15     When administered, compounds are often cleared rapidly from mucosal surfaces or the circulation and may therefore elicit relatively short-lived pharmacological activity. Consequently, frequent administrations of relatively large doses of bioactive compounds may be required to sustain therapeutic efficacy. Compounds modified by

20     the covalent attachment of water-soluble polymers such as polyethylene glycol, copolymers of polyethylene glycol and polypropylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone or polyproline are known to exhibit substantially longer half-lives in blood following intravenous injection than do the corresponding unmodified compounds (Abuchowski et al., 1981; Newmark et al.,

25     1982; and Katre et al., 1987). Such modifications may also increase the compound's solubility in aqueous solution, eliminate aggregation, enhance the physical and chemical stability of the compound, and greatly reduce the immunogenicity and reactivity of the compound. As a result, the desired *in vivo* biological activity may be achieved by the administration of such polymer-compound abducts less frequently or

30     in lower doses than with the unmodified compound.

*Dosages.* The sufficient amount may include but is not limited to from about 1  $\mu$ g/kg to about 1000 mg/kg. The amount may be 10 mg/kg. The pharmaceutically acceptable form of the composition includes a pharmaceutically acceptable carrier.

- 5 As noted above, the present invention provides therapeutic compositions comprising pharmaceutical compositions comprising vectors, vaccines, polypeptides, nucleic acids and antibodies, anti-antibodies, and agents, to compete with the Group B streptococcus bacterium for pathogenic activities, such as adherence to host cells.
- 10 The preparation of therapeutic compositions which contain an active component is well understood in the art. Typically, such compositions are prepared as an aerosol of the polypeptide delivered to the nasopharynx or as injectables, either as liquid solutions or suspensions, however, solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared. The preparation can also be
- 15 emulsified. The active therapeutic ingredient is often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof. In addition, if desired, the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering
- 20 agents which enhance the effectiveness of the active ingredient.

An active component can be formulated into the therapeutic composition as neutralized pharmaceutically acceptable salt forms. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide or antibody molecule) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed from the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.

A composition comprising "A" (where "A" is a single protein, DNA molecule, vector, etc.) is substantially free of "B" (where "B" comprises one or more contaminating

proteins, DNA molecules, vectors, etc.) when at least about 75% by weight of the proteins, DNA, vectors (depending on the category of species to which A and B belong) in the composition is "A". Preferably, "A" comprises at least about 90% by weight of the A+B species in the composition, most preferably at least about 99% by 5 weight.

The phrase "therapeutically effective amount" is used herein to mean an amount sufficient to reduce by at least about 15 percent, preferably by at least 50 percent, more preferably by at least 90 percent, and most preferably prevent, a clinically 10 significant deficit in the activity, function and response of the host. Alternatively, a therapeutically effective amount is sufficient to cause an improvement in a clinically significant condition in the host. In the context of the present invention, a deficit in the response of the host is evidenced by continuing or spreading bacterial infection. An improvement in a clinically significant condition in the host includes a decrease in 15 bacterial load, clearance of bacteria from colonized host cells, reduction in fever or inflammation associated with infection, or a reduction in any symptom associated with the bacterial infection.

According to the invention, the component or components of a therapeutic 20 composition of the invention may be introduced parenterally, transmucosally, *e.g.*, orally, nasally, pulmonarily, or rectally, or transdermally. Preferably, administration is parenteral, *e.g.*, via intravenous injection, and also including, but is not limited to, intra-arteriole, intramuscular, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial administration. Oral or pulmonary delivery may be 25 preferred to activate mucosal immunity; since Group B streptococci generally colonize the nasopharyngeal and pulmonary mucosa, particularly that of neonates, mucosal immunity may be a particularly effective preventive treatment. The term "unit dose" when used in reference to a therapeutic composition of the present invention refers to physically discrete units suitable as unitary dosage for humans, each unit containing a 30 predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required diluent; *i.e.*, carrier, or vehicle.

In another embodiment, the active compound can be delivered in a vesicle, in particular a liposome (see Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, *ibid.*, pp. 317-5 327; see generally *ibid.*).

In yet another embodiment, the therapeutic compound can be delivered in a controlled release system. For example, the polypeptide may be administered using intravenous infusion, an implantable osmotic pump, a transdermal patch, liposomes, or other 10 modes of administration. In one embodiment, a pump may be used (see Langer, *supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); *Controlled Drug* 15 *Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, *J. Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., *Science* 228:190 (1985); During et al., *Ann. Neurol.* 25:351 (1989); Howard et al., *J. Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic 20 target, i.e., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in *Medical Applications of Controlled Release*, *supra*, vol. 2, pp. 115-138 (1984)). Preferably, a controlled release device is introduced into a subject in proximity of the site of inappropriate immune activation or a tumor. Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 25 (1990)).

A subject in whom administration of an active component as set forth above is an effective therapeutic regimen for a bacterial infection is preferably a human, but can be any animal. Thus, as can be readily appreciated by one of ordinary skill in the art, the 30 methods and pharmaceutical compositions of the present invention are particularly suited to administration to any animal, particularly a mammal, and including, but by no means limited to, domestic animals, such as feline or canine subjects, farm animals, such as but not limited to bovine, equine, caprine, ovine, and porcine subjects, wild

animals (whether in the wild or in a zoological garden), research animals, such as mice, rats, rabbits, goats, sheep, pigs, dogs, cats, etc., *i.e.*, for veterinary medical use.

In the therapeutic methods and compositions of the invention, a therapeutically effective dosage of the active component is provided. A therapeutically effective dosage can be determined by the ordinary skilled medical worker based on patient characteristics (age, weight, sex, condition, complications, other diseases, etc.), as is well known in the art. Furthermore, as further routine studies are conducted, more specific information will emerge regarding appropriate dosage levels for treatment of various conditions in various patients, and the ordinary skilled worker, considering the therapeutic context, age and general health of the recipient, is able to ascertain proper dosing. Generally, for intravenous injection or infusion, dosage may be lower than for intraperitoneal, intramuscular, or other route of administration. The dosing schedule may vary, depending on the circulation half-life, and the formulation used. The compositions are administered in a manner compatible with the dosage formulation in the therapeutically effective amount. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner and are peculiar to each individual. However, suitable dosages may range from about 0.1 to 20, preferably about 0.5 to about 10, and more preferably one to several, milligrams of active ingredient per kilogram body weight of individual per day and depend on the route of administration. Suitable regimes for initial administration and booster shots are also variable, but are typified by an initial administration followed by repeated doses at one or more hour intervals by a subsequent injection or other administration. Alternatively, continuous intravenous infusion sufficient to maintain concentrations of ten nanomolar to ten micromolar in the blood are contemplated.

*Administration with other compounds.* For treatment of a bacterial infection, one may administer the present active component in conjunction with one or more pharmaceutical compositions used for treating bacterial infection, including but not limited to (1) antibiotics; (2) soluble carbohydrate inhibitors of bacterial adhesin; (3) other small molecule inhibitors of bacterial adhesin; (4) inhibitors of bacterial metabolism, transport, or transformation; (5) stimulators of bacterial lysis, or (6) anti-bacterial antibodies or vaccines directed at other bacterial antigens. Other potential

active components include anti-inflammatory agents, such as steroids and non-steroidal anti-inflammatory drugs. Administration may be simultaneous (for example, administration of a mixture of the present active component and an antibiotic), or may be *in seriatim*.

5

Accordingly, in specific embodiment, the therapeutic compositions may further include an effective amount of the active component, and one or more of the following active ingredients: an antibiotic, a steroid, etc.

10 Thus, in a specific instance where it is desired to reduce or inhibit the infection resulting from a bacterium mediated binding of bacteria to a host cell, or an antibody thereto, or a ligand thereof or an antibody to that ligand, the polypeptide is introduced to block the interaction of the bacteria with the host cell.

15 Also contemplated herein is pulmonary delivery of an inhibitor of the polypeptide of the present invention having which acts as adhesin inhibitory agent (or derivatives thereof). The adhesin inhibitory agent (or derivative) is delivered to the lungs of a mammal, where it can interfere with bacterial, *i.e.*, streptococcal, and preferably Group B streptococcal binding to host cells. Other reports of preparation of proteins for

20 pulmonary delivery are found in the art [Adjei *et al.* (1990) *Pharmaceutical Research*, 7:565-569; Adjei *et al.* (1990) *International Journal of Pharmaceutics*, 63:135-144 (leuprolide acetate); Braquet *et al* (1989), *Journal of Cardiovascular Pharmacology*, 13(suppl. 5):143-146 (endothelin-1); Hubbard *et al.* (1989) *Annals of Internal Medicine*, Vol. III, pp. 206-212 ( $\alpha$ 1-antitrypsin); Smith *et al.* (1989) *J. Clin. Invest.* 84:1145-1146 ( $\alpha$ -1-proteinase); Oswein *et al.*, "Aerosolization of Proteins", *Proceedings of Symposium on Respiratory Drug Delivery II*, Keystone, Colorado, March, (1990) (recombinant human growth hormone); Debs *et al.* (1988) *J. Immunol.* 140:3482-3488 (interferon- $\gamma$  and tumor necrosis factor alpha); Platz *et al.*, U.S. Patent No. 5,284,656 (granulocyte colony stimulating factor)]. A method and composition

25 for pulmonary delivery of drugs is described in U.S. Patent No. 5,451,569, issued

30 September 19, 1995 to Wong *et al.*

All such devices require the use of formulations suitable for the dispensing of adhesin inhibitory agent (or derivative). Typically, each formulation is specific to the type of device employed and may involve the use of an appropriate propellant material, in addition to the usual diluents, adjuvant and/or carriers useful in therapy. Also, the use

5 of liposomes, microcapsules or microspheres, inclusion complexes, or other types of carriers is contemplated. Chemically modified adhesin inhibitory agent may also be prepared in different formulations depending on the type of chemical modification or the type of device employed.

10 Formulations suitable for use with a nebulizer, either jet or ultrasonic, will typically comprise adhesin inhibitory agent (or derivative) dissolved in water at a concentration of about 0.1 to 25 mg of biologically active adhesin inhibitory agent per ml of solution. The formulation may also include a buffer and a simple sugar (e.g., for adhesin inhibitory agent stabilization and regulation of osmotic pressure). The nebulizer

15 formulation may also contain a surfactant, to reduce or prevent surface induced aggregation of the adhesin inhibitory agent caused by atomization of the solution in forming the aerosol.

20 Formulations for use with a metered-dose inhaler device will generally comprise a finely divided powder containing the adhesin inhibitory agent (or derivative) suspended in a propellant with the aid of a surfactant. The propellant may be any conventional material employed for this purpose, such as a chlorofluorocarbon, a hydrochlorofluorocarbon, a hydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, and

25 1,1,1,2-tetrafluoroethane, or combinations thereof. Suitable surfactants include sorbitan trioleate and soya lecithin. Oleic acid may also be useful as a surfactant.

30 The liquid aerosol formulations contain adhesin inhibitory agent and a dispersing agent in a physiologically acceptable diluent. The dry powder aerosol formulations of the present invention consist of a finely divided solid form of adhesin inhibitory agent and a dispersing agent. With either the liquid or dry powder aerosol formulation, the formulation must be aerosolized. That is, it must be broken down into liquid or solid particles in order to ensure that the aerosolized dose actually reaches the mucous

membranes of the nasal passages or the lung. The term "aerosol particle" is used herein to describe the liquid or solid particle suitable for nasal or pulmonary administration, *i.e.*, that will reach the mucous membranes. Other considerations, such as construction of the delivery device, additional components in the formulation, and 5 particle characteristics are important. These aspects of pulmonary administration of a drug are well known in the art, and manipulation of formulations, aerosolization means and construction of a delivery device require at most routine experimentation by one of ordinary skill in the art. In a particular embodiment, the mass median dynamic diameter will be 5 micrometers or less in order to ensure that the drug particles reach 10 the lung alveoli [Wearley, L.L. (1991) *Crit. Rev. in Ther. Drug Carrier Systems* 8:333].

Systems of aerosol delivery, such as the pressurized metered dose inhaler and the dry powder inhaler are disclosed in Newman, S.P., *Aerosols and the Lung*, Clarke, S.W. 15 and Davia, D. editors, pp. 197-22 and can be used in connection with the present invention.

In a further embodiment, as discussed in detail *infra*, an aerosol formulation of the present invention can include other therapeutically or pharmacologically active 20 ingredients in addition to adhesin inhibitory agent, such as but not limited to an antibiotic, a steroid, a non-steroidal anti-inflammatory drug, etc.

*Liquid Aerosol Formulations.* The present invention provides aerosol formulations and dosage forms for use in treating subjects suffering from bacterial, *e.g.*, 25 streptococcal, in particularly streptococcal, infection. In general such dosage forms contain adhesin inhibitory agent in a pharmaceutically acceptable diluent. Pharmaceutically acceptable diluents include but are not limited to sterile water, saline, buffered saline, dextrose solution, and the like. In a specific embodiment, a diluent that may be used in the present invention or the pharmaceutical formulation of the 30 present invention is phosphate buffered saline, or a buffered saline solution generally between the pH 7.0-8.0 range, or water.

The liquid aerosol formulation of the present invention may include, as optional ingredients, pharmaceutically acceptable carriers, diluents, solubilizing or emulsifying agents, surfactants and excipients. The formulation may include a carrier. The carrier is a macromolecule which is soluble in the circulatory system and which is

- 5 physiologically acceptable where physiological acceptance means that those of skill in the art would accept injection of said carrier into a patient as part of a therapeutic regime. The carrier preferably is relatively stable in the circulatory system with an acceptable plasma half life for clearance. Such macromolecules include but are not limited to Soya lecithin, oleic acid and sorbitan trioleate, with sorbitan trioleate
- 10 preferred.

The formulations of the present embodiment may also include other agents useful for pH maintenance, solution stabilization, or for the regulation of osmotic pressure.

Examples of the agents include but are not limited to salts, such as sodium chloride, or

- 15 potassium chloride, and carbohydrates, such as glucose, galactose or mannose, and the like.

The present invention further contemplates liquid aerosol formulations comprising adhesin inhibitory agent and another therapeutically effective drug, such as an

- 20 antibiotic, a steroid, a non-steroidal anti-inflammatory drug, etc.

*Aerosol Dry Powder Formulations.* It is also contemplated that the present aerosol formulation can be prepared as a dry powder formulation comprising a finely divided powder form of adhesin inhibitory agent and a dispersant.

- 25 Formulations for dispensing from a powder inhaler device will comprise a finely divided dry powder containing adhesin inhibitory agent (or derivative) and may also include a bulking agent, such as lactose, sorbitol, sucrose, or mannitol in amounts which facilitate dispersal of the powder from the device, *e.g.*, 50 to 90% by weight of the formulation. The adhesin inhibitory agent (or derivative) should most
- 30 advantageously be prepared in particulate form with an average particle size of less than 10 mm (or microns), most preferably 0.5 to 5 mm, for most effective delivery to the distal lung. In another embodiment, the dry powder formulation can comprise a finely divided dry powder containing adhesin inhibitory agent, a dispersing agent and

also a bulking agent. Bulking agents useful in conjunction with the present formulation include such agents as lactose, sorbitol, sucrose, or mannitol, in amounts that facilitate the dispersal of the powder from the device.

5 The present invention further contemplates dry powder formulations comprising adhesin inhibitory agent and another therapeutically effective drug, such as an antibiotic, a steroid, a non-steroidal anti-inflammatory drug, etc.

Contemplated for use herein are oral solid dosage forms, which are described generally 10 in *Remington's Pharmaceutical Sciences*, 18th Ed. 1990 (Mack Publishing Co. Easton PA 18042) at Chapter 89, which is herein incorporated by reference. Solid dosage forms include tablets, capsules, pills, troches or lozenges, cachets or pellets. Also, liposomal or proteinoid encapsulation may be used to formulate the present 15 compositions (as, for example, proteinoid microspheres reported in U.S. Patent No. 4,925,673). Liposomal encapsulation may be used and the liposomes may be derivatized with various polymers (e.g., U.S. Patent No. 5,013,556). A description of possible solid dosage forms for the therapeutic is given by Marshall, K. In: *Modern 20 Pharmaceutics* Edited by G.S. Banker and C.T. Rhodes Chapter 10, 1979, herein incorporated by reference. In general, the formulation will include the component or components (or chemically modified forms thereof) and inert ingredients which allow for protection against the stomach environment, and release of the biologically active 25 material in the intestine.

Also specifically contemplated are oral dosage forms of the above derivatized 25 component or components. The component or components may be chemically modified so that oral delivery of the derivative is efficacious. Generally, the chemical modification contemplated is the attachment of at least one moiety to the component molecule itself, where said moiety permits (a) inhibition of proteolysis; and (b) uptake into the blood stream from the stomach or intestine. Also desired is the increase in 30 overall stability of the component or components and increase in circulation time in the body. Examples of such moieties include: polyethylene glycol, copolymers of ethylene glycol and propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone and polyproline. Abuchowski and Davis, 1981,

"Soluble Polymer-Enzyme Abducts" In: *Enzymes as Drugs*, Hocenberg and Roberts, eds., Wiley-Interscience, New York, NY, pp. 367-383; Newmark, *et al.* (1982) *J. Appl. Biochem.* 4:185-189. Other polymers that could be used are poly-1,3-dioxolane and poly-1,3,6-tioxocane. Preferred for pharmaceutical usage, as indicated above, are 5 polyethylene glycol moieties.

For the component (or derivative) the location of release may be the stomach, the small intestine (the duodenum, the jejunum, or the ileum), or the large intestine. One skilled in the art has available formulations which will not dissolve in the stomach, yet 10 will release the material in the duodenum or elsewhere in the intestine. Preferably, the release will avoid the deleterious effects of the stomach environment, either by protection of the protein (or derivative) or by release of the biologically active material beyond the stomach environment, such as in the intestine.

15 To ensure full gastric resistance a coating impermeable to at least pH 5.0 is essential. Examples of the more common inert ingredients that are used as enteric coatings are cellulose acetate trimellitate (CAT), hydroxypropylmethylcellulose phthalate (HPMCP), HPMCP 50, HPMCP 55, polyvinyl acetate phthalate (PVAP), Eudragit L30D, Aquateric, cellulose acetate phthalate (CAP), Eudragit L, Eudragit S, and 20 Shellac. These coatings may be used as mixed films.

A coating or mixture of coatings can also be used on tablets, which are not intended for protection against the stomach. This can include sugar coatings, or coatings which make the tablet easier to swallow. Capsules may consist of a hard shell (such as 25 gelatin) for delivery of dry therapeutic i.e. powder; for liquid forms, a soft gelatin shell may be used. The shell material of cachets could be thick starch or other edible paper. For pills, lozenges, molded tablets or tablet triturates, moist massing techniques can be used.

30 The peptide therapeutic can be included in the formulation as fine multiparticulates in the form of granules or pellets of particle size about 1mm. The formulation of the material for capsule administration could also be as a powder, lightly compressed plugs or even as tablets. The therapeutic could be prepared by compression.

Colorants and flavoring agents may all be included. For example, the protein (or derivative) may be formulated (such as by liposome or microsphere encapsulation) and then further contained within an edible product, such as a refrigerated beverage containing colorants and flavoring agents.

5

One may dilute or increase the volume of the therapeutic with an inert material. These diluents could include carbohydrates, especially mannitol,  $\alpha$ -lactose, anhydrous lactose, cellulose, sucrose, modified dextran and starch. Certain inorganic salts may be also be used as fillers including calcium triphosphate, magnesium carbonate and sodium chloride. Some commercially available diluents are Fast-Flo, Emdex, STA-Rx 1500, Emcompress and Avicell.

Disintegrants may be included in the formulation of the therapeutic into a solid dosage form. Materials used as disintegrates include but are not limited to starch, including 15 the commercial disintegrant based on starch, Explotab. Sodium starch glycolate, Amberlite, sodium carboxymethylcellulose, ultramylopectin, sodium alginate, gelatin, orange peel, acid carboxymethyl cellulose, natural sponge and bentonite may all be used. Another form of the disintegrants are the insoluble cationic exchange resins. Powdered gums may be used as disintegrants and as binders and these can include 20 powdered gums such as agar, Karaya or tragacanth. Alginic acid and its sodium salt are also useful as disintegrants. Binders may be used to hold the therapeutic agent together to form a hard tablet and include materials from natural products such as acacia, tragacanth, starch and gelatin. Others include methyl cellulose (MC), ethyl cellulose (EC) and carboxymethyl cellulose (CMC). Polyvinyl pyrrolidone (PVP) and 25 hydroxypropylmethyl cellulose (HPMC) could both be used in alcoholic solutions to granulate the therapeutic.

An antifrictional agent may be included in the formulation of the therapeutic to prevent sticking during the formulation process. Lubricants may be used as a layer between 30 the therapeutic and the die wall, and these can include but are not limited to; stearic acid including its magnesium and calcium salts, polytetrafluoroethylene (PTFE), liquid paraffin, vegetable oils and waxes. Soluble lubricants may also be used such as sodium

lauryl sulfate, magnesium lauryl sulfate, polyethylene glycol of various molecular weights, Carbowax 4000 and 6000.

Glidants that might improve the flow properties of the drug during formulation and to aid rearrangement during compression might be added. The glidants may include starch, talc, pyrogenic silica and hydrated silicoaluminate.

To aid dissolution of the therapeutic into the aqueous environment a surfactant might be added as a wetting agent. Surfactants may include anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate. Cationic detergents might be used and could include benzalkonium chloride or benzethonium chloride. The list of potential nonionic detergents that could be included in the formulation as surfactants are lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 and 60, glycerol monostearate, polysorbate 40, 60, 65 and 80, sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose. These surfactants could be present in the formulation of the protein or derivative either alone or as a mixture in different ratios.

Additives which potentially enhance uptake of the polypeptide (or derivative) are for instance the fatty acids oleic acid, linoleic acid and linolenic acid.

*Pulmonary Delivery.* Also contemplated herein is pulmonary delivery of the present polypeptide (or derivatives thereof). The polypeptide (or derivative) is delivered to the lungs of a mammal while inhaling and coats the mucosal surface of the alveoli. Other reports of this include Adjei *et al.* (1990) *Pharmaceutical Research* 7:565-569; Adjei *et al.* (1990) *International Journal of Pharmaceutics* 63:135-144 (leuprolide acetate); Braquet *et al.* (1989) *Journal of Cardiovascular Pharmacology*, 13(suppl. 5):143-146 (endothelin-1); Hubbard *et al.* (1989) *Annals of Internal Medicine*, Vol. III, pp. 206-212 (a1- antitrypsin); Smith *et al.* (1989) *J. Clin. Invest.* 84:1145-1146 (a-1-proteinase); Oswein *et al.* (1990) "Aerosolization of Proteins", *Proceedings of Symposium on Respiratory Drug Delivery II*, Keystone, Colorado, March, (recombinant human growth hormone); Debs *et al.* (1988) *J. Immunol.* 140:3482-3488 (interferon-g and tumor necrosis factor alpha) and Platz *et al.*, U.S.

Patent No. 5,284,656 (granulocyte colony stimulating factor). A method and composition for pulmonary delivery of drugs for systemic effect is described in U.S. Patent No. 5,451,569, issued September 19, 1995 to Wong et al.

- 5 Contemplated for use in the practice of this invention are a wide range of mechanical devices designed for pulmonary delivery of therapeutic products, including but not limited to nebulizers, metered dose inhalers, and powder inhalers, all of which are familiar to those skilled in the art.
- 10 Formulations suitable for use with a nebulizer, either jet or ultrasonic, will typically comprise polypeptide (or derivative) dissolved in water at a concentration of about 0.1 to 25 mg of biologically active protein per mL of solution. The formulation may also include a buffer and a simple sugar (e.g., for protein stabilization and regulation of osmotic pressure). The nebulizer formulation may also contain a surfactant, to reduce 15 or prevent surface induced aggregation of the protein caused by atomization of the solution in forming the aerosol.

Formulations for use with a metered-dose inhaler device will generally comprise a finely divided powder containing the polypeptide (or derivative) suspended in a 20 propellant with the aid of a surfactant. The propellant may be any conventional material employed for this purpose, such as a chlorofluorocarbon, a hydrochlorofluorocarbon, a hydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, and 1,1,1,2-tetrafluoroethane, or combinations thereof. Suitable surfactants include 25 sorbitan trioleate and soya lecithin. Oleic acid may also be useful as a surfactant.

Formulations for dispensing from a powder inhaler device will comprise a finely divided dry powder containing polypeptide (or derivative) and may also include a bulking agent, such as lactose, sorbitol, sucrose, or mannitol in amounts which 30 facilitate dispersal of the powder from the device, e.g., 50 to 90% by weight of the formulation. The protein (or derivative) should most advantageously be prepared in particulate form with an average particle size of less than 10 mm (or microns), most preferably 0.5 to 5 mm, for most effective delivery to the distal lung.

*Nasal Delivery.* Nasal or nasopharyngeal delivery of the polypeptide (or derivative) is also contemplated. Nasal delivery allows the passage of the polypeptide directly over the upper respiratory tract mucosal after administering the therapeutic product to the nose, without the necessity for deposition of the product in the lung. Formulations for

5 nasal delivery include those with dextran or cyclodextran.

tide nomenclature, *J. Biol. Chem.*, 243:3552-59 (1969), abbreviations for amino acid

The therapeutic polypeptide-, analog- or active fragment-containing compositions are conventionally administered intravenously, as by injection of a unit dose, for example.

10 The term "unit dose" when used in reference to a therapeutic composition of the present invention refers to physically discrete units suitable as unitary dosage for humans, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required diluent; i.e., carrier, or vehicle.

15

The compositions are administered in a manner compatible with the dosage formulation, and in a therapeutically effective amount. The quantity to be administered depends on the subject to be treated, capacity of the subject's immune system to utilize the active ingredient, and degree of inhibition or neutralization of ~

20 binding capacity desired. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner and are peculiar to each individual. However, suitable dosages may range from about 0.1 to 20, preferably about 0.5 to about 10, and more preferably one to several, milligrams of active ingredient per kilogram body weight of individual per day and depend on the route of administration. Suitable regimes for initial administration and booster shots are also variable, but are typified by an initial administration followed by repeated doses at one or more hour intervals by a subsequent injection or other administration.

25 Alternatively, continuous intravenous infusion sufficient to maintain concentrations of ten nanomolar to ten micromolar in the blood are contemplated.

30

The invention may be better understood by reference to the following non-limiting Examples, which are provided as exemplary of the invention. The following examples are presented in order to more fully illustrate the preferred embodiments of the

invention and should in no way be construed, however, as limiting the broad scope of the invention.

EXAMPLE 1

5

IDENTIFICATION OF GROUP B STREPTOCOCCUS GENES

Comparing the genetic and phenotypic composition of genetically-related groups of a bacterial species facilitates identifying virulence factors present in the most pathogenic 10 groups. Type III GBS can be subdivided into three groups of related strains based on the analysis of restriction digest patterns (RDPs) produced by digestion of chromosomal DNA with Hind III and Sse 8387 (5, 6). Over 90% of invasive type III GBS disease in neonates in Japan and in Salt Lake City is caused by bacteria from one of three RDP types, termed RDP type III-3, while RDP type III-2 are significantly 15 more likely to be isolated from vagina than from blood or CSF (6). These results suggest that this genetically-related cluster of type III-3 GBS are more virulent than III-2 strains and could be responsible for the majority of invasive type III disease globally. We proposed that bacterial factors that contribute to the increased virulence of III-3 strains can be identified by characterizing the differences between the genetic 20 composition of III-3 and III-2 strains. Such genetic differences will be found in the bacterial chromosomes since these strains do not contain plasmids (6).

To identify genes present in virulent type III-3 GBS strains and not in the avirulent type III-2 strains we used a modification of the technique described by Lisitsyn et al 25 (7). High molecular weight genomic DNA from an invasive RDP type III-3 GBS strain (strain 874391) and a colonizing ("avirulent") RDP type III-2 strain (strain 865043) was prepared by cell lysis with mutanolysin and Proteinase K digestion (5). For genetic subtraction, genomic DNA from both strains was digested with Taq I. Taq I-digested DNA from the virulent strain was mixed with two complementary 30 oligonucleotides (TaqA (5'-CTAGGTGGATCCTCGGCAAT-3' (SEQ ID NO: 11)) and TaqB (5'-CGATTGCCGA-3' (SEQ ID NO: 12)), heated to 50°C for 5 minutes, then allowed to cool slowly to 16°C in T4 ligase buffer. Oligonucleotides were ligated to the virulent strain DNA by incubation with 20 units of T4 ligase at 16°C for 12

hours. After ligation, 500 ng of DNA from the virulent strain, with ligated linkers, and 40 ug of DNA from the avirulent strain, without linkers, was mixed together, denatured by heating, and hybridized at 68°C for 20 hours.

- 5    Ten percent of the resulting hybridization mixture was incubated with Taq DNA polymerase and dNTPs to fill in the ends of annealed virulent strain DNA. The hybridized DNA was amplified by Taq DNA polymerase for 10 cycles using the TaqA oligonucleotide as the forward and reverse amplification primer. After amplification, single stranded products remaining after amplification were digested with mung bean 10    nuclease. Twenty percent of the resulting product was then reamplified for 20 cycles. This process of subtraction followed by PCR amplification results in enhanced amplification of DNA segments from the III-3 strains that do not hybridize with DNA segments from the III-2 strains.
- 15    A total of four cycles of subtraction and amplification were carried out, using successively smaller quantities of III-3 specific PCR products and alternating two sets of adaptors (TaqA/B (SEQ IDNOS: 11 and 12, respectively) and TaqE/F (TaqE (5'-AGGCAACTGTGCTAACCGAGGGAAT-3' (SEQ ID NO: 13)); and TaqF (5'-CGATTCCCTCG-3' (SEQ ID NO: 14)). The final amplification products were 20    ligated into pBS KS+ vectors. Thirteen clones were randomly selected for analysis. These probes were used in slot and dot blot experiments to determine whether subtraction was successful and to identify probes hybridizing with all III-3 strains. Each of the 6 unique probes hybridized with the parental III-3 virulent strain, while 25    none of the probes hybridized with the avirulent III-2 strains. Two of the amplified sequence tags (clones DY1-1 and DY1-11) hybridized with genomic DNA from all 62 type III isolates, but did not hybridize with DNA prepared from the III-2 and III-1 isolates (FIGURE 1). To obtain additional sequence information, we constructed a genomic GBS III-3 library. Multiple plaques hybridizing with each of the III-3 30    GBS-specific probes have been purified for further characterization.

30

## RESULTS

### THE *spb* LOCUS

Three overlapping genomic clones hybridizing with probe DY1-1 were identified. A 6.4 kb Sal I-Bgl II fragment present in each clone was subcloned and sequenced. This genomic DNA is present in all RDP type III-3 strains but not in serotype III-2, III-1 or other GBS serotype strains.

5

Over 90% of this genomic DNA fragment has been sequenced and found to contain 5 open reading frames (ORFs). Two ORFs appear to be candidates for virulence genes. *spb1* is a 1509 bp ORF. The predicted protein (502 amino acids and Mr 53,446) has the characteristics of a cell-wall bound protein. The nucleic acid and predicted amino acid sequences of *spb1* are provided in SEQ ID NOS: 15 and 16, respectively. The 10 N-terminus of the predicted protein is a hydrophilic, basic stretch of 6 amino acids followed by a 23 amino acid hydrophobic, proline-rich core, consistent with a signal peptide. The hydrophilic mature protein terminates in a typical LPXTG (SEQ ID NO: 17) domain that immediately precedes a hydrophobic 20 amino acid core and a short, 15 basic hydrophilic terminus. The nucleotide sequence is not homologous to sequences of other known bacterial genes. The translated amino acid sequence, however, shares segmental homology with a number of characterized proteins, including the fimbrial type 2 protein of *Actinomyces naeslundii* (27% identity over 350 amino acids) and the fimbrial type 1 protein of *Actinomyces viscosus* (25% homology over 420 amino acids) (16), the T6 surface protein of *S. pyogenes* (23% identity over 359 amino acids) (20), and the hsf (27% identity over 260 amino acids) and HMW1 adhesins (25% identity over 285 amino acids) of *Haemophilus influenzae* (21, 22). The 20 function of the *S. pyogenes* T6 protein is unknown. Each of the other homologs plays a role in bacterial adhesion and/or invasion.

25

A *spb1*<sup>-</sup> isogenic deletion mutant GBS strain was created by homologous recombination (using the method as described in Example 2 below) and the ability of the *spb1*<sup>-</sup> mutant to adhere to and invade A549 respiratory epithelial cells was determined. Compared to the wild type strain, the number of *spb1*<sup>+</sup> bacteria adherent 30 to A549 monolayers was reduced by 60.0% (p<0.01) and the number of intracellular invading bacteria was reduced by 53.6% (p<0.01). This data suggests *spb1* may contribute to the pathogenesis of GBS pneumonia and bacterial entry into the bloodstream.

The second ORF, *spb2*, terminates 37 bp upstream from *spb1* and is in the same transcriptional orientation. This 1692 bp ORF has a deduced amino acid sequence of 579 residues and Mr 64,492. The nucleic acid and predicted amino acid sequences of *spb2* are provided in SEQ ID NOS: 18 and 19, respectively. *spb2* shares 50.5% nucleic acid identity and 20.7% amino acid identity with *spb1*. Conservation is highest in the carboxy-terminal regions, including a shared LPSTGG (SEQ ID NO: 20) motif. In contrast to *spb1*, *spb2* does not have a obvious signal sequence. Its secretion may be mediated by carboxy-terminal recognition sequences or by accessory peptides (23). The deduced amino acid sequence of Spb2 is also homologous with *S. pyogenes* T6 and *Actinomyces naeslundii* proteins, and to *Listeria monocytogenes* internalin A (22% identity over 308 amino acids); again, proteins important in adhesion and invasion (24).

#### THE *ema* LOCUS

Two genomic clones hybridizing with probe DY1-11 were identified. A 7 kb Hind III fragment present in each clone was subcloned and sequenced. Unlike the serotype III specific *spb* sequences, this genomic DNA, which is adjacent to a region of serotype III-3 specific DNA, was found to be present in all GBS tested to date, including serotype Ia, Ib, II and V strains. This region of the GBS chromosome, which we have designated the extracellular matrix adhesin (*ema*) locus, contains 5 significant ORFs.

#### *emaA*

The first ORF, *emaA*, is 738 bp long, with a predicted protein product of 246 amino acids and Mr 26.2. The nucleic acid sequence (SEQ ID NO: 1) and predicted amino acid sequence (SEQ ID NO: 2) of *emaA* are shown in FIGURE 2. The EmaA protein is a non-repetitive protein. The 27 amino acid N-terminus of the predicted protein is consistent with a signal peptide. The mature protein has an imperfect cell wall binding domain (XPXTGG (SEQ ID NO:21)) followed by a transmembrane spanning domain encompassing residues 219 - 235 and a terminal hydrophilic tail. The *emaA* nucleotide sequence is not homologous to known sequences of bacterial genes. The translated amino acid sequence, however, shares segmental homology with a number of characterized proteins, including a collagen adhesin, Bbp, of *Staphylococcus aureus*

(37% identity over 103 aa) (15), a type 2 fimbrial structural subunit of *Actinomyces naeslundii* (39% homology over 112 aa) (16), and the FimP protein of *Actinomyces viscosus* (28% homology over 228 aa) (17). The function of the *S. pyogenes* T6 protein is unknown. The type 1 and type 2 fimbria of *Actinomyces* mediate bacterial adhesion to salivary glycoproteins and various host cells, contributing to the pathogenesis of dental caries.

5 ***emaB***

The second ORF, *emaB*, begins 94 bp 3' of *emaA* and is in the same transcriptional orientation. The nucleic acid sequence (SEQ ID NO: 3) and predicted amino acid sequence (SEQ ID NO: 4) of *emaB* are shown in FIGURE 3. It is 924 bp long, with a predicted protein product of 308 amino acids and Mr 33.9. The predicted EmaB protein is a nonrepetitive protein. The 27 amino acids N-terminus of the predicted protein is consistent with a signal peptide. The mature protein has an imperfect cell wall binding domain (XPXTG) followed by a transmembrane spanning domain encompassing residues 279-294. The *emaB* nucleotide sequence is not homologous to known sequences of bacterial genes. The translated amino acid sequence, however, shares segmental homology with a number of characterized proteins, including a type 2 fimbrial structural subunit of *Actinomyces naeslundii* (28% homology over 222 amino acids), the T6 protein of *S. pyogenes* (26% homology over 266 amino acids) (20), and a *S. epidermidis* putative cell-surface adhesin (24% identity over 197 amino acids). The first of these proteins mediates adhesion of *S. aureus* to collagen and is postulated to contribute to the pathogenesis of osteomyelitis and infectious arthritis.

25 ***emaC***

The third ORF, *emaC*, begins 2 bp 3' of *emaB* and is the same transcriptional orientation. It is 918 bp long, with a predicted protein product of 305 amino acids and Mr 34.5. The nucleic acid sequence (SEQ ID NO: 5) and predicted amino acid sequence (SEQ ID NO: 6) of *emaC* are depicted in FIGURE 4. The EmaC protein is a nonrepetitive protein. The 30 amino acid N-terminus of the predicted protein is consistent with a signal peptide. The mature protein has a transmembrane spanning domain encompassing residues 265 - 281. The *emaC* nucleotide sequence is not homologous to known sequences of bacterial genes. The translated amino acid

sequence, however, shares segmental homology with a number of characterized proteins, including proteins associated with the assembly of type 2 fimbrial structural subunit of *Actinomyces naeslundii* (38% homology over 234 amino acids) (16). These proteins are required for the assembly of type 2 fimbria.

5

emaD

The fourth ORF, *emaD*, is 852 bp long, overlaps *emaC* by 47 bp, and is in the same transcriptional orientation. The predicted protein product is 284 amino acids and Mr 33.1. The nucleic acid sequence (SEQ ID NO: 7) and predicted amino acid sequence 10 (SEQ ID NO:8) of *emaD* are shown in FIGURE 5. No indentifiable N-terminal signal sequence is present and potential transmembrane segments are present at positions 19-35 and 252-280. The mature protein is not repetitive and lacks a cell wall binding domain. The *emaD* nucleotide sequence is not homologous to known sequences of bacterial genes. The translated amino acid sequence, shares segmental homology with 15 the same fimbria-associated proteins of *Actinomyces* as does EmaC.

emaE

The fifth ORF, *emaE*, begins 42 bp 3' of *emaD* and is in the same transcriptional orientation. It is 2712 bp long, with a predicted protein product of 904 aa and Mr 20 100.9. FIGURE 6 depicts the nucleic acid sequence (SEQ ID NO: 9) and predicted amino acid sequence (SEQ ID NO: 10) of *emaE*. The predicted EmaE protein is a nonrepetitive protein. An obvious N-terminal signal peptide is not evident but a putative transmembrane region is located at residues 24-40. The mature protein has an imperfect cell wall binding domain (XPXTGG (SEQ ID NO: 21)) followed by a 25 transmembrane spanning domain encompassing residues 880 - 896. The *emaE* nucleotide sequence is not homologous to known sequences of bacterial genes. The translated amino acid sequence, however, shares segmental homology with a number of characterized proteins, including the F1 and F2 fibronectin binding proteins of *S. pyogenes* (31% homology over 207 amino acids) (18, 19). These proteins mediate 30 high affinity binding to fibronectin, and are important in the adhesion of *S. pyogenes* to respiratory cells.

The similarity of the protein products of the *ema* locus to physiologically important adhesins and invasins of other bacterial species suggests that the Ema proteins have a role in facilitating the adhesion of GBS to extracellular matrix components and to cell surfaces and subsequent invasion of epithelial and endothelial cells, the initial steps in 5 the pathogenesis of infection.

Several lines of evidence suggest the members of the *ema* and the *spb* locus may have similar functions, but are likely to represent distinct classes of proteins. The *ema* and *spb* locus genes are each and all similar to physiologically important adhesions and 10 invasions of the bacterial species, however, both *Spb1* and *Spb2* have prototypical gram positive cell-wall binding domains, whereas the members of the *ema* locus have an unusual motif, suggesting a distinct mechanism of cell surface anchoring. Second, the *spb* locus is restricted to virulent serotype III-3 strains of GBS, whereas the *ema* locus appears to be ubiquitous in all GBS serotypes. Third, *spb1* and *spb2* are more 15 homologous to one another than to members of the *ema* locus and *ema* genes are more closely homologous to one another than to *spb1* and *spb2*.

#### EXAMPLE 2

#### 20                   **BIOLOGIC CHARACTERIZATION OF NOVEL GBS GENES**

##### Isogenic Mutant Bacterial Strains

To identify biologic activity of these novel GBS genes, isogenic mutant bacterial 25 strains are created which are identical in all respects except for the presence or absence of a particular gene. Deletion mutants are created by allelic replacement. The relevant gene, with 100-300 bp of flanking sequences, is subcloned and modified by the deletion of an intragenic portion of the coding sequence and, in some cases, the insertion of a kanamycin resistance gene. The mutant gene is cloned into the suicide 30 vector pHY304 (kindly provided by Dr. Craig Rubens), a broad host range plasmid containing a temperature sensitive ori, erythromycin resistance gene (*erm*<sup>TS</sup>), and a pBS multiple cloning site. The pHY304 vector is a derivative of the vector pWV01 (Framson, P.E. et al (1997) *Applied Environ Microbiology* 63:3539-3547). Plasmids

containing mutant genes are electroporated into strain 874391 and single cross-over mutants are selected by antibiotic resistance at 37°C. The resulting antibiotic resistant colonies are subjected to a temperature shift to 30°C. Integration of the plasmid is unstable at this permissive temperature because there are two functional ori's on the

5 chromosome. Excised plasmid is eliminated by growth on nonselective media for many generations, then colonies are screened for the presence of the mutant allele by erythromycin-sensitivity. Double-crossover mutants are stable and do not require maintenance under drug selection. The mutant genotype is confirmed by Southern blotting or PCR demonstrating the appropriate deletion. The resulting mutants are

10 screened for the presence of gene expression by Northern and Western blot analysis. The phenotype of the knockout mutants is then compared with that of the wild type strain 874391 by examining growth rate and colony morphology, and the expression of β-hemolysin and CAMP factor. Surface protein expression is assessed by Western blot, using polyclonal sera from rabbits immunized with whole, heat-killed type III

15 GBS.

#### In Vitro Models

A. Adherence

20 Adhesion of GBS to host cells is a prerequisite for invasive disease. Three different cell types have the potential to be important in this process: i) adhesion to respiratory epithelial cells is likely to facilitate most early onset neonatal infections, ii) adhesion to gastrointestinal epithelial cells has been postulated to be important in the pathogenesis of late onset neonatal infections, and iii) adhesion to endothelial cells is necessary for

25 both endocarditis and other endovascular infections, and is likely to be the initial event in GBS meningitis. The ability of wild type and mutant strains to adhere to epithelial and endothelial cells is compared in adhesion assays.

30 Four different cell lines are used to investigate the role of novel GBS genes in adhesion. GBS adhere to and invade A549 human alveolar epithelial carcinoma cells and surface proteins appear to play an important role in this process (8). GBS binding to A549 cells is used as an *in vitro* model for respiratory colonization. GBS also adhere to C2BBeL, a human intestinal epithelial cell line, which is used as a model for

## 100

gastrointestinal colonization, and to HeLa cervical epithelial cells, a model for genital colonization and maternal infection. For endothelial adhesion, two cell lines are studied: freshly isolated human umbilical vein endothelial (HUVE) cells; and an immortalized human brain microvascular endothelial cell line (BMEC). Adhesion assays are performed as described by Tamura et al (9). Cell lines are grown to confluence in 96-well tissue culture plates in recommended media. Monolayers are washed with PBS and fixed with 0.5% gluteraldehyde. Following blocking with 5% BSA in PBS, cells are inoculated with various inocula of GBS, centrifuged for 10 minutes at 2000 rpm and incubated for 1 hour at 4°C. Nonadherent bacteria are removed by washing three times with 5% nonfat dry milk in PBS and bound bacteria are then eluted and plated quantitatively.

**B. Invasion**

GBS adhere to and invade respiratory epithelium, endothelium and BMEC (8, 10, 11). The ability of wild type and isogenic mutant GBS strains to invade the above epithelial and endothelial cells are tested as previously described (8, 10, 11). Assays that distinguish the ability of GBS to invade eukaryotic cells versus adhere to cells capitalize on the inability of penicillin and gentamicin to enter host cells, allowing quantification of intracellular bacteria after extracellular bacteria are killed. GBS are grown to the desired growth phase in TH broth, washed twice with PBS and resuspended in tissue culture media containing 10% fetal calf serum. Tissue culture monolayers grown to confluence in 24-well plates are inoculated with varying inocula of GBS, centrifuged at 800xg and incubated at 37°C in 5% CO<sub>2</sub> for 2-6 hours. Extracellular bacteria are removed by washing four times with PBS. Cells are then incubated in fresh medium with 5 mg/ml penicillin and 100 mg/ml gentamicin for 2 hours. Media is then removed, monolayers washed, and cells lysed by treatment with 0.025% Triton X-100. Cell lysates are sonicated to disrupt bacterial chains and aliquots plated quantitatively.

**30 C. Antibody to GBS Proteins**

The ability of specific antibody to the novel GBS proteins to promote opsonophagocytic killing of GBS is tested (12). Rabbits are immunized with recombinant or purified GBS proteins produced by standard techniques. Rabbit

antiserum of different dilutions (ranging from 1/50 to 1/5,000) that has been exhaustively absorbed with the relevant isogenic mutant strain at 4°C will be incubated with GBS in the presence of human complement and polymorphonuclear leukocytes (3 x 10<sup>6</sup>). Opsonophagocytic killing is expressed as the log number of CFU surviving 5 following 1 hour of incubation subtracted from the log of the number of CFU at the zero time point. Killing of wild type strains is compared to that of isogenic mutants lacking novel GBS proteins.

In Vivo Models

10

The neonatal rat has been used by numerous laboratories as a model of GBS infection because it closely mimics human neonatal infection (13). The contribution of novel genes to the pathogenesis of GBS infections is tested by comparing wild type and mutant in this system. Rat pups are inoculated by two routes. First, pups are 15 inoculated intranasally to mimic the respiratory infection and sepsis typical of early onset GBS infection. Secondly, intraperitoneal or subcutaneous inoculation reproduces the high grade bacteremia associated with GBS sepsis and that precedes GBS meningitis (14).

20 Rat pups are inoculated with varying doses of GBS strains and mortality is determined. The level of bacteremia is determined by quantitative blood cultures. Lung, liver, spleen and meningeal tissue are preserved for histologic examination.

The ability of antiserum to the GBS proteins to protect neonatal rats from GBS 25 infection is tested (13). Newborn rats (<18 hours old) receive an intraperitoneal injection of 0.5 ml of undiluted rabbit antiserum, followed by the intraperitoneal inoculation of the equivalent of one LD<sub>50</sub> unit of GBS (usually about 5000 bacteria) in PBS. Mortality and morbidity are then determined.

30 Role of Novel GBS Proteins in Vaccines

Several surface proteins of GBS, including C and Rib are immunogenic and protective against GBS infection in infant rodent models (25, 26). None of these proteins are

present in all GBS strains (27). Furthermore, each of these proteins has a repetitive structure. The phenotypic variability of these repetitive proteins allows escape mutants expressing variant forms to evade host immune systems and may limit the effectiveness of these vaccines (28). It is notable that each of the predicted proteins of 5 the *spb* and *ema* loci do not have a repetitive structure and would not have this disadvantage.

The novel GBS proteins we describe here may be useful antigens for a GBS vaccine. The data presented herein indicates these proteins have a role in mediating adhesion to 10 and invasion of GBS to human epithelial cells, thus antibody against these antigens may prevent these initial steps in infection. It is highly desirable to develop a vaccine that prevents colonization of pregnant women and other individuals at increased risk of invasive GBS infection, as this would eliminate most infections. Our data suggests that antibody against *Spb1* is effective in reducing colonization or infection following 15 colonization with highly virulent strains of serotype III, and therefore this protein is a particularly useful vaccine antigen. Members of the *ema* locus, unlike *spb1* and *spb2*, are ubiquitous in GBS and therefore have a role in the prevention of infection by multiple serotypes of GBS. An optimal vaccine formulation includes combinations of 20 these antigens.

20

Two strategies are used to design GBS vaccines using these novel proteins. First, purified recombinant or affinity-purified proteins are used as vaccine antigens, singly or in combination (25). Second, these proteins are used as carrier proteins for 25 capsular polysaccharide or oligosaccharide-based vaccines. GBS polysaccharides and oligosaccharides are generally poorly immunogenic and fail to elicit significant memory and booster responses (29). Conjugation of these polysaccharides or oligosaccharides to protein carriers increases immunogenicity. GBS polysaccharide conjugated to tetanus toxoid, for example, has been used to immunize pregnant women and results in high levels of maternal serum anti-polysaccharide antibody which may be transferred 30 to the fetus in the third trimester of pregnancy (30). Selection of appropriate carrier proteins is important for the development of polysaccharide-protein vaccine formulations. For example, *Haemophilus influenzae* type b poly- or oligosaccharide conjugated to different protein carriers has variable immunogenicity and elicits

antibody with varying avidity (31, 32). Repeated immunization with the same carrier protein may also suppress immune responses by competition for specific B cells (epitopic suppression) or other mechanisms. This is of particular concern for the development of GBS vaccines since recently developed polyaccharide and

5       oligosaccharide-protein conjugate vaccines against the bacteria *H. influenzae*, *S. pneumoniae*, and *N. meningitidis* all utilize a restricted number of carrier proteins (tetanus toxoid, CRM197, diphtheria toxoid), increasing the number of exposures to these carriers an individual is likely to receive. A "designer" vaccine, composed of a GBS polysaccharide or oligosaccharide coupled to a GBS-specific carrier protein,

10      such as the novel GBS polypeptides provided herein, particularly including Spb1, EmaC and EmaE, may be a preferable strategy. The large size of certain of these novel GBS antigens may also be an advantage to traditional carrier proteins as increasing size is associated with improved immunogenicity.

15

### EXAMPLE 3

#### EMA HOMOLOGS IN STREPTOCOCCI AND OTHER BACTERIA

As noted above, the GBS Ema proteins share segmental homology with certain characterized proteins from other bacterial species, including bacterial adhesion and

20     invasion proteins. The segmental homolog is noted as in the range of 24-39%. In addition, the Ema proteins demonstrate some homology to one another. A comparison of the *ema* genes shows that EmaA and EmaB are 47% homologous, however, due to the difference in their predicted lengths it is necessary to insert gaps in the EmaA sequence in order to line them up. The two Ema proteins which are most

25     similar in structure, EmaC and EmaD share 48.7% amino acid homology to one another. EmaA/B, EmaC/D and EmaE are each ≤ 20% homologous to one another.

The *ema* sequences were used to search the unannotated microbial genomes (Eubacteria). The predicted Ema proteins were searched against translations in all six

30     frames (tblast x) of finished and unfinished unannotated microbial genomes available at the web site of the National Center for Biotechnology Information (NCBI). Segmental amino acid homolog was identified.

EmaA has some segmental homolog with *S. pneumoniae*, *E. faecalis*, *B. anthracis* and *C. diphteriae*. Ema B has some segmental homolog with *B. anthracis*. EmaE has segmental homology to *S. pyogenes* and lesser homology to *B. anthracis*.

- 5 Significant homology was identified between the GBS EmaC and EmaD and proteins in other bacterial species. EmaC has significant (55% identity over 149 amino acids) homology to a region of the *S. pneumoniae* chromosome and the *S. pyogenes* chromosome (47% identity over 150 amino acids). Lesser segmental homology was found to *E. faecalis*, *S. equi*, and *C. diphteriae*. EmaD has strong segmental
- 10 homology (66% over 184 amino acids) to a region of the *S. pneumoniae* chromosome, and lesser segmental homology to *C. diphteriae* and *S. pyogenes*.

We have identified two Ema homologs in *S. pneumoniae*. These *S. pneumoniae* homologs show homology to EmaC and EmaD and, like EmaC and EmaD, also demonstrate homology to fimbria-associated protein of *Actinomyces*. The encoding nucleic acid and predicted amino acid sequence of the first *S. pneumoniae* EmaC/D homolog are provided in SEQ ID NOS: 24 and 23, respectively. The genome region nucleic acid including the first homolog encoding sequence is provided in SEQ ID NO: 22. The nucleic acid and predicted amino acid sequence of the second *S. pneumoniae* EmaC/D homolog are provided in SEQ ID NOS: 27 and 26 respectively. The genomic region nucleic acid of this second homolog is found in SEQ ID NO: 25. An EmaC/D homolog has been identified in *Enterococcus faecalis* by search and analysis. The *E. faecalis* EmaC/D homolog predicted amino acid sequence is provided in SEQ ID NO: 29. The nucleic acid sequence encoding this *E. faecalis* Ema homolog is provided in SEQ ID NO: 30. The nucleic acid sequence of *E. faecalis* which genomic region encodes the EmaC/D homolog is provided in SEQ ID NO: 28.

We have also identified an EmaD homolog in *Corynebacterium diphtheriae*. The predicted amino acid sequence of the *C. diphtheriae* EmaD homolog is provided in SEQ ID NO: 32. *C. diphtheriae* nucleic acid sequence which encodes the homolog is found in SEQ ID NO: 33. The corresponding genomic region sequence of *C. diphtheriae* is provided in SEQ ID NO: 31.

A predicted EmaC/D homolog has been identified in *S. pyogenes*. The predicted partial amino acid sequence of this Ema homolog provided in SEQ ID NO: 37.

A region of amino acids TLLTCTPYMINS/THRLLVR/KG (SEQ ID NO: 34) is 5 found in GBS EmaC, GBS EmaD, in both the EmaC/D homologs of *S. pneumoniae*, and in the *E. faecalis* Ema homolog. A similar sequence TLVTCTPYGINTHRLLVTA (SEQ ID NO: 35) is also found in the *C. diphtheriae* Ema homolog. The *S. pyogenes* predicted Ema homolog has a similar sequence TLVTCTPYGVNTKRLLVRG (SEQ ID NO: 36) as well.

10

The following is a list of the references referred to in this Example section.

#### References

- 15 1 Baker CJ. Group B streptococcal infections. In Streptococcal infections. Clinical aspects, microbiology, and molecular pathogenesis. (D. L. Stevens and E. L. Kaplan), New York: Oxford University Press, 222-237, 2000.
- 20 2 Blumberg HM, Stephens DS, Modansky M, Erwin M, Elliot J, Facklam RR, Schuchat A, Baughman W and Farley MM. Invasive group B streptococcal disease: The emergence of serotype V. *Journal of Infectious Diseases* 173:365-373, 1996.
- 25 3 Kogan G, Uhrin D, Brisson J-R, Paoletti LC, Blodgett AE, Kasper DL and Jennings HJ. Structural and immunochemical characterization of the type VIII group B *Streptococcus* capsular polysaccharide. *The Journal of Biological Chemistry* 271:8786-8790, 1996.
- 4 Rubens CE, Raff HV, Jackson CJ, Chi EY, Bielitzki JT and Hillier SL. Pathophysiology and histopathology of group B streptococcal sepsis in Macaca 30 nemestrina primates induced after intraamniotic inoculation: evidence for bacterial cellular invasion. *Journal of Infectious Diseases* 164:320--330, 1991.

5 Nagano Y, Nagano N, Takahashi S, Murono K, Fujita K, Taguchi F and Okuwaki Y. Restriction endonuclease digest patterns of chromosomal DNA from group B b-haemolytic streptococci. *Journal of Medical Microbiology* 35:297-303, 1991.

5

6 Takahashi S, Adderson EE, Nagano Y, Nagano N, Briesacher MR and Bohnsack JF. Identification of a highly encapsulated, genetically related group of invasive type III group B streptococci. *The Journal of Infectious Diseases* 177:1116-1119, 1998.

10

7 Lisitsyn N, Lisitsyn N and Wigler M. Cloning the differences between two complex genomes. *Science* 259:946-951, 1993.

15

8 Rubens CE, Smith S, Hulse M, Chi EY and van Belle G. Respiratory epithelial cell invasion by group B streptococci. *Infection & Immunity* 60:5157-63, 1992.

9 Tamura GS, Kuypers JM, Smith S, Raff H and Rubens CE. Adherence of group B streptococci to cultured epithelial cells: roles of environmental factors and bacterial surface components. *Infection and Immunity* 62:2450-8, 1994.

20

10 Nizet V, Kim KS, Stins M, Jonas M, Chi EY, Nguyen D and Rubens CE. Invasion of bran microvascular endothelial celss by group B streptococci. *Infection and Immunity* 65:5074-5081, 1997.

25

11 Gibson RL, Lee MK, Soderland C, Chi EY and Rubens CE. Group B streptococci invade endothelial cells: type III capsular polysaccharide attenuates invasion. *Infection & Immunity* 61:478-85, 1993.

12

12 Gravekamp C, Kasper DL, Michel JL, Kling DE, Carey V and Madoff LC. 30 Immunogenicity and protective efficacy of the alpha C protein of group B streptococci are inversely related to the number of repeats. *Infection and Immunity* 65:5216-5221, 1997.

13 Hill HR, Gonzales LA, Knappe WA, Fischer GW, Kelsey DK and Raff HV. Comparative protective activity of human monoclonal and hyperimmune polyclonal antibody against group B streptococci. *Journal of Infectious Diseases* 163:792-797, 1991.

5

14 Kim KS, Wass CA and Cross AS. Blood-brain barrier permeability during the development of experimental bacterial meningitis in the rat. *Experimental Neurology* 145:253-257, 1997.

10 15 Patti JM, Jonsson H, Guss B, Switalski LM, Wiberg K, Lindberg M and Hook M. Molecular characterization and expression of a gene encoding a *Staphylococcus aureus* collagen adhesin. *The Journal of Biologic Chemistry* 267:4766-4772, 1992.

16 Yeung MK and Cisar JO. Sequence homology between the subunits of two immunologically and functionally distinct types of fimbriae of *Actinomyces* spp. *The Journal of Bacteriology* 172:2462-8, 1990.

15

17 Li T, Johansson I, Hay DI and Stromberg N. Strains of *Actinomyces naeslundii* and *Actinomyces viscosus* exhibit structurally variant fimbrial subunit proteins and bind to different peptide motifs in salivary proteins. *Infection and Immunity* 67:2053-2059, 1999.

20

18 Jaffe J, Natanson-Yaron S, Caparon MG and Hanski E. Protein F2, a novel fibronectin-binding protein from *Streptococcus pyogenes*, possesses two binding domains. *Molecular Microbiology* 21:2720-728, 1996.

25

19 Rocha CL and Fischetti VA. Identification and characterization of a novel fibronectin-binding protein on the surface of Group A streptococci. *Infection and Immunity* 66:1482-1491, 1999.

30

20 Schneewind O, Jones KF and Fischetti VA. Sequence and structural characteristics of the trypsin-resistant T6 protein of group A streptococci. *The Journal of Bacteriology* 172:3310-7, 1990.

21 St. Geme III JW, Cutter D and Barenkamp SJ. Characterization of the genetic locus encoding *Haemophilus influenzae* type b surface fibrils. *The Journal of Bacteriology* 178:6281-6287, 1996.

5 22 Barenkamp SJ and Leininger E. Cloning, expression, and DNA sequence analysis of genes encoding nontypeable *Haemophilus influenzae* high-molecular-weight surface-exposed proteins related to filamentous hemagglutinin of *Bordatella pertussis*. *Infection and Immunity* 60:1302-1313, 1992.

10 23 Micheils T, Wattiau P, Brasseur R, Ruysschaert JM and Cornelis G. Secretion of Yop proteins by *Yersinia*. *Infection and Immunity* 58:2840-2849, 1990.

24 Gaillard JL, Berche P, Frehel C, Gouin E and Cossart P. Entry of *L. monocytogenes* into cells is mediated by internalin, a repeat protein reminiscent of 15 surface antigens from gram-positive cocci. *Cell* 65:1127-1141, 1991.

25 Madoff LC, Michel JL, Gong EW, Rodewald AK and Kasper DL. Protection of neonatal mice from group B streptococcal infection by maternal immunization with beta C protein. *Infection and Immunity* 60:4989-4994, 1992.

20

26 Stalhammar-Carlemalm M, Stenberg L and Lindahl G. Protein Rib: A novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections. *The Journal of Experimental Medicine* 177:1593-1603, 1993.

25

27 Ferrieri P and Flores AE. Surface protein expression in group B streptococcal invasive isolates. *Advances in Experimental Medicine* 418:635-637, 1997.

28 Madoff LC, Michel JT, Gong EW, Kling DE and Kasper DL. Group B

30 streptococci escape host immunity by deletion of tandem repeat elements of the alpha C protein. *Proceedings of the National Academy of Science U.S.A.* 93:4131-4136, 1996.

29 Baker CJ, Rench MA and Edwards MS. Immunization of pregnant women with a polysaccharide vaccine of group B Streptococcus. New England Journal of Medicine 319:1180-1185, 1988.

5 30 Baker CJ, Paoletti LC, Wessels MR, Guttormsen H-K, Rench MA, Hickman ME and Kasper DL. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. The Journal of Infectious Diseases 179:142-150, 1999.

10 31 Decker MD, Edwards KM, Bradley R and Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. The Journal of Pediatrics 120:184-189, 1992.

32 Schlesinger Y, Granoff DM and Group TVS. Avidity and bactericidal activity 15 of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. Journal of the American Medical Association 267:1489-1494, 1992.

This invention may be embodied in other forms or carried out in other ways without departing from the spirit or essential characteristics thereof. The present disclosure is 20 therefore to be considered as in all aspects illustrate and not restrictive, the scope of the invention being indicated by the appended Claims, and all changes which come within the meaning and range of equivalency are intended to be embraced therein.

Various references are cited throughout this Specification, each of which is 25 incorporated herein by reference in its entirety.

WHAT IS CLAIMED IS:

1. An isolated streptococcal polypeptide EmaA.
2. The EmaA polypeptide of Claim 1 which comprises the amino acid sequence set out in SEQ ID NO: 2, and analogs, variants and immunogenic fragments thereof.
3. An isolated streptococcal polypeptide EmaB.
4. The EmaC polypeptide of Claim 3 which comprises the amino acid sequence set out in SEQ ID NO: 4, and analogs, variants and immunogenic fragments thereof.
5. An isolated streptococcal polypeptide EmaC.
6. The EmaC polypeptide of Claim 5 which comprises the amino acid sequence set out in SEQ ID NO: 6, and analogs, variants and immunogenic fragments thereof.
7. An isolated streptococcal polypeptide EmaD.
8. The EmaD polypeptide of Claim 7 which comprises the amino acid sequence set out in SEQ ID NO: 8, and analogs, variants and immunogenic fragments thereof.
9. An isolated streptococcal polypeptide EmaE.
10. The EmaE polypeptide of Claim 9 which comprises the amino acid sequence set out in SEQ ID NO: 10, and analogs, variants and immunogenic fragments thereof.

11. The streptococcal polypeptide of any of Claims 1, 3, 5, 7 or 9 labeled with a detectable label.
12. A vaccine comprising one or more streptococcal polypeptides selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable adjuvant.
13. The vaccine of Claim 12, further comprising an antigen selected from the group consisting of:
  - a. the polypeptide Spb1 or an immunogenic fragment thereof;
  - b. the polypeptide Spb2 or an immunogenic fragment thereof;
  - c. the polypeptide C protein alpha antigen or an immunogenic fragment thereof;
  - d. the polypeptide Rib or an immunogenic fragment thereof;
  - e. the polypeptide Lmb or an immunogenic fragment thereof;
  - f. the polypeptide C5a-ase or an immunogenic fragment thereof;
  - g. Group B streptococcal polysaccharides or oligosaccharides; and
  - h. any combination of one or more of the foregoing.
14. An immunogenic composition comprising one or more streptococcal polypeptides selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable adjuvant.
15. The immunogenic composition of Claim 14, further comprising an antigen selected from the group consisting of:
  - a. the polypeptide Spb1 or an immunogenic fragment thereof;
  - b. the polypeptide Spb2 or an immunogenic fragment thereof;
  - c. the polypeptide C protein alpha antigen or an immunogenic fragment thereof;
  - d. the polypeptide Rib or an immunogenic fragment thereof;
  - e. the polypeptide Lmb or an immunogenic fragment thereof;
  - f. the polypeptide C5a-ase or an immunogenic fragment thereof;
  - g. Group B streptococcal polysaccharides or oligosaccharides; and

- h. any combination of one or more of the foregoing.
- 16. A pharmaceutical composition comprising one or more streptococcal polypeptides selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable carrier.
- 17. The pharmaceutical composition of Claim 16, further comprising an active ingredient selected from the group consisting of:
  - a. Spb1 or Spb2 polypeptide;
  - b. C protein alpha antigen;
  - c. Rib polypeptide;
  - d. Lmb polypeptide;
  - e. C5a-ase polypeptide;
  - f. a Group B streptococcal polysaccharide or oligosaccharide; and
  - g. an anti-streptococcal vaccine.
- 18. A purified antibody to a streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE.
- 19. A monoclonal antibody to a streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE.
- 20. An immortal cell line that produces a monoclonal antibody according to Claim 19.
- 21. The antibody of any of Claims 19 or 20 labeled with a detectable label.
- 22. The antibody of Claim 21 wherein the label is selected from the group consisting of an enzyme, a chemical which fluoresces, and a radioactive element.

23. A pharmaceutical composition comprising one or more antibodies to a streptococcal protein selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, and a pharmaceutically acceptable carrier.
24. A pharmaceutical composition comprising a combination of at least two antibodies to streptococcal proteins and a pharmaceutically acceptable carrier, wherein at least one antibody to a protein selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, is combined with at least one antibody to a protein selected from the group of Spb1 and Spb2, Rib, Lmb, C5a-ase and C protein alpha antigen.
25. An isolated nucleic acid which encodes the streptococcal polypeptide of Claim 1, or a fragment thereof.
26. The isolated nucleic acid of Claim 25, wherein the nucleic acid is selected from the group consisting of:
  - a. the DNA sequence of SEQ ID NO: 1;
  - b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions;
  - c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b);
  - d. degenerate variants thereof;
  - e. alleles thereof; and
  - f. hybridizable fragments thereof.
27. An isolated nucleic acid which encodes the streptococcal polypeptide of Claim 3.
28. The isolated nucleic acid of Claim 27, wherein the nucleic acid is selected from the group consisting of:
  - a. the DNA sequence of SEQ ID NO: 3;
  - b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions;

- c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b);
- d. degenerate variants thereof;
- e. alleles thereof; and
- f. hybridizable fragments thereof

29. An isolated nucleic acid which encodes the streptococcal polypeptide of Claim 5.

30. The isolated nucleic acid of Claim 29, wherein the nucleic acid is selected from the group consisting of:

- a. the DNA sequence of SEQ ID NO: 5;
- b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions;
- c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b);
- d. degenerate variants thereof;
- e. alleles thereof; and
- f. hybridizable fragments thereof

31. An isolated nucleic acid which encodes the streptococcal polypeptide of Claim 7.

32. The isolated nucleic acid of Claim 31, wherein the nucleic acid is selected from the group consisting of:

- a. the DNA sequence of SEQ ID NO: 7;
- b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions;
- c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b);
- d. degenerate variants thereof;
- e. alleles thereof; and
- f. hybridizable fragments thereof

33. An isolated nucleic acid which encodes the streptococcal polypeptide of Claim 9.
34. The isolated nucleic acid of Claim 33, wherein the nucleic acid is selected from the group consisting of:
  - a. the DNA sequence of SEQ ID NO: 9;
  - b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions;
  - c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b);
  - d. degenerate variants thereof;
  - e. alleles thereof; and
  - f. hybridizable fragments thereof
35. A vector which comprises the nucleic acid of any of Claims 25, 27, 29, 31 or 33 and a promoter.
36. The vector of Claim 35, wherein the promoter comprises a bacterial, yeast, insect or mammalian promoter.
37. The vector of Claim 35, wherein the vector is a plasmid, cosmid, yeast artificial chromosome (YAC), bacteriophage or eukaryotic viral DNA.
38. A host vector system for the production of a polypeptide which comprises the vector of Claim 35 in a suitable host cell.
39. The host vector system of Claim 38, wherein the suitable host cell comprises a prokaryotic or eukaryotic cell.
40. The nucleic acid of any of Claims 25, 27, 29, 31 or 33 which is a recombinant DNA molecule.

41. The recombinant DNA molecule of Claim 40, wherein the DNA molecule is operatively linked to an expression control sequence.
42. A unicellular host transformed with a recombinant DNA molecule of Claim 40.
43. A nucleic acid vaccine comprising the recombinant DNA molecule of Claim 40.
44. A method for detecting the presence of a streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE, wherein the streptococcal polypeptide is measured by:
  - a. contacting a sample in which the presence or activity of a streptococcal polypeptide selected from the group of EmaA, EmaB, EmaC, EmaD and EmaE is suspected with an antibody to the said streptococcal polypeptide under conditions that allow binding of the streptococcal polypeptide to antibody to occur; and
  - b. detecting whether binding has occurred between the streptococcal polypeptide from the sample and the antibody;wherein the detection of binding indicates the presence or activity of the streptococcal polypeptide in the sample.
45. A method for detecting the presence of a bacterium having a gene encoding a streptococcal polypeptide selected from the group of *emaA*, *emaB*, *emaC*, *emaD* and *emaE*, comprising:
  - a. contacting a sample in which the presence or activity of the bacterium is suspected with an oligonucleotide which hybridizes to a streptococcal polypeptide gene selected from the group of *emaA*, *emaB*, *emaC*, *emaD* and *emaE*, under conditions that allow specific hybridization of the oligonucleotide to the gene to occur; and
  - b. detecting whether hybridization has occurred between the oligonucleotide and the gene;wherein the detection of hybridization indicates that presence or activity of the bacterium in the sample.

46. A method for preventing infection with a bacterium that expresses a streptococcal Ema polypeptide comprising administering an immunogenically effective dose of a vaccine of Claim 12 to a subject.
47. A method for preventing infection with a bacterium that expresses a streptococcal Ema polypeptide comprising administering an immunogenically effective dose of the immunogenic composition of Claim 14 to a subject.
48. A method for treating infection with a bacterium that expresses a streptococcal Ema polypeptide comprising administering a therapeutically effective dose of a pharmaceutical composition of Claim 16 to a subject.
49. A method for treating infection with a bacterium that expresses a streptococcal Ema polypeptide comprising administering a therapeutically effective dose of a pharmaceutical composition of Claim 23 to a subject.
50. A method of inducing an immune response in a subject which has been exposed to or infected with a streptococcal bacterium comprising administering to the subject an amount of the pharmaceutical composition of Claim 16, thereby inducing an immune response.
51. A method for preventing infection by a streptococcal bacterium in a subject comprising administering to the subject an amount of a pharmaceutical composition of Claim 23 and a pharmaceutically acceptable carrier or diluent, thereby preventing infection by a streptococcal bacterium.
52. An isolated streptococcal Ema polypeptide comprising the amino acid sequence set out in SEQ ID NO:23.
53. An isolated nucleic acid which encodes the streptococcal polypeptide of Claim 52.

5 54. The isolated nucleic acid of Claim 53, wherein the nucleic acid is selected from the group consisting of:

- a. the DNA sequence of SEQ ID NO: 24;
- b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions;
- 10 c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b);
- d. degenerate variants thereof;
- e. alleles thereof; and
- f. hybridizable fragments thereof.

15 55. An isolated streptococcal Ema polypeptide comprising the amino acid sequence set out in SEQ ID NO:26.

56. An isolated nucleic acid which encodes the streptococcal polypeptide of Claim 55.

57. The isolated nucleic acid of Claim 56, wherein the nucleic acid is selected from the group consisting of:

- a. the DNA sequence of SEQ ID NO: 27;
- b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions;
- 20 c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b);
- d. degenerate variants thereof;
- e. alleles thereof; and
- f. hybridizable fragments thereof.

25 58. An isolated streptococcal Ema polypeptide comprising the amino acid sequence set out in SEQ ID NO:37.

30 59. An isolated nucleic acid which encodes the streptococcal polypeptide of Claim 58.

60. An enterococcal Ema polypeptide comprising the amino acid sequence set out in SEQ ID NO:29.

35 61. An isolated nucleic acid which encodes the enterococcal polypeptide of Claim 60.

62. The isolated nucleic acid of Claim 61, wherein the nucleic acid is selected from the group consisting of:

40 a. the DNA sequence of SEQ ID NO: 30;

b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions;

c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b);

d. degenerate variants thereof;

45 e. alleles thereof; and

f. hybridizable fragments thereof.

63. An isolated *Corynebacterium* Ema polypeptide comprising the amino acid sequence set out in SEQ ID NO: 32.

50 64. An isolated nucleic acid which encodes the *Corynebacterium* polypeptide of Claim 63.

65. The isolated nucleic acid of Claim 64, wherein the nucleic acid is selected from the group consisting of:

55 a. the DNA sequence of SEQ ID NO: 33;

b. DNA sequences that hybridize to the sequence of subpart (a) under moderate stringency hybridization conditions;


c. DNA sequences capable of encoding the amino acid sequence encoded by the DNA sequences of (a) or (b);

d. degenerate variants thereof;

e. alleles thereof; and

60 f. hybridizable fragments thereof.

66. An isolated bacterial polypeptide comprising the amino acid sequence TLLTCTPYMINS/THRLLVR/KG (SEQ ID NO: 34), wherein the polypeptide is not isolated from *Actinomyces*.
67. An isolated streptococcal polypeptide comprising the amino acid sequence TLLTCTPYMINS/THRLLVR/KG (SEQ ID NO: 34).
68. An isolated bacterial polypeptide comprising the amino acid sequence TLVTCTPYGINTHRLLVTA (SEQ ID NO: 35).
69. An isolated bacterial polypeptide comprising the amino acid sequence TLVTCTPYGVNTKRLLVRG (SEQ ID NO: 36).
- 70 70. An isolated streptococcal polypeptide comprising the amino acid sequence TLVTCTPYGVNTKRLLVRG (SEQ ID NO: 36).
71. An isolated polypeptide having the amino acid sequence selected from the group of TLLTCTPYMINS/THRLLVR/KG (SEQ ID NO: 34), TLVTCTPYGINTHRLLVTA (SEQ ID NO: 35), and TLVTCTPYGVNTKRLLVRG (SEQ ID NO: 36).



**Figure 1. RDP type III-3 specific probes.** Dot blot hybridization of probe DY1-1 with genomic DNA isolated from type III GBS. 10 ug of genomic DNA from each of 62 type III GBS strains was transferred to nylon membrane. Radiolabeled probe 1 hybridized with DNA from all III-3 strains (rows A-D) including the original type III-3 strain (well E-1). The probe failed to hybridize with DNA from III-2 strains (F1- F10, G1-7) including the original strain used in the subtraction hybridization (well E 10) and III-1 strains (wells H1-3; cf. Figure 3). The same pattern of hybridization was observed using probe DY1-11.

## FIGURE 1

**EmaA**

atg acc ctt gtt aaa aat caa gat gct ctt gat aaa gct act gca aat	48
Met Thr Leu Val Lys Asn Gln Asp Ala Leu Asp Lys Ala Thr Ala Asn	
1 5 10 15	
aca gat gat gcg gca ttt ttg gaa att cca gtt gca tca act att aat	96
Thr Asp Asp Ala Ala Phe Leu Glu Ile Pro Val Ala Ser Thr Ile Asn	
20 25 30	
gaa aaa gca gtt tta gga aaa gca att gaa aat act ttt gaa ctt caa	144
Glu Lys Ala Val Leu Gly Lys Ala Ile Glu Asn Thr Phe Glu Leu Gln	
35 40 45	
tat gac cat act cct gat aaa gct gac aat cca aaa cca tct aat cct	192
Tyr Asp His Thr Pro Asp Lys Ala Asp Asn Pro Lys Pro Ser Asn Pro	
50 55 60	
cca aga aaa cca gaa gtt cat act ggt ggg aaa cga ttt gta aag aaa	240
Pro Arg Lys Pro Glu Val His Thr Gly Gly Lys Arg Phe Val Lys Lys	
65 70 75 80	
gac tca aca gaa aca caa aca cta ggt ggt gct gag ttt gat ttg ttg	288
Asp Ser Thr Glu Thr Gln Thr Leu Gly Gly Ala Glu Phe Asp Leu Leu	
85 90 95	
gct tct gat ggg aca gca gta aaa tgg aca gat gct ctt att aaa gcg	336
Ala Ser Asp Gly Thr Ala Val Lys Trp Thr Asp Ala Leu Ile Lys Ala	
100 105 110	
aat act aat aaa aac tat att gct gga gaa gct gtt act ggg caa cca	384
Asn Thr Asn Lys Asn Tyr Ile Ala Gly Glu Ala Val Thr Gly Gln Pro	
115 120 125	
atc aaa ttg aaa tca cat aca gac ggt acg ttt gag att aaa ggt ttg	432
Ile Lys Leu Lys Ser His Thr Asp Gly Thr Phe Glu Ile Lys Gly Leu	
130 135 140	
gct tat gca gtt gat gcg aat gca gag ggt aca gca gta act tac aaa	480
Ala Tyr Ala Val Asp Ala Asn Ala Glu Gly Thr Ala Val Thr Tyr Lys	
145 150 155 160	
tta aaa gaa aca aaa gca cca gaa ggt tat gta atc cct gat aaa gaa	528
Leu Lys Glu Thr Lys Ala Pro Glu Gly Tyr Val Ile Pro Asp Lys Glu	
165 170 175	
atc gag ttt aca gta tca caa aca tct tat aat aca aaa cca act gac	576
Ile Glu Phe Thr Val Ser Gln Thr Ser Tyr Asn Thr Lys Pro Thr Asp	
180 185 190	
atc acg gtt gat agt gct gat gca aca cct gat aca att aaa aac aac	624
Ile Thr Val Asp Ser Ala Asp Ala Thr Pro Asp Thr Ile Lys Asn Asn	
195 200 205	
aaa cgt cct tca atc cct aat act ggt ggt att ggt acg gct atc ttt	672
Lys Arg Pro Ser Ile Pro Asn Thr Gly Gly Ile Thr Ala Ile Phe	
210 215 220	
gtc gct atc ggt gct gcg gtc atg gct ttt gct gtt aag ggg atg aag	720
Val Ala Ile Gly Ala Ala Val Met Ala Phe Ala Val Lys Gly Met Lys	
225 230 235 240	
cgt cgt aca aaa gat aac taa	738
Arg Arg Thr Lys Asp Asn	
245	

**FIGURE 2**

**EmaB**

atg aaa caa aca tta aaa ctt atg ttt tct ctg ttg atg tta ggg Met Lys Gln Thr Leu Lys Leu Met Phe Ser Phe Leu Leu Met Leu Gly 1 5 10 15	48
act atg ttt gga att agc caa act gtt tta gcg caa gaa act cat cag Thr Met Phe Gly Ile Ser Gin Thr Val Leu Ala Gln Glu Thr His Gln 20 25 30	96
ttg acg att gtt cat ctt gaa gca agg gat att gat cgt cca aat cca Leu Thr Ile Val His Leu Glu Ala Arg Asp Ile Asp Arg Pro Asn Pro 35 40 45	144
cag ttg gag att gcc cct aaa gaa ggg act cca att gaa gga gta ctc Gln Leu Glu Ile Ala Pro Lys Glu Gly Thr Pro Ile Glu Gly Val Leu 50 55 60	192
tat cag ttg tac caa tta aaa tca act gaa gat ggc gat ttg ttg gca Tyr Gln Leu Tyr Gln Leu Lys Ser Thr Glu Asp Gly Asp Leu Leu Ala 65 70 75 80	240
cat tgg aat tcc cta act atc aca gaa ttg aaa aaa cag gcg cag cag His Trp Asn Ser Leu Thr Ile Thr Glu Leu Lys Lys Gln Ala Gln Gln 85 90 95	288
gtt ttt gaa gcc act act aat caa caa gga'ag gct aca ttt aac caa Val Phe Glu Ala Thr Thr Asn Gln Gln Gly Lys Ala Thr Phe Asn Gln 100 105 110	336
cta cca gat gga att tat tat ggt ctg gcg gtt aaa gcc ggt gaa aaa Leu Pro Asp Gly Ile Tyr Tyr Gly Leu Ala Val Lys Ala Gly Glu Lys 115 120 125	384
aat cgt aat gtc tca gct ttc ttg gtt gac ttg tct gag gat aaa gtg Asn Arg Asn Val Ser Ala Phe Leu Val Asp Leu Ser Glu Asp Lys Val 130 135 140	432
att tat cct aaa atc atc tgg tcc aca ggt gag ttg gac ttg ctt aaa Ile Tyr Pro Lys Ile Ile Trp Ser Thr Gly Glu Leu Asp Leu Leu Lys 145 150 155 160	480
gtt ggt gtg gat ggt gat acc aaa aaa cca cta gca ggc gtt gtc ttt Val Gly Val Asp Gly Asp Thr Lys Lys Pro Leu Ala Gly Val Val Phe 165 170 175	528
gaa ctt tat gaa aag aat ggt agg act cct att cgt gtg aaa aat ggg Glu Leu Tyr Glu Lys Asn Gly Arg Thr Pro Ile Arg Val Lys Asn Gly 180 185 190	576
gtg cat tct caa gat att gac gct gca aaa cat tta gaa aca gat tca Val His Ser Gln Asp Ile Asp Ala Ala Lys His Leu Glu Thr Asp Ser 195 200 205	624
tca ggg cat atc aga att tcc ggg ctc atc cat ggg gac tat gtc tta Ser Gly His Ile Arg Ile Ser Gly Leu Ile His Gly Asp Tyr Val Leu 210 215 220	672
aaa gaa atc gag aca cag tca gga tat cag atc gga cag gca gag act Lys Glu Ile Glu Thr Gln Ser Gly Tyr Gln Ile Gly Gln Ala Glu Thr 225 230 235 240	720
gct gtg act att gaa aaa tca aaa aca gta aca gta acg att gaa aat Ala Val Thr Ile Glu Lys Ser Lys Thr Val Thr Val Thr Ile Glu Asn 245 250 255	768
aaa aaa gtt ccc aca cct aaa gtg cca tct cga gga ggt ctt att ccc Lys Lys Val Pro Thr Pro Lys Val Pro Ser Arg Gly Gly Leu Ile Pro 260 265 270	816

**FIGURE 3A**

aaa aca ggt gag caa cag gca atg gca ctt gta att att ggt ggt att	864	
Lys Thr Gly Glu Gln Gln Ala Met Ala Leu Val Ile Ile Gly Gly Ile		
275	280	285
..		
tta att gct tta gcc tta cga tta cta tca aaa cat cgg aaa cat caa	912	
Leu Ile Ala Leu Ala Leu Arg Leu Leu Ser Lys His Arg Lys His Gln		
290	295	300
aat aag gat tag	924	
Asn Lys Asp		
305		

## FIGURE 3B

**EmaC**

atg gga caa aaa tca aaa ata tct cta gct acg aat att cgt ata tgg	48
Met Gly Gln Lys Ser Lys Ile Ser Leu Ala Thr Asn Ile Arg Ile Trp	
1 5 10 15	
att ttt cgt tta att ttc tta gcg ggt ttc ctt gtt ttg gca ttt ccc	96
Ile Phe Arg Leu Ile Phe Leu Ala Gly Phe Leu Val Leu Ala Phe Pro	
20 25 30	
atc gtt agt cag gtc atg tac ttt caa gcc tct cac gcc aat att aat	144
Ile Val Ser Gln Val Met Tyr Phe Gln Ala Ser His Ala Asn Ile Asn	
35 40 45	
gct ttt aaa gaa gct gtt acc aag att gac cgg gtg gag att aat cgg	192
Ala Phe Lys Glu Ala Val Thr Lys Ile Asp Arg Val Glu Ile Asn Arg	
50 55 60	
cgt tta gaa ctt gct tat gct tat aac gcc agt ata gca ggt gcc aaa	240
Arg Leu Glu Leu Ala Tyr Ala Tyr Asn Ala Ser Ile Ala Gly Ala Lys	
65 70 75 80	
act aat ggc gaa tat cca gcg ctt aaa gac ccc tac tct gct gaa caa	288
Thr Asn Gly Glu Tyr Pro Ala Leu Lys Asp Pro Tyr Ser Ala Glu Gln	
85 90 95	
aag cag gca ggg gtc gtt gag tac gcc cgc atg ctt gaa gtc aaa gaa	336
Lys Gln Ala Gly Val Val Glu Tyr Ala Arg Met Leu Glu Val Lys Glu	
100 105 110	
caa ata ggt cat gtg att att cca aga att aat cag gat atc cct att	384
Gln Ile Gly His Val Ile Ile Pro Arg Ile Asn Gln Asp Ile Pro Ile	
115 120 125	
tac gct ggc tct gct gaa gaa aat ctt cag agg ggc gtt gga cat tta	432
Tyr Ala Gly Ser Ala Glu Glu Asn Leu Gln Arg Gly Val Gly His Leu	
130 135 140	
gag ggg acc agt ctt cca gtc ggt ggt gag tca act cat gcc gtt cta	480
Glu Gly Thr Ser Leu Pro Val Gly Gly Glu Ser Thr His Ala Val Leu	
145 150 155 160	
act gcc cat cga ggg cta cca acg gcc aag cta ttt acc aat tta gac	528
Thr Ala His Arg Gly Leu Pro Thr Ala Lys Leu Phe Thr Asn Leu Asp	
165 170 175	
aag gta aca gta ggt gac cgt ttt tac att gaa cac atc ggc gga aag	576
Lys Val Thr Val Gly Asp Arg Phe Tyr Ile Glu His Ile Gly Gly Lys	
180 185 190	
att gct tat cag gta gac caa atc aaa gtt atc gcc cct gat cag tta	624
Ile Ala Tyr Gln Val Asp Gln Ile Lys Val Ile Ala Pro Asp Gln Leu	
195 200 205	
gag gat ttg tac gtg att caa gga gaa gat cac gtc acc cta tta act	672
Glu Asp Leu Tyr Val Ile Gln Gly Glu Asp His Val Thr Leu Leu Thr	
210 215 220	
tgc aca cct tat atg ata aat agt cat cgc ctc ctc gtt cga ggc aag	720
Cys Thr Pro Tyr Met Ile Asn Ser His Arg Leu Leu Val Arg Gly Lys	
225 230 235 240	
cga att cct tat gtg gaa aaa aca gtg cag aaa gat tca aag acc ttc	768
Arg Ile Pro Tyr Val Glu Lys Thr Val Gln Lys Asp Ser Lys Thr Phe	
245 250 255	
agg caa caa caa tac cta acc tat gct atg tgg gta gtc gtt gga ctt	816
Arg Gln Gln Gln Tyr Leu Thr Tyr Ala Met Trp Val Val Gly Leu	
260 265 270	
atc ttg ctg tcg ctt ctc att tgg ttt aaa aag acg aaa cag aaa aag	864
Ile Leu Ser Leu Leu Ile Trp Phe Lys Lys Thr Lys Gln Lys Lys	
275 280 285	
cggtt aag aat gaa aaa gcg gct agt caa aat agt cac aat aat tcg	912
Arg Arg Lys Asn Glu Lys Ala Ala Ser Gln Asn Ser His Asn Asn Ser	
290 295 300	
aaa taa	918
Lys	
305	

**FIGURE 4**

**EmaD**

atg aaa aag cgg cta gtc aaa ata gtc aca ata att cga aat aat aaa	48
Met Lys Lys Arg Leu Val Lys Ile Val Thr Ile Ile Arg Asn Asn Lys	
1 5 10 15	
atc aga acc ctc att ttt gtg atg gga agt ctg att ctc tta ttt ccg	96
Ile Arg Thr Leu Ile Phe Val Met Gly Ser Leu Ile Leu Phe Pro	
20 25 30	
att gtg agc cag gta agt tac tac ctt gct tcg cat caa aat att aat	144
Ile Val Ser Gln Val Ser Tyr Tyr Leu Ala Ser His Gln Asn Ile Asn	
35 40 45	
caa ttt aag cgg gaa gtc gct aag att gat act aat acg gtt gaa cga	192
Gln Phe Lys Arg Glu Val Ala Lys Ile Asp Thr Asn Thr Val Glu Arg	
50 55 60	
cgc atc gct tta gct aat gct tac aat gag acg tta tca agg aat ccc	240
Arg Ile Ala Leu Ala Asn Ala Tyr Asn Glu Thr Leu Ser Arg Asn Pro	
65 70 75 80	
ttg ctt ata gac cct ttt acc agt aag caa aaa gaa ggt ttg aga gag	288
Leu Leu Ile Asp Pro Phe Thr Ser Lys Gln Lys Glu Gly Leu Arg Glu	
85 90 95	
tat gct cgt atg ctt gaa gtt cat gag caa ata ggt cat gtg gca atc	336
Tyr Ala Arg Met Leu Glu Val His Glu Gln Ile Gly His Val Ala Ile	
100 105 110	
cca agt att ggg gtt gat att cca att tat gct gga aca tcc gaa act	384
Pro Ser Ile Gly Val Asp Ile Pro Ile Tyr Ala Gly Thr Ser Glu Thr	
115 120 125	
gtg ctt cag aaa ggt agt ggg cat ttg gag gga acc agt ctt cca gtg	432
Val Leu Gln Lys Gly Ser Gly His Leu Glu Gly Thr Ser Leu Pro Val	
130 135 140	
gga ggt ttg tca acc cat tca gta cta act gcc cac cgt ggc ttg cca	480
Gly Gly Leu Ser Thr His Ser Val Leu Thr Ala His Arg Gly Leu Pro	
145 150 155 160	
aca gct agg cta ttt acc cat gac tta aat aaa gtt aaa aaa ggc cag att	528
Thr Ala Arg Leu Phe Thr Asp Leu Asn Lys Val Lys Lys Gly Gln Ile	
165 170 175	
ttc tat gtg acg aac atc aag gaa aca ctt gcc tac aaa gtc gtg tct	576
Phe Tyr Val Thr Asn Ile Lys Glu Thr Leu Ala Tyr Lys Val Val Ser	
180 185 190	
atc aaa gtt gtg gat cca aca gct tta agt gag gtt aag att gtc aat	624
Ile Lys Val Val Asp Pro Thr Ala Leu Ser Glu Val Lys Ile Val Asn	
195 200 205	
ggt aag gat tat ata acc ttg ctg act tgc aca cct tac atg atc aat	672
Gly Lys Asp Tyr Ile Thr Leu Leu Thr Cys Thr Pro Tyr Met Ile Asn	
210 215 220	
agt cat cgt ctc ttg gta aaa gga gag cgt att cct tat gat tct acc	720
Ser His Arg Leu Leu Val Lys Gly Glu Arg Ile Pro Tyr Asp Ser Thr	
225 230 235 240	
gag gcg gaa aag cac aaa gaa caa acc gta caa gat tat cgt ttg tca	768
Glu Ala Glu Lys His Lys Glu Gln Thr Val Gln Asp Tyr Arg Leu Ser	
245 250 255	
cta gtg ttg aag ata cta cta gta tta att gga ctc ttc atc gtg	816
Leu Val Leu Lys Ile Leu Leu Val Leu Ile Gly Leu Phe Ile Val	
260 265 270	
ata atg atg aga aga tgg atg caa cat cgt caa taa	852
Ile Met Met Arg Arg Trp Met Gln His Arg Gln	

## EmaE

atg atg att gtg aat aat ggt tat cta gaa ggg aga aaa atg aaa aag Met Met Ile Val Asn Asn Gly Tyr Leu Glu Gly Arg Lys Met Lys Lys 1 5 10 15	48
aga caa aaa ata tgg aga ggg tta tca gtt act tta cta atc ctg tcc Arg Gln Lys Ile Trp Arg Gly Leu Ser Val Thr Leu Leu Ile Leu Ser 20 25 30	96
caa att cca ttt ggt ata ttg gta caa ggt gaa acc caa gat acc aat Gln Ile Pro Phe Gly Ile Leu Val Gln Gly Glu Thr Gln Asp Thr Asn 35 40 45	144
caa gca ctt gga aaa gta att gtt aaa aaa acg gga gac aat gct aca Gln Ala Leu Gly Lys Val Ile Val Lys Thr Gly Asp Asn Ala Thr 50 55 60	192
cca tta ggc aaa gcg act ttt gtg tta aaa aat gac aat gat aag tca Pro Leu Gly Lys Ala Thr Phe Val Leu Lys Asn Asp Asn Asp Lys Ser 65 70 75 80	240
gaa aca agt cac gaa acg gta gag ggt tct gga gaa gca acc ttt gaa Glu Thr Ser His Glu Thr Val Glu Gly Ser Gly, Glu Ala Thr Phe Glu 85 90 95	288
aac ata aaa cct gga gac tac aca tta aga gaa gaa aca gca cca att Asn Ile Lys Pro Gly Asp Tyr Thr Leu Arg Glu Glu Thr Ala Pro Ile 100 105 110	336
ggg tat aaa aaa act gat aaa acc tgg aaa gtt aaa gtt gca gat aac Gly Tyr Lys Lys Thr Asp Lys Thr Trp Lys Val Lys Val Ala Asp Asn 115 120 125	384
gga gca aca ata atc gag ggt atg gat gca gat aaa gca gag aaa cga Gly Ala Thr Ile Ile Glu Gly Met Asp Ala Asp Lys Ala Glu Lys Arg 130 135 140	432
aaa gaa gtt ttg aat gcc caa tat cca aaa tca gct att tat gag gat Lys Glu Val Leu Asn Ala Gln Tyr Pro Lys Ser Ala Ile Tyr Glu Asp 145 150 155 160	480
aca aaa gaa aat tac cca tta gtt aat gta gag ggt tcc aaa gtt ggt Thr Lys Glu Asn Tyr Pro Leu Val Asn Val Glu Gly Ser Lys Val Gly 165 170 175	528
gaa caa tac aaa gca ttg aat cca ata aat gga aaa gat ggt cga aga Glu Gln Tyr Lys Ala Leu Asn Pro Ile Asn Gly Lys Asp Gly Arg Arg 180 185 190	576
gag att gct gaa ggt tgg tta tca aaa aaa aat aca ggg gtc aat gat Glu Ile Ala Glu Gly Trp Leu Ser Lys Lys Asn Thr Gly Val Asn Asp 195 200 205	624
ctc gat aag aat aaa tat aaa att gaa tta act gtt gag ggt aaa acc Leu Asp Lys Asn Lys Tyr Ile Glu Leu Thr Val Glu Gly Lys Thr 210 215 220	672
act gtt gaa acg aaa gaa ctt aat caa cca cta gat gtc gtt gtt gta Thr Val Glu Thr Lys Glu Leu Asn Gln Pro Leu Asp Val Val Val Leu 225 230 235 240	720
tta gat aat tca aat agt atg aat aat gaa aga gca aat aat tct caa Leu Asp Asn Ser Asn Ser Met Asn Asn Glu Arg Ala Asn Asn Ser Gln 245 250 255	768
aga gca tta aaa gct ggg gaa gca gtt gaa aag ctg att gat aaa att Arg Ala Leu Lys Ala Gly Glu Ala Val Glu Lys Leu Ile Asp Lys Ile 260 265 270	816
aca tca aat aaa gac aat aga gta gct ctt gtg aca tat gcc tca acc Thr Ser Asn Lys Asp Asn Arg Val Ala Leu Val Thr Tyr Ala Ser Thr	864

## FIGURE 6A

275	280	285	
att ttt gat ggt act gaa gca acc gta tca aag gga gtt gcc gat caa Ile Phe Asp Gly Thr Glu Ala Thr Val Ser Lys Gly Val Ala Asp Gln 290 295 300			912
aat ggt aaa gcg ctg aat gat agt gta tca tgg gat tat cat aaa act Asn Gly Lys Ala Leu Asn Asp Ser Val Ser Trp Asp Tyr His Lys Thr 305 310 315 320			960
act ttt aca gca act aca cat aat tac agt tat tta aat tta aca aat Thr Phe Thr Ala Thr His Asn Tyr Ser Tyr Leu Asn Leu Thr Asn 325 330 335			1008
gat gct aac gaa gtt aat att cta aag tca aga att cca aag gaa gcg Asp Ala Asn Glu Val Asn Ile Leu Lys Ser Arg Ile Pro Lys Glu Ala 340 345 350			1056
gag cat ata aat ggg gat cgc acg ctc tat caa ttt ggt gcg aca ttt Glu His Ile Asn Gly Asp Arg Thr Leu Tyr Gln Phe Gly Ala Thr Phe 355 360 365			1104
act caa aaa gct cta atg aaa gca aat gaa att tta gag aca caa agt Thr Gln Lys Ala Leu Met Lys Ala Asn Glu Ile Leu Glu Thr Gln Ser 370 375 380			1152
tct aat gct aga aaa aaa ctt att ttt cac gta act gat ggt gtc cct Ser Asn Ala Arg Lys Lys Leu Ile Phe His Val Thr Asp Gly Val Pro 385 390 395 400			1200
acg atg tct tat gcc ata aat ttt aat cct tat ata tca aca tct tac Thr Met Ser Tyr Ala Ile Asn Phe Asn Pro Tyr Ile Ser Thr Ser Tyr 405 410 415			1248
caa aac cag ttt aat tct ttt tta aat aaa ata cca gat aga agt ggt Gln Asn Gln Phe Asn Ser Phe Leu Asn Lys Ile Pro Asp Arg Ser Gly 420 425 430			1296
att ctc caa gag gat ttt ata atc aat ggt gat gat tat caa ata gta Ile Leu Gln Glu Asp Phe Ile Ile Asn Gly Asp Asp Tyr Gln Ile Val 435 440 445			1344
aaa gga gat gga gag agt ttt aaa ctg ttt tcg gat aga aaa gtt cct Lys Gly Asp Gly Glu Ser Phe Lys Leu Phe Ser Asp Arg Lys Val Pro 450 455 460			1392
gtt act gga gga acg aca caa gca gct tat cga gta ccg caa aat caa Val Thr Gly Gly Thr Thr Gln Ala Ala Tyr Arg Val Pro Gln Asn Gln 465 470 475 480			1440
ctc tct gta atg agt aat gag gga tat gca att aat agt gga tat att Leu Ser Val Met Ser Asn Glu Gly Tyr Ala Ile Asn Ser Gly Tyr Ile 485 490 495			1488
tat ctc tat tgg aga gat tac aac tgg gtc tat cca ttt gat cct aag Tyr Leu Tyr Trp Arg Asp Tyr Asn Trp Val Tyr Pro Phe Asp Pro Lys 500 505 510			1536
aca aag aaa gtt tct gca acg aaa caa atc aaa act cat ggt gag cca Thr Lys Lys Val Ser Ala Thr Lys Gln Ile Lys Thr His Gly Glu Pro 515 520 525			1584
aca aca tta tac ttt aat gga aat ata aga cct aaa ggt tat gac att Thr Thr Leu Tyr Phe Asn Gly Asn Ile Arg Pro Lys Gly Tyr Asp Ile 530 535 540			1632
ttt act gtt ggg att ggt gta aac gga gat cct ggt gca act cct ctt Phe Thr Val Gly Ile Gly Val Asn Gly Asp Pro Gly Ala Thr Pro Leu 545 550 555 560			1680
gaa gct gag aaa ttt atg caa tca ata tca agt aaa aca gaa aat tat			1728

Glu Ala Glu Lys Phe Met Gln Ser Ile Ser Ser Lys Thr Glu Asn Tyr			
565	570	575	
act aat gtt gat gat aca aat aaa att tat gat gag cta aat aaa tac		1776	
Thr Asn Val Asp Asp Thr Asn Lys Ile Tyr Asp Glu Leu Asn Lys Tyr			
580	585	590	
ttt aaa aca att gtt gag gaa aaa cat tct att gtt gat gga aat gtg		1824	
Phe Lys Thr Ile Val Glu Glu Lys His Ser Ile Val Asp Gly Asn Val			
595	600	605	
act gat cct atg gga gag atg att gaa ttc caa tta aaa aat ggt caa		1872	
Thr Asp Pro Met Gly Glu Met Ile Glu Phe Gln Leu Lys Asn Gly Gln			
610	615	620	
agt ttt aca cat gat gat tac gtt ttg gtt gga aat gat ggc agt caa		1920	
Ser Phe Thr His Asp Asp Tyr Val Leu Val Gly Asn Asp Gly Ser Gln			
625	630	635	640
tta aaa aat ggt gtg gct ctt ggt gga cca aac agt gat ggg gga att		1968	
Leu Lys Asn Gly Val Ala Leu Gly Gly Pro Asn Ser Asp Gly Gly Ile			
645	650	655	
tta aaa gat gtt aca gtg act tat gat aag aca tct caa acc acc atc aaa		2016	
Leu Lys Asp Val Thr Val Thr Tyr Asp Lys Thr Ser Gln Thr Ile Lys			
660	665	670	
atc aat cat ttg aac tta gga agt gga caa aaa gta gtt ctt acc tat		2064	
Ile Asn His Leu Asn Leu Gly Ser Gly Gln Lys Val Val Leu Thr Tyr			
675	680	685	
gat gta cgt tta aaa gat aac tat ata agt aac aaa ttt tac aat aca		2112	
Asp Val Arg Leu Lys Asp Asn Tyr Ile Ser Asn Lys Phe Tyr Asn Thr			
690	695	700	
aat aat cgt aca acg cta agt ccg aag agt gaa aaa gaa cca aat act		2160	
Asn Asn Arg Thr Thr Leu Ser Pro Lys Ser Glu Lys Glu Pro Asn Thr			
705	710	715	720
att cgt gat ttg cca att ccc aaa att cgt gat gtt cgt gag ttt ccg		2208	
Ile Arg Asp Phe Pro Ile Pro Lys Ile Arg Asp Val Arg Glu Phe Pro			
725	730	735	
gta cta acc atc agt aat cag aag aaa atg ggt gag gtt gaa ttt att		2256	
Val Leu Thr Ile Ser Asn Gln Lys Lys Met Gly Glu Val Glu Phe Ile			
740	745	750	
aaa gtt aat aaa gac aaa cat tca gaa tcg ctt ttg gga gct aag ttt		2304	
Lys Val Asn Lys Asp Lys His Ser Glu Ser Leu Leu Gly Ala Lys Phe			
755	760	765	
caa ctt cag ata gaa aaa gat ttt tct ggg tat aag caa ttt gtt cca		2352	
Gln Leu Gln Ile Glu Lys Asp Phe Ser Gly Tyr Lys Gln Phe Val Pro			
770	775	780	
gag gga agt gat gtt aca aca aag aat gat ggt aaa att tat ttt aaa		2400	
Glu Gly Ser Asp Val Thr Thr Lys Asn Asp Gly Lys Ile Tyr Phe Lys			
785	790	795	800
gca ctt caa gat ggt aac tat aaa tta tat gaa att tca agt cca gat		2448	
Ala Leu Gln Asp Gly Asn Tyr Lys Leu Tyr Glu Ile Ser Ser Pro Asp			
805	810	815	
ggc tat ata gag gtt aaa acg aaa cct gtt gtg aca ttt aca att caa		2496	
Gly Tyr Ile Glu Val Lys Thr Lys Pro Val Val Thr Phe Thr Ile Gln			
820	825	830	
aat gga gaa gtt acg aac ctg aaa gca gat cca aat gct aat aaa aat		2544	
Asn Gly Glu Val Thr Asn Leu Lys Ala Asp Pro Asn Ala Asn Lys Asn			
835	840	845	

FIGURE 6C

caa atc ggg tat ctt gaa gga aat ggt aaa cat ctt att acc aac act	2592		
Gln Ile Gly Tyr Leu Glu Gly Asn Gly Lys His Leu Ile Thr Asn Thr			
850	855	860	
ccc aaa cgc cca cca ggt gtt ttt cct aaa aca ggg gga att ggt aca	2640		
Pro Lys Arg Pro Pro Gly Val Phe Pro Lys Thr Gly Gly Ile Gly Thr			
865	870	875	880
att gtc tat ata tta gtt ggt tct act ttt atg ata ctt acc att tgt	2688		
Ile Val Tyr Ile Leu Val Gly Ser Thr Phe Met Ile Leu Thr Ile Cys			
885	890	895	
tct ttc cgt cgt aaa caa ttg taa	2712		
Ser Phe Arg Arg Lys Gln Leu			
900			

## FIGURE 6D

## SEQUENCE LISTING

<110> Adderson, Elisabeth  
Bohnsack, John

<120> GROUP B STREPTOCOCCUS POYPEPTIDES NUCLEIC ACIDS AND  
THERAPEUTIC COMPOSITIONS AND VACCINES THEREOF

<130> 2511-1-001

<140> UNKNOWN

<141> 2000-08-08

<160> 37

<170> PatentIn Ver. 2.0

<210> 1

<211> 737

<212> DNA

<213> Streptococcus agalactiae

<400> 1

atgacccttg ttaaaaatca agatgctttt gataaagcta ctgcaaatac agatgatg 60

gcatttttgg aaattccagt tgcatcaact attaatgaaa aagcagttt aggaaaagca 120

attgaaaata ctttgaact tcaatatgac catactcctg ataaagctga caatccaaa 180

ccatctaatac ctccaagaaa accagaagtt catactgggt ggaaacgatt tgtaaagaaa 240

gactcaacag aaacacaaaac actagggtt gctgagttt atttgttgc ttctgatgg 300

acagcagtaa aatggacaga tgctcttatt aaagcgaata ctaataaaaa ctaatattgt 360

ggagaagctg ttactggca accaatcaaa ttgaaatcac atacagacgg tacgtttgag 420

attaaagggtt tggcttatgc agttgatg 480

gtatcacaaa catcttataa tacaaaacca actgacatca cggttgatag tgctgatgca 600

acacctgata caataaaaaa caacaaacgt cttcaatcc ctaatactgg tggatttgtt 660

acggctatct ttgtcgctat cggtgctg 720

cgtcgtaaaa aagataa 737

<210> 2  
<211> 245  
<212> PRT  
<213> Streptococcus agalactiae

<400> 2  
Met Thr Leu Val Lys Asn Gln Asp Ala Leu Asp Lys Ala Thr Ala Asn  
1 5 10 15  
Thr Asp Asp Ala Ala Phe Leu Glu Ile Pro Val Ala Ser Thr Ile Asn  
20 25 30  
Glu Lys Ala Val Leu Gly Lys Ala Ile Glu Asn Thr Phe Glu Leu Gln  
35 40 45  
Tyr Asp His Thr Pro Asp Lys Ala Asp Asn Pro Lys Pro Ser Asn Pro  
50 55 60  
Pro Arg Lys Pro Glu Val His Thr Gly Gly Lys Arg Phe Val Lys Lys  
65 70 75 80  
Asp Ser Thr Glu Thr Gln Thr Leu Gly Gly Ala Glu Phe Asp Leu Leu  
85 90 95  
Ala Ser Asp Gly Thr Ala Val Lys Trp Thr Asp Ala Leu Ile Lys Ala  
100 105 110  
Asn Thr Asn Lys Asn Tyr Ile Ala Gly Glu Ala Val Thr Gly Gln Pro  
115 120 125  
Ile Lys Leu Lys Ser His Thr Asp Gly Thr Phe Glu Ile Lys Gly Leu  
130 135 140  
Ala Tyr Ala Val Asp Ala Asn Ala Glu Gly Thr Ala Val Thr Tyr Lys  
145 150 155 160  
Leu Lys Glu Thr Lys Ala Pro Glu Gly Tyr Val Ile Pro Asp Lys Glu  
165 170 175  
Ile Glu Phe Thr Val Ser Gln Thr Ser Tyr Asn Thr Lys Pro Thr Asp  
180 185 190  
Ile Thr Val Asp Ser Ala Asp Ala Thr Pro Asp Thr Ile Lys Asn Asn  
195 200 205  
Lys Arg Pro Ser Ile Pro Asn Thr Gly Gly Ile Gly Thr Ala Ile Phe

210

215

220

Val Ala Ile Gly Ala Ala Val Met Ala Phe Ala Val Lys Gly Met Lys  
225 230 235 240

Arg Arg Thr Lys Asp  
245

<210> 3

<211> 924

<212> DNA

<213> *Streptococcus agalactiae*

<400> 3

atgaaaacaaa cattaaaact tatgtttct tttctgttga tgtagggac tatgtttgga 60  
attagccaaa ctgttttagc gcaagaaaact catcagttga cgattgttca tcttgaagca 120  
agggatattg atcgtccaaa tccacagttg gagattgccctaaagaagg gactccaaatt 180  
gaaggagtagc tctatcagtt gtaccaatta aaatcaactg aagatggcga tttgttggca 240  
cattggaatt ccctaactat cacagaattt aaaaaacagg cgccagcaggt ttttgaagcc 300  
actactaatc aacaaggaaa ggctacatTT aaccaactac cagatggaat ttattatgg 360  
ctggcgggta aagccggta aaaaaatcgt aatgtctcag ctttcttggc tgacttgc 420  
gaggataaag tgatttatcc taaaatcatc tggtccacag gtgagttgga cttgcttaaa 480  
gttggtgtgg atggtgatac caaaaaccca ctagcaggcg ttgtcttga actttatgaa 540  
aagaatggta ggactcctat tcgtgtgaaa aatgggggc attctcaaga tattgacgct 600  
gcaaaacatt tagaaacaga ttcatcaggg catatcagaa tttccgggct catccatggg 660  
gactatgtct taaaagaaaat cgagacacag tcaggatatc agatcggaca ggcagagact 720  
gctgtgacta ttgaaaaatc aaaaacagta acagtaacga ttgaaaataa aaaagttccg 780  
acacctaag tgccatctcg aggaggtctt attccaaaa caggtgagca acaggcaatg 840  
gcacttgtaa ttattgggtgg tatttttaatt gcttttagcct tacgattact atcaaaaacat 900  
cgaaaaacatc aaaataagga ttag 924

<210> 4  
<211> 307  
<212> PRT  
<213> *Streptococcus agalactiae*

<400> 4  
Met Lys Gln Thr Leu Lys Leu Met Phe Ser Phe Leu Leu Met Leu Gly  
1 5 10 15  
  
Thr Met Phe Gly Ile Ser Gln Thr Val Leu Ala Gln Glu Thr His Gln  
20 25 30  
  
Leu Thr Ile Val His Leu Glu Ala Arg Asp Ile Asp Arg Pro Asn Pro  
35 40 45  
  
Gln Leu Glu Ile Ala Pro Lys Glu Gly Thr Pro Ile Glu Gly Val Leu  
50 55 60  
  
Tyr Gln Leu Tyr Gln Leu Lys Ser Thr Glu Asp Gly Asp Leu Leu Ala  
65 70 75 80  
  
His Trp Asn Ser Leu Thr Ile Thr Glu Leu Lys Lys Gln Ala Gln Gln  
85 90 95  
  
Val Phe Glu Ala Thr Thr Asn Gln Gln Gly Lys Ala Thr Phe Asn Gln  
100 105 110  
  
Leu Pro Asp Gly Ile Tyr Tyr Gly Leu Ala Val Lys Ala Gly Glu Lys  
115 120 125  
  
Asn Arg Asn Val Ser Ala Phe Leu Val Asp Leu Ser Glu Asp Lys Val  
130 135 140  
  
Ile Tyr Pro Lys Ile Ile Trp Ser Thr Gly Glu Leu Asp Leu Leu Lys  
145 150 155 160  
  
Val Gly Val Asp Gly Asp Thr Lys Lys Pro Leu Ala Gly Val Val Phe  
165 170 175  
  
Glu Leu Tyr Glu Lys Asn Gly Arg Thr Pro Ile Arg Val Lys Asn Gly  
180 185 190  
  
Val His Ser Gln Asp Ile Asp Ala Ala Lys His Leu Glu Thr Asp Ser  
195 200 205  
  
Ser Gly His Ile Arg Ile Ser Gly Leu Ile His Gly Asp Tyr Val Leu  
210 215 220

Lys Glu Ile Glu Thr Gln Ser Gly Tyr Gln Ile Gly Gln Ala Glu Thr  
225 230 235 240

Ala Val Thr Ile Glu Lys Ser Lys Thr Val Thr Val Thr Ile Glu Asn  
245 250 255

Lys Lys Val Pro Thr Pro Lys Val Pro Ser Arg Gly Gly Leu Ile Pro  
260 265 270

Lys Thr Gly Glu Gln Gln Ala Met Ala Leu Val Ile Ile Gly Gly Ile  
275 280 285

Leu Ile Ala Leu Ala Leu Arg Leu Leu Ser Lys His Arg Lys His Gln  
290 295 300

Asn Lys Asp  
305

<210> 5

<211> 918

<212> DNA

<213> *Streptococcus agalactiae*

<400> 5

atgggacaaa aatcaaaaat atctctagct acgaatattc gtatatggat ttttcgttta 60

attttcttag cgggtttcct tgggttggca ttcccacatcg ttatgtcaggt catgtacttt 120

caaggcctctc acgccaatata taatgctttt aaagaagctg ttaccaagat tgaccgggtg 180

gagattaatc ggcgtttaga acttgcttat gcttataacg ccagtatagc aggtgcacaa 240

actaatggcg aatatccagc gcttaagac ccctactctg ctgaacaaaa gcaggcaggg 300

gtcggtgagt acgccccat gcttgaagtc aaagaacaaa taggtcatgt gattattcca 360

agaattaatc aggatatccc tatttacgct ggctctgctg aagaaaaatct tcagagggc 420

gttggacatt tagagggac cagtcttcca gtcgggtggtg agtcaactca tgccgttcta 480

actgcccacatc gagggctacc aacggcaag ctattnacca atttagacaa ggtaacagta 540

ggtgaccgtt ttacattga acacatccgc ggaaagattt cttatcaggt agaccaaatc 600

aaagttatcg cccctgatca gtttagaggat ttgtacgtga ttcaaggaga agatcacgtc 660

accctattaa cttgcacacc ttatatgata aatagtcatc gcctcctcgt tcgaggcaag 720

cgaattcctt atgtggaaaa aacagtgcag aaagattcaa agacccatcg gcaacaacaa 780  
 tacctaacct atgctatgtg ggttagtcgtt ggacttatct tgctgtcgct tctcatttgg 840  
 tttaaaaaga cgaaacagaa aaagcggaga aagaatgaaa aagcggctag tcaaaatagt 900  
 cacaataatt cgaaataaa 918

<210> 6  
 <211> 305  
 <212> PRT  
 <213> Streptococcus agalactiae

<400> 6  
 Met Gly Gln Lys Ser Lys Ile Ser Leu Ala Thr Asn Ile Arg Ile Trp  
 1 5 10 15  
 Ile Phe Arg Leu Ile Phe Leu Ala Gly Phe Leu Val Leu Ala Phe Pro  
 20 25 30  
 Ile Val Ser Gln Val Met Tyr Phe Gln Ala Ser His Ala Asn Ile Asn  
 35 40 45  
 Ala Phe Lys Glu Ala Val Thr Lys Ile Asp Arg Val Glu Ile Asn Arg  
 50 55 60  
 Arg Leu Glu Leu Ala Tyr Ala Tyr Asn Ala Ser Ile Ala Gly Ala Lys  
 65 70 75 80  
 Thr Asn Gly Glu Tyr Pro Ala Leu Lys Asp Pro Tyr Ser Ala Glu Gln  
 85 90 95  
 Lys Gln Ala Gly Val Val Glu Tyr Ala Arg Met Leu Glu Val Lys Glu  
 100 105 110  
 Gln Ile Gly His Val Ile Ile Pro Arg Ile Asn Gln Asp Ile Pro Ile  
 115 120 125  
 Tyr Ala Gly Ser Ala Glu Glu Asn Leu Gln Arg Gly Val Gly His Leu  
 130 135 140  
 Glu Gly Thr Ser Leu Pro Val Gly Glu Ser Thr His Ala Val Leu  
 145 150 155 160  
 Thr Ala His Arg Gly Leu Pro Thr Ala Lys Leu Phe Thr Asn Leu Asp  
 165 170 175

Lys Val Thr Val Gly Asp Arg Phe Tyr Ile Glu His Ile Gly Gly Lys  
 180 185 190

Ile Ala Tyr Gln Val Asp Gln Ile Lys Val Ile Ala Pro Asp Gln Leu  
 195 200 205

Glu Asp Leu Tyr Val Ile Gln Gly Glu Asp His Val Thr Leu Leu Thr  
 210 215 220

Cys Thr Pro Tyr Met Ile Asn Ser His Arg Leu Leu Val Arg Gly Lys  
 225 230 235 240

Arg Ile Pro Tyr Val Glu Lys Thr Val Gln Lys Asp Ser Lys Thr Phe  
 245 250 255

Arg Gln Gln Gln Tyr Leu Thr Tyr Ala Met Trp Val Val Val Gly Leu  
 260 265 270

Ile Leu Leu Ser Leu Leu Ile Trp Phe Lys Lys Thr Lys Gln Lys Lys  
 275 280 285

Arg Arg Lys Asn Glu Lys Ala Ala Ser Gln Asn Ser His Asn Asn Ser  
 290 295 300

Lys  
 305

<210> 7  
 <211> 852  
 <212> DNA  
 <213> *Streptococcus agalactiae*

<400> 7  
 atgaaaaagc ggctagtcaa aatagtcaca ataattcgaa ataataaaat cagaaccctc 60  
 atttttgtga tggaaagtct gattctctta tttccgattt tgagccaggt aagttactac 120  
 cttgettcgc atcaaaatat taatcaattt aagcgggaag tcgcttaatg tgataactat 180  
 acggttgaac gacgcattgc ttttagctat gcttacaatg agacgttatac aaggaatccc 240  
 ttgcttatac acccttttac cagtaagcaa aaagaagggt tgagagagta tgctcgtatg 300  
 cttgaagttc atgagcaaat aggtcatgtg gcaatccaa gtattggggt tgatattcca 360  
 atttatgtg gaacatccga aactgtgctt cagaaaggta gtggcattt ggagggaacc 420

agtcttcag tggaggttt gtcacccat tcagtaactaa ctgcccaccc tggcttgc 480  
 acagcttaggc tatttaccga cttaaataaa gttaaaaaag gccagatttt ctatgtgac 540  
 aacatcaagg aaacacttgc ctacaaagtc gtgtctatca aagttgtgga tccaaacagct 600  
 ttaagtgagg ttaagattgt caatggtaag gattatataa ctttgctgac ttgcacac 660  
 tacatgatca atagtcatcg tctcttgta aaaggagagc gtattcctta tgattctacc 720  
 gaggcggaaa agcacaaaga acaaaccgta caagattatc gtttgtcact agtgttgaag 780  
 atactactag tattatataat tggactcttc atcgtgataa tgatgagaag atggatgcaa 840  
 catcgtaat aa 852

&lt;210&gt; 8

&lt;211&gt; 283

&lt;212&gt; PRT

&lt;213&gt; Streptococcus agalactiae

&lt;400&gt; 8

Met	Lys	Lys	Arg	Leu	Val	Lys	Ile	Val	Thr	Ile	Ile	Arg	Asn	Asn	Lys
1															15

Ile	Arg	Thr	Leu	Ile	Phe	Val	Met	Gly	Ser	Leu	Ile	Leu	Phe	Pro
														30
20														

Ile	Val	Ser	Gln	Val	Ser	Tyr	Tyr	Leu	Ala	Ser	His	Gln	Asn	Ile	Asn
															45
35															

Gln	Phe	Lys	Arg	Glu	Val	Ala	Lys	Ile	Asp	Thr	Asn	Thr	Val	Glu	Arg
															60
50															

Arg	Ile	Ala	Leu	Ala	Asn	Ala	Tyr	Asn	Glu	Thr	Leu	Ser	Arg	Asn	Pro
															80
65															

Leu	Leu	Ile	Asp	Pro	Phe	Thr	Ser	Lys	Gln	Lys	Glu	Gly	Leu	Arg	Glu
															95
85															

Tyr	Ala	Arg	Met	Leu	Glu	Val	His	Glu	Gln	Ile	Gly	His	Val	Ala	Ile
															110
100															

Pro	Ser	Ile	Gly	Val	Asp	Ile	Pro	Ile	Tyr	Ala	Gly	Thr	Ser	Glu	Thr
															125
115															

Val Leu Gln Lys Gly Ser Gly His Leu Glu Gly Thr Ser Leu Pro Val  
 130 135 140  
  
 Gly Gly Leu Ser Thr His Ser Val Leu Thr Ala His Arg Gly Leu Pro  
 145 150 155 160  
  
 Thr Ala Arg Leu Phe Thr Asp Leu Asn Lys Val Lys Lys Gly Gln Ile  
 165 170 175  
  
 Phe Tyr Val Thr Asn Ile Lys Glu Thr Leu Ala Tyr Lys Val Val Ser  
 180 185 190  
  
 Ile Lys Val Val Asp Pro Thr Ala Leu Ser Glu Val Lys Ile Val Asn  
 195 200 205  
  
 Gly Lys Asp Tyr Ile Thr Leu Leu Thr Cys Thr Pro Tyr Met Ile Asn  
 210 215 220  
  
 Ser His Arg Leu Leu Val Lys Gly Glu Arg Ile Pro Tyr Asp Ser Thr  
 225 230 235 240  
  
 Glu Ala Glu Lys His Lys Glu Gln Thr Val Gln Asp Tyr Arg Leu Ser  
 245 250 255  
  
 Leu Val Leu Lys Ile Leu Leu Val Leu Leu Ile Gly Leu Phe Ile Val  
 260 265 270  
  
 Ile Met Met Arg Arg Trp Met Gln His Arg Gln  
 275 280

<210> 9  
 <211> 2712  
 <212> DNA  
 <213> *Streptococcus agalactiae*  
  
 <400> 9  
 atgatgattg tgaataatgg ttatctagaa gggagaaaaa tgaaaaagag acaaaaaata 60  
  
 tggagaggggt tatcagttac tttactaatac ctgtcccaaa ttccatggat tatattggta 120  
  
 caaggtgaaa cccaagatac caatcaagca cttggaaaag taattgttaa aaaaacggga 180  
  
 gacaatgcta caccattagg caaagcgact tttgtgttaa aaaaatgacaa tgataagtca 240  
  
 gaaacaagtc acgaaacggt agagggttct ggagaagcaa cctttgaaaa cataaaacacct 300  
  
 ggagactaca cattaagaga agaaacagca ccaattggtt ataaaaaaac tgataaaaacc 360

tggaaagtta aagttgcaga taacggagca acaaataatcg agggtatgga tgcagataaa 420  
gcagagaaac gaaaagaagt tttgaatgcc caatatccaa aatcagctat ttatgaggat 480  
acaaaagaaa attaccatt agttaatgta gagggttcca aagttggta acaatacaaa 540  
gcattgaatc caataaatgg aaaagatggt cgaagagaga ttgctgaagg ttggttatca 600  
aaaaaaaaata caggggtcaa tgatctcgat aagaataat ataaaattga attaactgtt 660  
gagggtaaaa ccactgtga aacgaaagaa cttaatcaac cactagatgt cggtgtgcta 720  
ttagataatt caaatagtagt gaataatgaa agagccaata attctcaaag agcattaaaa 780  
gctggggaaag cagttgaaaa gctgattgat aaaattacat caaataaaga caatagagta 840  
gctcttgtga catatgcctc aaccattttt gatggtactg aagcgaccgt atcaaaggga 900  
gttgcgatc aaaatggtaa agcgctgaat gatagtgtat catgggatta tcataaaaact 960  
acttttacag caactacaca taattacagt tatttaaatt taacaaatga tgctaacgaa 1020  
gttaatattc taaagtcaag aattccaaag gaagcggagc atataaatgg ggatcgcacg 1080  
ctctatcaat ttggtgcgac atttactcaa aaagctctaa tgaaagcaaa tgaaatttta 1140  
gagacacaaa gttctaatgc tagaaaaaaaaa cttatttttc acgtaactga tggtgtccct 1200  
acgatgtctt atgccataaa ttttaatcct tatatatcaa catcttacca aaaccagttt 1260  
aattctttt taaataaaaat accagataga agtggatttc tccaaagagga ttttataatc 1320  
aatggtgatg attatcaa atgaaaaagga gatggagaga gttttaact gtttccggat 1380  
agaaaagttc ctgttactgg aggaacgaca caaggcgtt atcgagtacc gcaaaatcaa 1440  
ctctctgtaa tgagtaatga gggatatgca attaatacgatg gatataattta tctctatgg 1500  
agagattaca actgggtcta tccatttgat cctaagacaa agaaagttc tgcaacgaaa 1560  
caaataaaaa ctcatggtga gccaacaaca ttatacttta atggaaatata aagacctaaa 1620  
ggttatgaca ttttactgt tgggattgggt gttaaacggag atcctggtgc aactcctctt 1680  
gaagctgaga aatttatgca atcaatatac agtaaaacag aaaattatac taatgttgat 1740  
gatacaaata aaatttatga tgagctaaat aaatacttta aaacaattgt tgagggaaaaa 1800

cattctattt ttgatggaaa tgtgactgat cctatggag agatgattga attccaatta 1860  
 aaaaatggtc aaagtttac acatgatgat tacgtttgg ttggaaatga tggcagtcaa 1920  
 taaaaaaatg gtgtggctct tggtgacca aacagtatg gggaaattt aaaagatgtt 1980  
 acagtgactt atgataagac atctcaaacc atcaaaatca atcatttcaa ctttaggaagt 2040  
 ggacaaaaag tagttcttac ctatgatgta cgttaaaag ataactata aagtaacaaa 2100  
 ttttacaata caaataatcg tacaacgcta agtccgaaga gtgaaaaaga accaaatact 2160  
 attcgtgatt tcccaattcc caaaattcgt gatgttcgtg agttccgggt actaaccatc 2220  
 agtaatcaga agaaaatggg tgaggttcaa tttattaaag ttaataaaga caaacattca 2280  
 gaatcgctt tggagctaa gtttcaactt cagatagaaa aagatttttc tgggtataag 2340  
 caatttggc cagagggaaag tggatgttaca acaaagaatg atggtaaaat ttatttaaa 2400  
 gcacttcaag atggtaacta taaattataa gaaatttcaa gtccagatgg ctatataag 2460  
 gttaaaacga aacctgttgt gacatttaca attcaaaatg gagaagttac gaacctgaaa 2520  
 gcagatccaa atgctaataa aaatcaaattc gggtatctt aagggaaatgg taaacatctt 2580  
 attaccaaca ctcccaaacg cccaccaggt gttttccta aaacaggggg aattggtaca 2640  
 attgtctata tattagttgg ttctactttt atgataactta ccatttggc tttccgtcgt 2700  
 aaacaattgt aa 2712

<210> 10  
 <211> 903  
 <212> PRT  
 <213> *Streptococcus agalactiae*

<400> 10  
 Met Met Ile Val Asn Asn Gly Tyr Leu Glu Gly Arg Lys Met Lys Lys  
 1 5 10 15  
 Arg Gln Lys Ile Trp Arg Gly Leu Ser Val Thr Leu Leu Ile Leu Ser  
 20 25 30  
 Gln Ile Pro Phe Gly Ile Leu Val Gln Gly Glu Thr Gln Asp Thr Asn  
 35 40 45

Gln Ala Leu Gly Lys Val Ile Val Lys Lys Thr Gly Asp Asn Ala Thr  
50 55 60

Pro Leu Gly Lys Ala Thr Phe Val Leu Lys Asn Asp Asn Asp Lys Ser  
65 70 75 80

Glu Thr Ser His Glu Thr Val Glu Gly Ser Gly Glu Ala Thr Phe Glu  
85 90 95

Asn Ile Lys Pro Gly Asp Tyr Thr Leu Arg Glu Glu Thr Ala Pro Ile  
100 105 110

Gly Tyr Lys Lys Thr Asp Lys Thr Trp Lys Val Lys Val Ala Asp Asn  
115 120 125

Gly Ala Thr Ile Ile Glu Gly Met Asp Ala Asp Lys Ala Glu Lys Arg  
130 135 140

Lys Glu Val Leu Asn Ala Gln Tyr Pro Lys Ser Ala Ile Tyr Glu Asp  
145 150 155 160

Thr Lys Glu Asn Tyr Pro Leu Val Asn Val Glu Gly Ser Lys Val Gly  
165 170 175

Glu Gln Tyr Lys Ala Leu Asn Pro Ile Asn Gly Lys Asp Gly Arg Arg  
180 185 190

Glu Ile Ala Glu Gly Trp Leu Ser Lys Lys Asn Thr Gly Val Asn Asp  
195 200 205

Leu Asp Lys Asn Lys Tyr Lys Ile Glu Leu Thr Val Glu Gly Lys Thr  
210 215 220

Thr Val Glu Thr Lys Glu Leu Asn Gln Pro Leu Asp Val Val Val Leu  
225 230 235 240

Leu Asp Asn Ser Asn Ser Met Asn Asn Glu Arg Ala Asn Asn Ser Gln  
245 250 255

Arg Ala Leu Lys Ala Gly Glu Ala Val Glu Lys Leu Ile Asp Lys Ile  
260 265 270

Thr Ser Asn Lys Asp Asn Arg Val Ala Leu Val Thr Tyr Ala Ser Thr  
275 280 285

Ile Phe Asp Gly Thr Glu Ala Thr Val Ser Lys Gly Val Ala Asp Gln  
290 295 300

Asn Gly Lys Ala Leu Asn Asp Ser Val Ser Trp Asp Tyr His Lys Thr  
 305 310 315 320

Thr Phe Thr Ala Thr Thr His Asn Tyr Ser Tyr Leu Asn Leu Thr Asn  
 325 330 335

Asp Ala Asn Glu Val Asn Ile Leu Lys Ser Arg Ile Pro Lys Glu Ala  
 340 345 350

Glu His Ile Asn Gly Asp Arg Thr Leu Tyr Gln Phe Gly Ala Thr Phe  
 355 360 365

Thr Gln Lys Ala Leu Met Lys Ala Asn Glu Ile Leu Glu Thr Gln Ser  
 370 375 380

Ser Asn Ala Arg Lys Lys Leu Ile Phe His Val Thr Asp Gly Val Pro  
 385 390 395 400

Thr Met Ser Tyr Ala Ile Asn Phe Asn Pro Tyr Ile Ser Thr Ser Tyr  
 405 410 415

Gln Asn Gln Phe Asn Ser Phe Leu Asn Lys Ile Pro Asp Arg Ser Gly  
 420 425 430

Ile Leu Gln Glu Asp Phe Ile Ile Asn Gly Asp Asp Tyr Gln Ile Val  
 435 440 445

Lys Gly Asp Gly Glu Ser Phe Lys Leu Phe Ser Asp Arg Lys Val Pro  
 450 455 460

Val Thr Gly Gly Thr Thr Gln Ala Ala Tyr Arg Val Pro Gln Asn Gln  
 465 470 475 480

Leu Ser Val Met Ser Asn Glu Gly Tyr Ala Ile Asn Ser Gly Tyr Ile  
 485 490 495

Tyr Leu Tyr Trp Arg Asp Tyr Asn Trp Val Tyr Pro Phe Asp Pro Lys  
 500 505 510

Thr Lys Lys Val Ser Ala Thr Lys Gln Ile Lys Thr His Gly Glu Pro  
 515 520 525

Thr Thr Leu Tyr Phe Asn Gly Asn Ile Arg Pro Lys Gly Tyr Asp Ile  
 530 535 540

Phe Thr Val Gly Ile Gly Val Asn Gly Asp Pro Gly Ala Thr Pro Leu  
 545 550 555 560

Glu Ala Glu Lys Phe Met Gln Ser Ile Ser Ser Lys Thr Glu Asn Tyr  
 565 570 575  
 Thr Asn Val Asp Asp Thr Asn Lys Ile Tyr Asp Glu Leu Asn Lys Tyr  
 580 585 590  
 Phe Lys Thr Ile Val Glu Glu Lys His Ser Ile Val Asp Gly Asn Val  
 595 600 605  
 Thr Asp Pro Met Gly Glu Met Ile Glu Phe Gln Leu Lys Asn Gly Gln  
 610 615 620  
 Ser Phe Thr His Asp Asp Tyr Val Leu Val Gly Asn Asp Gly Ser Gln  
 625 630 635 640  
 Leu Lys Asn Gly Val Ala Leu Gly Gly Pro Asn Ser Asp Gly Gly Ile  
 645 650 655  
 Leu Lys Asp Val Thr Val Thr Tyr Asp Lys Thr Ser Gln Thr Ile Lys  
 660 665 670  
 Ile Asn His Leu Asn Leu Gly Ser Gly Gln Lys Val Val Leu Thr Tyr  
 675 680 685  
 Asp Val Arg Leu Lys Asp Asn Tyr Ile Ser Asn Lys Phe Tyr Asn Thr  
 690 695 700  
 Asn Asn Arg Thr Thr Leu Ser Pro Lys Ser Glu Lys Glu Pro Asn Thr  
 705 710 715 720  
 Ile Arg Asp Phe Pro Ile Pro Lys Ile Arg Asp Val Arg Glu Phe Pro  
 725 730 735  
 Val Leu Thr Ile Ser Asn Gln Lys Lys Met Gly Glu Val Glu Phe Ile  
 740 745 750  
 Lys Val Asn Lys Asp Lys His Ser Glu Ser Leu Leu Gly Ala Lys Phe  
 755 760 765  
 Gln Leu Gln Ile Glu Lys Asp Phe Ser Gly Tyr Lys Gln Phe Val Pro  
 770 775 780  
 Glu Gly Ser Asp Val Thr Thr Lys Asn Asp Gly Lys Ile Tyr Phe Lys  
 785 790 795 800  
 Ala Leu Gln Asp Gly Asn Tyr Lys Leu Tyr Glu Ile Ser Ser Pro Asp  
 805 810 815

Gly Tyr Ile Glu Val Lys Thr Lys Pro Val Val Thr Phe Thr Ile Gln  
820 825 830

Asn Gly Glu Val Thr Asn Leu Lys Ala Asp Pro Asn Ala Asn Lys Asn  
835 840 845

Gln Ile Gly Tyr Leu Glu Gly Asn Gly Lys His Leu Ile Thr Asn Thr  
850 855 860

Pro Lys Arg Pro Pro Gly Val Phe Pro Lys Thr Gly Gly Ile Gly Thr  
865 870 875 880

Ile Val Tyr Ile Leu Val Gly Ser Thr Phe Met Ile Leu Thr Ile Cys  
885 890 895

Ser Phe Arg Arg Lys Gln Leu  
900

<210> 11

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
oligonucleotide

<400> 11

ctagggtggat ccttcggcaa t

21

<210> 12

<211> 10

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
oligonucleotide

<400> 12

cgattgccga

10

<210> 13

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
oligonucleotide

<400> 13

aggcaactgt gctaaccgag ggaat

25

<210> 14

<211> 11

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
oligonucleotide

<400> 14

cgattccctc g

11

<210> 15

<211> 1509

<212> DNA

<213> Streptococcus agalactiae

<220>

<221> CDS

<222> (1)..(1509)

<400> 15

atg aaa aag aaa atg att caa tcg ctg tta gtg gcg agt tta gca ttt  
Met Lys Lys Lys Met Ile Gln Ser Leu Leu Val Ala Ser Leu Ala Phe  
1 5 10 15

48

ggt atg gct gta tca cca gtt acg ccg ata gct ttt gcc gct gag aca  
Gly Met Ala Val Ser Pro Val Thr Pro Ile Ala Phe Ala Ala Glu Thr  
20 25 30

96

ggg aca att aca gtt caa gat act caa aaa ggc gca acc tat aaa gca  
Gly Thr Ile Thr Val Gln Asp Thr Gln Lys Gly Ala Thr Tyr Lys Ala  
35 40 45

144

tat aaa gtt ttt gat gca gaa ata gat aat gca aat gta tct gat tcg  
Tyr Lys Val Phe Asp Ala Glu Ile Asp Asn Ala Asn Val Ser Asp Ser

192

50	55	60	
aat aaa gat gga gct tct tat tta att cct caa ggt aaa gaa gct gag			240
Asn Lys Asp Gly Ala Ser Tyr Leu Ile Pro Gln Gly Lys Glu Ala Glu			
65	70	75	80
tat aaa gct tca act gat ttt aat tct ctt ttt acg aca act act aat			288
Tyr Lys Ala Ser Thr Asp Phe Asn Ser Leu Phe Thr Thr Thr Asn			
85	90	95	
gga ggg aga aca tat gta act aaa aaa gat act gcg tca gca aat gag			336
Gly Gly Arg Thr Tyr Val Thr Lys Lys Asp Thr Ala Ser Ala Asn Glu			
100	105	110	
att gcg aca tgg gct aaa tct ata tca gct aat act aca cca gtt tcc			384
Ile Ala Thr Trp Ala Lys Ser Ile Ser Ala Asn Thr Thr Pro Val Ser			
115	120	125	
act gtt act gag tca aat aat gat ggt act gag gtt att aat gtt tcc			432
Thr Val Thr Glu Ser Asn Asn Asp Gly Thr Glu Val Ile Asn Val Ser			
130	135	140	
caa tat gga tat tat tat gtt tct agc act gtt aat aat gga gct gta			480
Gln Tyr Gly Tyr Tyr Val Ser Ser Thr Val Asn Asn Gly Ala Val			
145	150	155	160
att atg gtt aca tct gta act cca aat gct act att cat gaa aag aat			528
Ile Met Val Thr Ser Val Thr Pro Asn Ala Thr Ile His Glu Lys Asn			
165	170	175	
act gat gcg aca tgg gga gat ggt ggt gga aaa act gta gat caa aaa			576
Thr Asp Ala Thr Trp Gly Asp Gly Gly Lys Thr Val Asp Gln Lys			
180	185	190	
acg tac tcg gtt ggt gat aca gtc aaa tat act att act tat aag aat			624
Thr Tyr Ser Val Gly Asp Thr Val Lys Tyr Thr Ile Thr Tyr Lys Asn			
195	200	205	
gca gtc aat tat cat ggt aca gaa aaa gtg tat caa tat gtt ata aag			672
Ala Val Asn Tyr His Gly Thr Glu Lys Val Tyr Gln Tyr Val Ile Lys			
210	215	220	
gat act atg cca tct gct tct gta gtt gat ttg aac gaa ggg tct tat			720
Asp Thr Met Pro Ser Ala Ser Val Val Asp Leu Asn Glu Gly Ser Tyr			
225	230	235	240
gaa gta act att act gat gga tca ggg aat att aca act cta act caa			768
Glu Val Thr Ile Thr Asp Gly Ser Gly Asn Ile Thr Thr Leu Thr Gln			

245

250

255

ggt tcg gaa aaa gca act ggg aag tat aac ctg tta gag gaa aat aat	260	265	270	816
Gly Ser Glu Lys Ala Thr Gly Lys Tyr Asn Leu Leu Glu Asn Asn				
aat ttc acg att act att ccg tgg gca gct acc aat act cca acc gga	275	280	285	864
Asn Phe Thr Ile Thr Ile Pro Trp Ala Ala Thr Asn Thr Pro Thr Gly				
aat actcaa aat gga gct aat gat gac ttt ttt tat aag gga ata aat	290	295	300	912
Asn Thr Gln Asn Gly Ala Asn Asp Asp Phe Phe Tyr Lys Gly Ile Asn				
aca atc aca gtc act tat aca gga gta tta aag agt gga gct aaa cca	305	310	315	960
Thr Ile Thr Val Thr Tyr Thr Gly Val Leu Lys Ser Gly Ala Lys Pro				
ggt tca gct gat tta cca gaa aat aca aac att gcg acc atc aac ccc	325	330	335	1008
Gly Ser Ala Asp Leu Pro Glu Asn Thr Asn Ile Ala Thr Ile Asn Pro				
aat act agc aat gat gac cca ggt caa aaa gta aca gtg agg gat ggt	340	345	350	1056
Asn Thr Ser Asn Asp Asp Pro Gly Gln Lys Val Thr Val Arg Asp Gly				
caa att act ata aaa aaa att gat ggt tcc aca aaa gct tca tta caa	355	360	365	1104
Gln Ile Thr Ile Lys Lys Ile Asp Gly Ser Thr Lys Ala Ser Leu Gln				
ggt gct ata ttt gtt tta aag aat gct acg ggt caa ttt cta aac ttt	370	375	380	1152
Gly Ala Ile Phe Val Leu Lys Asn Ala Thr Gly Gln Phe Leu Asn Phe				
aac gat aca aat aac gtt gaa tgg ggc aca gaa gct aat gca aca gaa	385	390	395	1200
Asn Asp Thr Asn Asn Val Glu Trp Gly Thr Glu Ala Asn Ala Thr Glu				
tat aca aca gga gca gat ggt ata att acc att aca ggc ttg aaa gaa	405	410	415	1248
Tyr Thr Thr Gly Ala Asp Gly Ile Ile Thr Ile Thr Gly Leu Lys Glu				
ggt aca tac tat cta gtt gag aaa aag gct ccc tta ggt tac aat ttg	420	425	430	1296
Gly Thr Tyr Tyr Leu Val Glu Lys Lys Ala Pro Leu Gly Tyr Asn Leu				
tta gat aac tct cag aag gtt att tta gga gat gga gcc act gat acg	440	445	450	1344
Leu Asp Asn Ser Gln Lys Val Ile Leu Gly Asp Gly Ala Thr Asp Thr				

435	440	445	
act aat tca gat aac ctt tta gtt aac cca act gtt gaa aat aac aaa			1392
Thr Asn Ser Asp Asn Leu	Leu Val Asn Pro	Thr Val Glu Asn Asn Lys	
450	455	460	
ggt act gag ttg cct tca aca ggt ggt att ggt aca aca att ttc tac			1440
Gly Thr Glu Leu Pro	Ser Thr Gly Gly Ile	Gly Thr Thr Ile Phe Tyr	
465	470	475	480
att ata ggt gca att tta gta ata gga gca ggt atc gtg ctt gtt gct			1488
Ile Ile Gly Ala Ile	Leu Val Ile Gly Ala Gly Ile Val Leu Val Ala		
485	490	495	
cgt cgt cgt tta cgt tct taa			1509
Arg Arg Arg	Leu Arg Ser		
500			

&lt;210&gt; 16

&lt;211&gt; 502

&lt;212&gt; PRT

&lt;213&gt; Streptococcus agalactiae

&lt;400&gt; 16

Met Lys Lys Met Ile Gln Ser Leu	Leu Val Ala Ser Leu Ala Phe		
1	5	10	15

Gly Met Ala Val Ser Pro Val Thr Pro Ile Ala Phe Ala Ala Glu Thr			
20	25	30	

Gly Thr Ile Thr Val Gln Asp Thr Gln Lys Gly Ala Thr Tyr Lys Ala			
35	40	45	

Tyr Lys Val Phe Asp Ala Glu Ile Asp Asn Ala Asn Val Ser Asp Ser			
50	55	60	

Asn Lys Asp Gly Ala Ser Tyr Leu Ile Pro Gln Gly Lys Glu Ala Glu			
65	70	75	80

Tyr Lys Ala Ser Thr Asp Phe Asn Ser Leu Phe Thr Thr Thr Asn			
85	90	95	

Gly Gly Arg Thr Tyr Val Thr Lys Lys Asp Thr Ala Ser Ala Asn Glu			
100	105	110	

Ile Ala Thr Trp Ala Lys Ser Ile Ser Ala Asn Thr Thr Pro Val Ser			
115	120	125	

Thr Val Thr Glu Ser Asn Asn Asp Gly Thr Glu Val Ile Asn Val Ser  
130 135 140

Gln Tyr Gly Tyr Tyr Tyr Val Ser Ser Thr Val Asn Asn Gly Ala Val  
145 150 155 160

Ile Met Val Thr Ser Val Thr Pro Asn Ala Thr Ile His Glu Lys Asn  
165 170 175

Thr Asp Ala Thr Trp Gly Asp Gly Gly Lys Thr Val Asp Gln Lys  
180 185 190

Thr Tyr Ser Val Gly Asp Thr Val Lys Tyr Thr Ile Thr Tyr Lys Asn  
195 200 205

Ala Val Asn Tyr His Gly Thr Glu Lys Val Tyr Gln Tyr Val Ile Lys  
210 215 220

Asp Thr Met Pro Ser Ala Ser Val Val Asp Leu Asn Glu Gly Ser Tyr  
225 230 235 240

Glu Val Thr Ile Thr Asp Gly Ser Gly Asn Ile Thr Thr Leu Thr Gln  
245 250 255

Gly Ser Glu Lys Ala Thr Gly Lys Tyr Asn Leu Leu Glu Glu Asn Asn  
260 265 270

Asn Phe Thr Ile Thr Ile Pro Trp Ala Ala Thr Asn Thr Pro Thr Gly  
275 280 285

Asn Thr Gln Asn Gly Ala Asn Asp Asp Phe Phe Tyr Lys Gly Ile Asn  
290 295 300

Thr Ile Thr Val Thr Tyr Thr Gly Val Leu Lys Ser Gly Ala Lys Pro  
305 310 315 320

Gly Ser Ala Asp Leu Pro Glu Asn Thr Asn Ile Ala Thr Ile Asn Pro  
325 330 335

Asn Thr Ser Asn Asp Asp Pro Gly Gln Lys Val Thr Val Arg Asp Gly  
340 345 350

Gln Ile Thr Ile Lys Lys Ile Asp Gly Ser Thr Lys Ala Ser Leu Gln  
355 360 365

Gly Ala Ile Phe Val Leu Lys Asn Ala Thr Gly Gln Phe Leu Asn Phe  
370 375 380

Asn Asp Thr Asn Asn Val Glu Trp Gly Thr Glu Ala Asn Ala Thr Glu  
385 390 395 400

Tyr Thr Thr Gly Ala Asp Gly Ile Ile Thr Ile Thr Gly Leu Lys Glu  
405 410 415

Gly Thr Tyr Tyr Leu Val Glu Lys Lys Ala Pro Leu Gly Tyr Asn Leu  
420 425 430

Leu Asp Asn Ser Gln Lys Val Ile Leu Gly Asp Gly Ala Thr Asp Thr  
435 440 445

Thr Asn Ser Asp Asn Leu Leu Val Asn Pro Thr Val Glu Asn Asn Lys  
450 455 460

Gly Thr Glu Leu Pro Ser Thr Gly Gly Ile Gly Thr Thr Ile Phe Tyr  
465 470 475 480

Ile Ile Gly Ala Ile Leu Val Ile Gly Ala Gly Ile Val Leu Val Ala,  
485 490 495

Arg Arg Arg Leu Arg Ser  
500

<210> 17

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: consensus

<220>

<223> X can be any amino acid

<400> 17

Leu Pro Xaa Thr Gly

1 5

<210> 18

<211> 1683

<212> DNA

<213> Streptococcus agalactiae

<220>

&lt;221&gt; CDS

&lt;222&gt; (1)..(1683)

&lt;400&gt; 18

atg	gtg	atc	gta	ttc	cgg	att	ata	cag	ata	tta	caa	ggg	att	ata	tcc	48
Met	Val	Ile	Val	Phe	Arg	Ile	Ile	Gln	Ile	Leu	Gln	Gly	Ile	Ile	Ser	
1	5								10					15		

aag	atc	ctt	cag	gta	cat	att	att	ata	agt	att	cac	gag	ata	aag	96	
Lys	Ile	Leu	Gln	Val	His	Ile	Ile	Ile	Ser	Met	Ile	His	Glu	Ile	Lys	
		20							25					30		

atc	ccg	act	caa	cta	aag	atg	cct	att	ata	cga	cag	ata	cta	gtc	tca	144
Ile	Pro	Thr	Gln	Leu	Lys	Met	Pro	Ile	Ile	Arg	Gln	Ile	Leu	Val	Ser	
						35		40				45				

tca	aat	gtt	gat	aca	aca	act	aag	tac	aag	tac	gta	aaa	gac	gct	tac	192
Ser	Asn	Val	Asp	Thr	Thr	Thr	Lys	Tyr	Lys	Tyr	Val	Lys	Asp	Ala	Tyr	
		50						55			60					

aaa	tta	gtc	ggt	tgg	tat	tat	gtt	aat	cca	tat	ggt	agt	att	aga	cct	240
Lys	Leu	Val	Gly	Trp	Tyr	Tyr	Val	Asn	Pro	Tyr	Gly	Ser	Ile	Arg	Pro	
	65				70				75			80				

tat	aac	ttt	tca	ggt	gct	gta	act	caa	gat	atc	aat	tta	aga	gct	att	288
Tyr	Asn	Phe	Ser	Gly	Ala	Val	Thr	Gln	Asp	Ile	Asn	Leu	Arg	Ala	Ile	
					85				90			95				

tgg	cga	aag	gct	gga	gat	tat	cat	att	ata	tac	agc	aat	gat	gct	gtt	336
Trp	Arg	Lys	Ala	Gly	Asp	Tyr	His	Ile	Ile	Tyr	Ser	Asn	Asp	Ala	Val	
					100			105			110					

ggt	aca	gat	gga	aag	cca	gca	ttg	gat	gct	tct	ggt	cag	caa	tta	caa	384
Gly	Thr	Asp	Gly	Lys	Pro	Ala	Leu	Asp	Ala	Ser	Gly	Gln	Gln	Leu	Gln	
					115			120			125					

aca	agt	aat	gag	cct	act	gac	cct	gat	tcc	tat	gac	gat	ggc	tcc	cat	432
Thr	Ser	Asn	Glu	Pro	Thr	Asp	Pro	Asp	Ser	Tyr	Asp	Asp	Gly	Ser	His	
					130			135			140					

tca	gcc	tta	ctg	aga	cgt	ccg	aca	atg	cca	gat	ggc	tat	cgt	ttc	cgt	480
Ser	Ala	Leu	Leu	Arg	Arg	Pro	Thr	Met	Pro	Asp	Gly	Tyr	Arg	Phe	Arg	
				145				150			155			160		

ggc	tgg	tgg	tac	aat	ggt	aaa	att	tat	aac	cca	tat	gat	tcc	att	gat	528
Gly	Trp	Trp	Tyr	Asn	Gly	Lys	Ile	Tyr	Asn	Pro	Tyr	Asp	Ser	Ile	Asp	
					165			170			175					

att gac gcc cat tta gca gat gct aat aaa aat atc acc ata aaa cct		576
Ile Asp Ala His Leu Ala Asp Ala Asn Lys Asn Ile Thr Ile Lys Pro		
180	185	190
gtc att att cca gta gga gat atc aaa tta gaa gat acc tcc atc aaa		624
Val Ile Ile Pro Val Gly Asp Ile Lys Leu Glu Asp Thr Ser Ile Lys		
195	200	205
tac aat ggt.aac ggt ggt act aga gta gaa aat ggt aat gtg gta aca		672
Tyr Asn Gly Asn Gly Gly Thr Arg Val Glu Asn Gly Asn Val Val Thr		
210	215	220
caa gtg gag aca ccg cgt atg gag ttg aat agc aca act aca att cct		720
Gln Val Glu Thr Pro Arg Met Glu Leu Asn Ser Thr Thr Ile Pro		
225	230	235
240		
gaa aac caa tac ttt aca agg aca ggt tac aac ctt att ggt tgg cat		768
Glu Asn Gln Tyr Phe Thr Arg Thr Gly Tyr Asn Leu Ile Gly Trp His		
245	250	255
cat gat aag gat tta gct gat aca gga cgt gtg gaa ttt aca gca ggt		816
His Asp Lys Asp Leu Ala Asp Thr Gly Arg Val Glu Phe Thr Ala Gly		
260	265	270
caa tca ata ggt att gat aac aac ctt gat gca aca aat acc tta tat		864
Gln Ser Ile Gly Ile Asp Asn Asn Leu Asp Ala Thr Asn Thr Leu Tyr		
275	280	285
gct gtt tgg caa cct aaa gaa tac acc gtc gga gta agt aaa act gtc		912
Ala Val Trp Gln Pro Lys Glu Tyr Thr Val Gly Val Ser Lys Thr Val		
290	295	300
gtt gga cta gat gaa gat aag acg aaa gac ttc ttg ttt aat cca agt		960
Val Gly Leu Asp Glu Asp Lys Thr Lys Asp Phe Leu Phe Asn Pro Ser		
305	310	315
320		
gaa acg ttg caa caa gag aat ttt ccg ctg aga gat ggt cag act aag		1008
Glu Thr Leu Gln Gln Glu Asn Phe Pro Leu Arg Asp Gly Gln Thr Lys		
325	330	335
gaa ttt aaa gta cct tat gga act tct ata tca ata gat gaa caa gcc		1056
Glu Phe Lys Val Pro Tyr Gly Thr Ser Ile Ser Ile Asp Glu Gln Ala		
340	345	350
tac gat gaa ttt aaa gta tct gag tca att aca gaa aaa aat cta gca		1104
Tyr Asp Glu Phe Lys Val Ser Glu Ser Ile Thr Glu Lys Asn Leu Ala		
355	360	365

act ggt gaa gct gat aaa act tat gat gct acc ggc tta caa tcc ctg	1152																																																																																										
Thr Gly Glu Ala Asp Lys Thr Tyr Asp Ala Thr Gly Leu Gln Ser Leu																																																																																											
370	375	380		aca gtt tca gga gac gta gat att agc ttt acc aat aca cgt atc aag	1200	Thr Val Ser Gly Asp Val Asp Ile Ser Phe Thr Asn Thr Arg Ile Lys		385	390	395	400	caa aaa gta cga cta cag aaa gtt aat gtc gaa aat gat aat aat ttt	1248	Gln Lys Val Arg Leu Gln Lys Val Asn Val Glu Asn Asp Asn Asn Phe		405	410	415		tta gca ggt gca gtt ttt gat att tat gaa tca gat gct aat ggg aat	1296	Leu Ala Gly Ala Val Phe Asp Ile Tyr Glu Ser Asp Ala Asn Gly Asn		420	425	430		aaa gct tca cat cct atg tat tca ggg ctg gtg aca aac gat aaa ggc	1344	Lys Ala Ser His Pro Met Tyr Ser Gly Leu Val Thr Asn Asp Lys Gly		435	440	445		ttg tta tta gtg gat gct aat aac tac ctc agt ttg cca gta gga aaa	1392	Leu Leu Leu Val Asp Ala Asn Asn Tyr Leu Ser Leu Pro Val Gly Lys		450	455	460		tac tac cta aca gag aca aag gcc cct cca ggg tac cta cta cct aaa	1440	Tyr Tyr Leu Thr Glu Thr Lys Ala Pro Pro Gly Tyr Leu Leu Pro Lys		465	470	475	480	aat gat gat ata tca gta tta gtg att tct acg gga gtt acc ttt gaa	1488	Asn Asp Asp Ile Ser Val Leu Val Ile Ser Thr Gly Val Thr Phe Glu		485	490	495		caa aat ggt aat aat gcg aca cca ata aaa gag aat tta gtg gat gga	1536	Gln Asn Gly Asn Asn Ala Thr Pro Ile Lys Glu Asn Leu Val Asp Gly		500	505	510		agt aca gta tat act ttt aaa att act aac agt aaa gga aca gaa ttg	1584	Ser Thr Val Tyr Thr Phe Lys Ile Thr Asn Ser Lys Gly Thr Glu Leu		515	520	525		cct agt act gga ggt att gga aca cac att tat atc cta gtt ggt tta	1632	Pro Ser Thr Gly Gly Ile Gly Thr His Ile Tyr Ile Leu Val Gly Leu		530	535	540		gct tta gct cta cca tca gga tta ata tta tac tat cga aaa aaa ata	1680	Ala Leu Ala Leu Pro Ser Gly Leu Ile Leu Tyr Tyr Arg Lys Lys Ile		545	550	555	560
380																																																																																											
aca gtt tca gga gac gta gat att agc ttt acc aat aca cgt atc aag	1200																																																																																										
Thr Val Ser Gly Asp Val Asp Ile Ser Phe Thr Asn Thr Arg Ile Lys																																																																																											
385	390	395	400	caa aaa gta cga cta cag aaa gtt aat gtc gaa aat gat aat aat ttt	1248	Gln Lys Val Arg Leu Gln Lys Val Asn Val Glu Asn Asp Asn Asn Phe		405	410	415		tta gca ggt gca gtt ttt gat att tat gaa tca gat gct aat ggg aat	1296	Leu Ala Gly Ala Val Phe Asp Ile Tyr Glu Ser Asp Ala Asn Gly Asn		420	425	430		aaa gct tca cat cct atg tat tca ggg ctg gtg aca aac gat aaa ggc	1344	Lys Ala Ser His Pro Met Tyr Ser Gly Leu Val Thr Asn Asp Lys Gly		435	440	445		ttg tta tta gtg gat gct aat aac tac ctc agt ttg cca gta gga aaa	1392	Leu Leu Leu Val Asp Ala Asn Asn Tyr Leu Ser Leu Pro Val Gly Lys		450	455	460		tac tac cta aca gag aca aag gcc cct cca ggg tac cta cta cct aaa	1440	Tyr Tyr Leu Thr Glu Thr Lys Ala Pro Pro Gly Tyr Leu Leu Pro Lys		465	470	475	480	aat gat gat ata tca gta tta gtg att tct acg gga gtt acc ttt gaa	1488	Asn Asp Asp Ile Ser Val Leu Val Ile Ser Thr Gly Val Thr Phe Glu		485	490	495		caa aat ggt aat aat gcg aca cca ata aaa gag aat tta gtg gat gga	1536	Gln Asn Gly Asn Asn Ala Thr Pro Ile Lys Glu Asn Leu Val Asp Gly		500	505	510		agt aca gta tat act ttt aaa att act aac agt aaa gga aca gaa ttg	1584	Ser Thr Val Tyr Thr Phe Lys Ile Thr Asn Ser Lys Gly Thr Glu Leu		515	520	525		cct agt act gga ggt att gga aca cac att tat atc cta gtt ggt tta	1632	Pro Ser Thr Gly Gly Ile Gly Thr His Ile Tyr Ile Leu Val Gly Leu		530	535	540		gct tta gct cta cca tca gga tta ata tta tac tat cga aaa aaa ata	1680	Ala Leu Ala Leu Pro Ser Gly Leu Ile Leu Tyr Tyr Arg Lys Lys Ile		545	550	555	560								
395	400																																																																																										
caa aaa gta cga cta cag aaa gtt aat gtc gaa aat gat aat aat ttt	1248																																																																																										
Gln Lys Val Arg Leu Gln Lys Val Asn Val Glu Asn Asp Asn Asn Phe																																																																																											
405	410	415		tta gca ggt gca gtt ttt gat att tat gaa tca gat gct aat ggg aat	1296	Leu Ala Gly Ala Val Phe Asp Ile Tyr Glu Ser Asp Ala Asn Gly Asn		420	425	430		aaa gct tca cat cct atg tat tca ggg ctg gtg aca aac gat aaa ggc	1344	Lys Ala Ser His Pro Met Tyr Ser Gly Leu Val Thr Asn Asp Lys Gly		435	440	445		ttg tta tta gtg gat gct aat aac tac ctc agt ttg cca gta gga aaa	1392	Leu Leu Leu Val Asp Ala Asn Asn Tyr Leu Ser Leu Pro Val Gly Lys		450	455	460		tac tac cta aca gag aca aag gcc cct cca ggg tac cta cta cct aaa	1440	Tyr Tyr Leu Thr Glu Thr Lys Ala Pro Pro Gly Tyr Leu Leu Pro Lys		465	470	475	480	aat gat gat ata tca gta tta gtg att tct acg gga gtt acc ttt gaa	1488	Asn Asp Asp Ile Ser Val Leu Val Ile Ser Thr Gly Val Thr Phe Glu		485	490	495		caa aat ggt aat aat gcg aca cca ata aaa gag aat tta gtg gat gga	1536	Gln Asn Gly Asn Asn Ala Thr Pro Ile Lys Glu Asn Leu Val Asp Gly		500	505	510		agt aca gta tat act ttt aaa att act aac agt aaa gga aca gaa ttg	1584	Ser Thr Val Tyr Thr Phe Lys Ile Thr Asn Ser Lys Gly Thr Glu Leu		515	520	525		cct agt act gga ggt att gga aca cac att tat atc cta gtt ggt tta	1632	Pro Ser Thr Gly Gly Ile Gly Thr His Ile Tyr Ile Leu Val Gly Leu		530	535	540		gct tta gct cta cca tca gga tta ata tta tac tat cga aaa aaa ata	1680	Ala Leu Ala Leu Pro Ser Gly Leu Ile Leu Tyr Tyr Arg Lys Lys Ile		545	550	555	560																
415																																																																																											
tta gca ggt gca gtt ttt gat att tat gaa tca gat gct aat ggg aat	1296																																																																																										
Leu Ala Gly Ala Val Phe Asp Ile Tyr Glu Ser Asp Ala Asn Gly Asn																																																																																											
420	425	430		aaa gct tca cat cct atg tat tca ggg ctg gtg aca aac gat aaa ggc	1344	Lys Ala Ser His Pro Met Tyr Ser Gly Leu Val Thr Asn Asp Lys Gly		435	440	445		ttg tta tta gtg gat gct aat aac tac ctc agt ttg cca gta gga aaa	1392	Leu Leu Leu Val Asp Ala Asn Asn Tyr Leu Ser Leu Pro Val Gly Lys		450	455	460		tac tac cta aca gag aca aag gcc cct cca ggg tac cta cta cct aaa	1440	Tyr Tyr Leu Thr Glu Thr Lys Ala Pro Pro Gly Tyr Leu Leu Pro Lys		465	470	475	480	aat gat gat ata tca gta tta gtg att tct acg gga gtt acc ttt gaa	1488	Asn Asp Asp Ile Ser Val Leu Val Ile Ser Thr Gly Val Thr Phe Glu		485	490	495		caa aat ggt aat aat gcg aca cca ata aaa gag aat tta gtg gat gga	1536	Gln Asn Gly Asn Asn Ala Thr Pro Ile Lys Glu Asn Leu Val Asp Gly		500	505	510		agt aca gta tat act ttt aaa att act aac agt aaa gga aca gaa ttg	1584	Ser Thr Val Tyr Thr Phe Lys Ile Thr Asn Ser Lys Gly Thr Glu Leu		515	520	525		cct agt act gga ggt att gga aca cac att tat atc cta gtt ggt tta	1632	Pro Ser Thr Gly Gly Ile Gly Thr His Ile Tyr Ile Leu Val Gly Leu		530	535	540		gct tta gct cta cca tca gga tta ata tta tac tat cga aaa aaa ata	1680	Ala Leu Ala Leu Pro Ser Gly Leu Ile Leu Tyr Tyr Arg Lys Lys Ile		545	550	555	560																								
430																																																																																											
aaa gct tca cat cct atg tat tca ggg ctg gtg aca aac gat aaa ggc	1344																																																																																										
Lys Ala Ser His Pro Met Tyr Ser Gly Leu Val Thr Asn Asp Lys Gly																																																																																											
435	440	445		ttg tta tta gtg gat gct aat aac tac ctc agt ttg cca gta gga aaa	1392	Leu Leu Leu Val Asp Ala Asn Asn Tyr Leu Ser Leu Pro Val Gly Lys		450	455	460		tac tac cta aca gag aca aag gcc cct cca ggg tac cta cta cct aaa	1440	Tyr Tyr Leu Thr Glu Thr Lys Ala Pro Pro Gly Tyr Leu Leu Pro Lys		465	470	475	480	aat gat gat ata tca gta tta gtg att tct acg gga gtt acc ttt gaa	1488	Asn Asp Asp Ile Ser Val Leu Val Ile Ser Thr Gly Val Thr Phe Glu		485	490	495		caa aat ggt aat aat gcg aca cca ata aaa gag aat tta gtg gat gga	1536	Gln Asn Gly Asn Asn Ala Thr Pro Ile Lys Glu Asn Leu Val Asp Gly		500	505	510		agt aca gta tat act ttt aaa att act aac agt aaa gga aca gaa ttg	1584	Ser Thr Val Tyr Thr Phe Lys Ile Thr Asn Ser Lys Gly Thr Glu Leu		515	520	525		cct agt act gga ggt att gga aca cac att tat atc cta gtt ggt tta	1632	Pro Ser Thr Gly Gly Ile Gly Thr His Ile Tyr Ile Leu Val Gly Leu		530	535	540		gct tta gct cta cca tca gga tta ata tta tac tat cga aaa aaa ata	1680	Ala Leu Ala Leu Pro Ser Gly Leu Ile Leu Tyr Tyr Arg Lys Lys Ile		545	550	555	560																																
445																																																																																											
ttg tta tta gtg gat gct aat aac tac ctc agt ttg cca gta gga aaa	1392																																																																																										
Leu Leu Leu Val Asp Ala Asn Asn Tyr Leu Ser Leu Pro Val Gly Lys																																																																																											
450	455	460		tac tac cta aca gag aca aag gcc cct cca ggg tac cta cta cct aaa	1440	Tyr Tyr Leu Thr Glu Thr Lys Ala Pro Pro Gly Tyr Leu Leu Pro Lys		465	470	475	480	aat gat gat ata tca gta tta gtg att tct acg gga gtt acc ttt gaa	1488	Asn Asp Asp Ile Ser Val Leu Val Ile Ser Thr Gly Val Thr Phe Glu		485	490	495		caa aat ggt aat aat gcg aca cca ata aaa gag aat tta gtg gat gga	1536	Gln Asn Gly Asn Asn Ala Thr Pro Ile Lys Glu Asn Leu Val Asp Gly		500	505	510		agt aca gta tat act ttt aaa att act aac agt aaa gga aca gaa ttg	1584	Ser Thr Val Tyr Thr Phe Lys Ile Thr Asn Ser Lys Gly Thr Glu Leu		515	520	525		cct agt act gga ggt att gga aca cac att tat atc cta gtt ggt tta	1632	Pro Ser Thr Gly Gly Ile Gly Thr His Ile Tyr Ile Leu Val Gly Leu		530	535	540		gct tta gct cta cca tca gga tta ata tta tac tat cga aaa aaa ata	1680	Ala Leu Ala Leu Pro Ser Gly Leu Ile Leu Tyr Tyr Arg Lys Lys Ile		545	550	555	560																																								
460																																																																																											
tac tac cta aca gag aca aag gcc cct cca ggg tac cta cta cct aaa	1440																																																																																										
Tyr Tyr Leu Thr Glu Thr Lys Ala Pro Pro Gly Tyr Leu Leu Pro Lys																																																																																											
465	470	475	480	aat gat gat ata tca gta tta gtg att tct acg gga gtt acc ttt gaa	1488	Asn Asp Asp Ile Ser Val Leu Val Ile Ser Thr Gly Val Thr Phe Glu		485	490	495		caa aat ggt aat aat gcg aca cca ata aaa gag aat tta gtg gat gga	1536	Gln Asn Gly Asn Asn Ala Thr Pro Ile Lys Glu Asn Leu Val Asp Gly		500	505	510		agt aca gta tat act ttt aaa att act aac agt aaa gga aca gaa ttg	1584	Ser Thr Val Tyr Thr Phe Lys Ile Thr Asn Ser Lys Gly Thr Glu Leu		515	520	525		cct agt act gga ggt att gga aca cac att tat atc cta gtt ggt tta	1632	Pro Ser Thr Gly Gly Ile Gly Thr His Ile Tyr Ile Leu Val Gly Leu		530	535	540		gct tta gct cta cca tca gga tta ata tta tac tat cga aaa aaa ata	1680	Ala Leu Ala Leu Pro Ser Gly Leu Ile Leu Tyr Tyr Arg Lys Lys Ile		545	550	555	560																																																
475	480																																																																																										
aat gat gat ata tca gta tta gtg att tct acg gga gtt acc ttt gaa	1488																																																																																										
Asn Asp Asp Ile Ser Val Leu Val Ile Ser Thr Gly Val Thr Phe Glu																																																																																											
485	490	495		caa aat ggt aat aat gcg aca cca ata aaa gag aat tta gtg gat gga	1536	Gln Asn Gly Asn Asn Ala Thr Pro Ile Lys Glu Asn Leu Val Asp Gly		500	505	510		agt aca gta tat act ttt aaa att act aac agt aaa gga aca gaa ttg	1584	Ser Thr Val Tyr Thr Phe Lys Ile Thr Asn Ser Lys Gly Thr Glu Leu		515	520	525		cct agt act gga ggt att gga aca cac att tat atc cta gtt ggt tta	1632	Pro Ser Thr Gly Gly Ile Gly Thr His Ile Tyr Ile Leu Val Gly Leu		530	535	540		gct tta gct cta cca tca gga tta ata tta tac tat cga aaa aaa ata	1680	Ala Leu Ala Leu Pro Ser Gly Leu Ile Leu Tyr Tyr Arg Lys Lys Ile		545	550	555	560																																																								
495																																																																																											
caa aat ggt aat aat gcg aca cca ata aaa gag aat tta gtg gat gga	1536																																																																																										
Gln Asn Gly Asn Asn Ala Thr Pro Ile Lys Glu Asn Leu Val Asp Gly																																																																																											
500	505	510		agt aca gta tat act ttt aaa att act aac agt aaa gga aca gaa ttg	1584	Ser Thr Val Tyr Thr Phe Lys Ile Thr Asn Ser Lys Gly Thr Glu Leu		515	520	525		cct agt act gga ggt att gga aca cac att tat atc cta gtt ggt tta	1632	Pro Ser Thr Gly Gly Ile Gly Thr His Ile Tyr Ile Leu Val Gly Leu		530	535	540		gct tta gct cta cca tca gga tta ata tta tac tat cga aaa aaa ata	1680	Ala Leu Ala Leu Pro Ser Gly Leu Ile Leu Tyr Tyr Arg Lys Lys Ile		545	550	555	560																																																																
510																																																																																											
agt aca gta tat act ttt aaa att act aac agt aaa gga aca gaa ttg	1584																																																																																										
Ser Thr Val Tyr Thr Phe Lys Ile Thr Asn Ser Lys Gly Thr Glu Leu																																																																																											
515	520	525		cct agt act gga ggt att gga aca cac att tat atc cta gtt ggt tta	1632	Pro Ser Thr Gly Gly Ile Gly Thr His Ile Tyr Ile Leu Val Gly Leu		530	535	540		gct tta gct cta cca tca gga tta ata tta tac tat cga aaa aaa ata	1680	Ala Leu Ala Leu Pro Ser Gly Leu Ile Leu Tyr Tyr Arg Lys Lys Ile		545	550	555	560																																																																								
525																																																																																											
cct agt act gga ggt att gga aca cac att tat atc cta gtt ggt tta	1632																																																																																										
Pro Ser Thr Gly Gly Ile Gly Thr His Ile Tyr Ile Leu Val Gly Leu																																																																																											
530	535	540		gct tta gct cta cca tca gga tta ata tta tac tat cga aaa aaa ata	1680	Ala Leu Ala Leu Pro Ser Gly Leu Ile Leu Tyr Tyr Arg Lys Lys Ile		545	550	555	560																																																																																
540																																																																																											
gct tta gct cta cca tca gga tta ata tta tac tat cga aaa aaa ata	1680																																																																																										
Ala Leu Ala Leu Pro Ser Gly Leu Ile Leu Tyr Tyr Arg Lys Lys Ile																																																																																											
545	550	555	560																																																																																								
555	560																																																																																										

tga

1683

<210> 19  
<211> 560  
<212> PRT  
<213> Streptococcus agalactiae

<400> 19  
Met Val Ile Val Phe Arg Ile Ile Gln Ile Leu Gln Gly Ile Ile Ser  
1 5 10 15  
  
Lys Ile Leu Gln Val His Ile Ile Ser Met Ile His Glu Ile Lys  
20 25 30  
  
Ile Pro Thr Gln Leu Lys Met Pro Ile Ile Arg Gln Ile Leu Val Ser  
35 40 45  
  
Ser Asn Val Asp Thr Thr Lys Tyr Lys Tyr Val Lys Asp Ala Tyr  
50 55 60  
  
Lys Leu Val Gly Trp Tyr Val Asn Pro Tyr Gly Ser Ile Arg Pro  
65 70 75 80  
  
Tyr Asn Phe Ser Gly Ala Val Thr Gln Asp Ile Asn Leu Arg Ala Ile  
85 90 95  
  
Trp Arg Lys Ala Gly Asp Tyr His Ile Ile Tyr Ser Asn Asp Ala Val  
100 105 110  
  
Gly Thr Asp Gly Lys Pro Ala Leu Asp Ala Ser Gly Gln Gln Leu Gln  
115 120 125  
  
Thr Ser Asn Glu Pro Thr Asp Pro Asp Ser Tyr Asp Asp Gly Ser His  
130 135 140  
  
Ser Ala Leu Leu Arg Arg Pro Thr Met Pro Asp Gly Tyr Arg Phe Arg  
145 150 155 160  
  
Gly Trp Trp Tyr Asn Gly Lys Ile Tyr Asn Pro Tyr Asp Ser Ile Asp  
165 170 175  
  
Ile Asp Ala His Leu Ala Asp Ala Asn Lys Asn Ile Thr Ile Lys Pro  
180 185 190  
  
Val Ile Ile Pro Val Gly Asp Ile Lys Leu Glu Asp Thr Ser Ile Lys  
195 200 205

Tyr Asn Gly Asn Gly Gly Thr Arg Val Glu Asn Gly Asn Val Val Thr  
210 215 220

Gln Val Glu Thr Pro Arg Met Glu Leu Asn Ser Thr Thr Thr Ile Pro  
225 230 235 240

Glu Asn Gln Tyr Phe Thr Arg Thr Gly Tyr Asn Leu Ile Gly Trp His  
245 250 255

His Asp Lys Asp Leu Ala Asp Thr Gly Arg Val Glu Phe Thr Ala Gly  
260 265 270

Gln Ser Ile Gly Ile Asp Asn Asn Leu Asp Ala Thr Asn Thr Leu Tyr  
275 280 285

Ala Val Trp Gln Pro Lys Glu Tyr Thr Val Gly Val Ser Lys Thr Val  
290 295 300

Val Gly Leu Asp Glu Asp Lys Thr Lys Asp Phe Leu Phe Asn Pro Ser  
305 310 315 320

Glu Thr Leu Gln Gln Glu Asn Phe Pro Leu Arg Asp Gly Gln Thr Lys  
325 330 335

Glu Phe Lys Val Pro Tyr Gly Thr Ser Ile Ser Ile Asp Glu Gln Ala  
340 345 350

Tyr Asp Glu Phe Lys Val Ser Glu Ser Ile Thr Glu Lys Asn Leu Ala  
355 360 365

Thr Gly Glu Ala Asp Lys Thr Tyr Asp Ala Thr Gly Leu Gln Ser Leu  
370 375 380

Thr Val Ser Gly Asp Val Asp Ile Ser Phe Thr Asn Thr Arg Ile Lys  
385 390 395 400

Gln Lys Val Arg Leu Gln Lys Val Asn Val Glu Asn Asp Asn Asn Phe  
405 410 415

Leu Ala Gly Ala Val Phe Asp Ile Tyr Glu Ser Asp Ala Asn Gly Asn  
420 425 430

Lys Ala Ser His Pro Met Tyr Ser Gly Leu Val Thr Asn Asp Lys Gly  
435 440 445

Leu Leu Leu Val Asp Ala Asn Asn Tyr Leu Ser Leu Pro Val Gly Lys  
450 455 460

Tyr Tyr Leu Thr Glu Thr Lys Ala Pro Pro Gly Tyr Leu Leu Pro Lys  
465 470 475 480

Asn Asp Asp Ile Ser Val Leu Val Ile Ser Thr Gly Val Thr Phe Glu  
485 490 495

Gln Asn Gly Asn Asn Ala Thr Pro Ile Lys Glu Asn Leu Val Asp Gly  
500 505 510

Ser Thr Val Tyr Thr Phe Lys Ile Thr Asn Ser Lys Gly Thr Glu Leu  
515 520 525

Pro Ser Thr Gly Gly Ile Gly Thr His Ile Tyr Ile Leu Val Gly Leu  
530 535 540

Ala Leu Ala Leu Pro Ser Gly Leu Ile Leu Tyr Tyr Arg Lys Lys Ile  
545 550 555 560

<210> 20

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: consensus

<400> 20

Leu Pro Ser Thr Gly Gly

1 5

<210> 21

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: consensus

<220>

<223> X can be any amino acid.

<400> 21

Xaa Pro Xaa Thr Gly Gly

1 5

<210> 22  
<211> 2714  
<212> DNA  
<213> *Streptococcus pneumoniae*

<400> 22  
caatcagaaa ttaccacgtg gcaatgttga ctatgaag gtggatggtc ggaccaatac 60  
ctctcttcaa gggcaatgt tcaaagtcat gaaagaagaa agcggacact atactcctgt 120  
tcttcaaaat ggttaaggaag tagttgtAAC atcaggAAA gatggtcgtt tccgagtggA 180  
aggtagttagt tatggacat actatTTATG ggagctccAA gctccaactg gttatgttca 240  
attaacatcg cctgtttcct ttacaatcgG gaaagatact cgtaaggaac tggtaacagt 300  
gtttaaaaat aacaagcgac cacggattga tggccagat acagggaaag aaaccttgta 360  
tatcttgatg cttgttgcca ttttgggtt tggtagtggT tattatcttA cgaaaaaa'cc 420  
aaataactga tattcaatgt acatcattat gaaaaagata gcaggctgaa ggaaagacca 480  
gagtaactcg aggtgatgtt aatcaggaat catggtgatg tggcatgaat cacaataacg 540  
gatatgagggc tggcagatt gtgccagct cattgtgggt tattgtttgtt aaaaacgatag 600  
gactggtctg gtaatcattt taggaatggA caggactggg attctgattt aaaaatggatg 660  
gtgaatcaga aagaaatgag attttctcgT ttctcttagc agataggatt gtctgttagg 720  
aaaagcgata aaatgatgag tttgaagata aaggatgct gataaaaatg gtaaaaacaa 780  
aaaagcaaaa acgaaataat ctcctattag gagtggtatt tttcattggA atggcggtaa 840  
tggcgtatcc gctgggtctt cgcttgcatt atcgagtggA atcaaataa caaattgctg 900  
actttgataa gaaaaaagca acgttggatg aggctgacat tggatggacgA atgaaattgg 960  
cacaaggcattt caatgactct ttgaataatg tagtgagtgg cgatccttgg tcggaaagaaa 1020  
tgaagaaaaa agggcgagca gagttatgcac gtatgttagA aatccatgag cggatggggc 1080  
atgtggaaat ccccggttatt gacgtggatt tgccggtttA tgctggtaact gctgaagagg 1140  
tattgcagca aggggctggg catctagagg gaacttctctt ggcgatcgGA ggcaattcgA 1200  
cccatgcggt gattacggca catacaggTT tgccaaacagc taagatgttt acggatttga 1260

ccaaacttaa agttggggat aagtttatg tgcacaatat caaggaagtg atggcctatc 1320  
aagtggatca agtaaagggtg attgagccga cgaactttga tgatttattg attgtaccag 1380  
gtcatgatta tgtgaccttg ctgacttgta cgccatacat gatcaatacc catcgcttat 1440  
tggttcgaaa gcatcgaaa ccgtacgtag cagaggttga ggaagaattt attgcagcaa 1500  
acaaactcag tcatactctat cgctacctgt tttatgtggc agttggttt attgtgattc 1560  
ttttatggat tattcgacgc ttgcgcaaga agaaaaaaaca accggaaaag gctttgaagg 1620  
cgctgaaagc agcaaggaag gaagtgaagg tggaggatgg acaacagtag acgttcacga 1680  
aaaaaaggca caaaaaagaa gaaacatccg ctgatccttc ttctgatttt cttagtagga 1740  
ttcgccgttg cgatatatcc attgggtgtct cgttattatt atcgtattga gtcaaacgag 1800  
gttattaaag agtttcatgtg gacggttcc cagatggata aggcagaact tgaggagcgt 1860  
tggcgcttgg ctcaaggcctt caatgcgacc ttgaaaccat ctgaaattct tgatccttt 1920  
acagagcaag agaaaaagaa aggcgtctca gaatatgcca atatgctaaa ggtccatgag 1980  
cggttggct atgtggaaat tcctgcgatt gatcaggaaa ttccgatgta tgtcgaaacg 2040  
agtgaggaca ttcttcagaa aggggcaggg ctgttagaaag gggcttcgct gcctgttgaa 2100  
ggtgaaaata cccatacagt gatcactgct cacagaggat tgccaaacggc agaattgttc 2160  
agtcaattgg ataagatgaa aaaagggat atctttatc ttacgtttt agatcaggtg 2220  
ttggcctacc aagtggatca gatagtgacg gtggagccga atgactttga gcctgtctt 2280  
attcaacatg gggaaagatta tgcgacccctt tgacttgta caccgtatata gattaacagt 2340  
catcgctgtg tggtagtgg gaagccgatt ccgtatacgg caccaattgc agagcgaat 2400  
cgagcgggtga gagagcgtgg gcaattctgg ttgtggttat tactaggagc gatggcggc 2460  
atccttcctt tgctgtatcg cgtgtatcg aatcgacggc ttgtcaaagg actagaaaag 2520  
caattggagg ggcgtcatgt caaggactaa actacgagcc ttattggat acttggat 2580  
gttggtagcc tggtagtgc ctatttattt tttggacag atgggtttgc agtctttgg 2640  
acaggtgaaa ggtcatgcta catttggaa atccatgaca actgaaatgt accaagaaca 2700

acagaaccat tctc

2714

&lt;210&gt; 23

&lt;211&gt; 297

&lt;212&gt; PRT

&lt;213&gt; Streptococcus pneumoniae

&lt;400&gt; 23

Met	Asp	Asn	Ser	Arg	Arg	Ser	Arg	Lys	Lys	Gly	Thr	Lys	Lys	Lys	Lys
1								10							15

His	Pro	Leu	Ile	Leu	Leu	Ile	Phe	Leu	Val	Gly	Phe	Ala	Val	Ala
			20					25						30

Ile	Tyr	Pro	Leu	Val	Ser	Arg	Tyr	Tyr	Tyr	Arg	Ile	Glu	Ser	Asn	Glu
							35			40				45	

Val	Ile	Lys	Glu	Phe	Asp	Glu	Thr	Val	Ser	Gln	Met	Asp	Lys	Ala	Glu
							50			55			60		

Leu	Glu	Glu	Arg	Trp	Arg	Leu	Ala	Gln	Ala	Phe	Asn	Ala	Thr	Leu	Lys
						65			70			75		80	

Pro	Ser	Glu	Ile	Leu	Asp	Pro	Phe	Thr	Glu	Gln	Glu	Lys	Lys	Gly
							85			90			95	

Val	Ser	Glu	Tyr	Ala	Asn	Met	Leu	Lys	Val	His	Glu	Arg	Ile	Gly	Tyr
							100			105			110		

Val	Glu	Ile	Pro	Ala	Ile	Asp	Gln	Glu	Ile	Pro	Met	Tyr	Val	Gly	Thr
							115			120			125		

Ser	Glu	Asp	Ile	Leu	Gln	Lys	Gly	Ala	Gly	Leu	Leu	Glu	Gly	Ala	Ser
							130			135			140		

Leu	Pro	Val	Gly	Gly	Glu	Asn	Thr	His	Thr	Val	Ile	Thr	Ala	His	Arg
							145			150			155		160

Gly	Leu	Pro	Thr	Ala	Glu	Leu	Phe	Ser	Gln	Leu	Asp	Lys	Met	Lys	Lys
							165			170			175		

Gly	Asp	Ile	Phe	Tyr	Leu	His	Val	Leu	Asp	Gln	Val	Leu	Ala	Tyr	Gln
							180			185			190		

Val	Asp	Gln	Ile	Val	Thr	Val	Glu	Pro	Asn	Asp	Phe	Glu	Pro	Val	Leu
							195			200			205		

Ile Gln His Gly Glu Asp Tyr Ala Thr Leu Leu Thr Cys Thr Pro Tyr  
210 215 220

Met Ile Asn Ser His Arg Leu Leu Val Arg Gly Lys Arg Ile Pro Tyr  
225 230 235 240

Thr Ala Pro Ile Ala Glu Arg Asn Arg Ala Val Arg Glu Arg Gly Gln  
245 250 255

Phe Trp Leu Trp Leu Leu Leu Gly Ala Met Ala Val Ile Leu Leu Leu  
260 265 270

Leu Tyr Arg Val Tyr Arg Asn Arg Arg Ile Val Lys Gly Leu Glu Lys  
275 280 285

Gln Leu Glu Gly Arg His Val Lys Asp  
290 295

<210> 24

<211> 894

<212> DNA

<213> *Streptococcus pneumoniae*

<400> 24

atggacaaca gtagacgttc acgaaaaaaaaa ggcacaaaaaaaaa agaagaaaca tccgctgatc 60

cttcttctga ttttcttagt aggattcgcc gttgcgatat atccattgggt gtctcggtat 120

tattatcgta ttgagtcaaa cgaggatttatt aaagagtttg atgagacggt ttcccagatg 180

gataaggcag aacttgagga gcgttggcgc ttggctcaag cttcaatgc gaccttgaaa 240

ccatctgaaa ttcttgatcc ttttacagag caagagaaaa agaaaggcgt ctcagaatat 300

gccaatatgc taaaggtcca tgagcggatt ggctatgtgg aaattcctgc gattgatcag 360

gaaattccga tgtatgtcgg aacgagttag gacattcttc agaaaggggc agggctgtta 420

gaagggggctt cgctgcctgt tggaggtgaa aataccata cagtgatcac tgctcacaga 480

ggattgccaa cggcagaatt gttcagtcaa ttggataaga tgaaaaaagg ggatatctt 540

tatcttcacg ttttagatca ggtgtggcc taccaagtgg atcagatagt gacggtggag 600

ccgaatgact ttgagcctgt cttgattcaa catgggaaag attatgcgac cttgttgact 660

tgtacaccgt atatgattaa cagtcatcgt ctgttggta c gtgggaagcg gattccgtat 720  
acggcaccaa ttgcagagcg gaatcgagcg gtgagagagc gtgggcaatt ctggttgtgg 780  
ttattactag gagcgatggc ggtcatcctt ctcttgcgt atcgcgtgta tcgtaatcga 840  
cggattgtca aaggactaga aaagcaattg gaggggcgtc atgtcaagga ctaa 894

<210> 25

<211> 3010

<212> DNA

<213> *Streptococcus pneumoniae*

<400> 25

tgttagaaaa agcgataaaa tcatgagttt gaagataaaag ggatgctgat aaaaatggta 60  
aaaacaaaaaa agcaaaaacg aaataatctc ctattaggag tggattttt cattggaatg 120  
gcggtaatgg cgtatccgct ggtgtctcgc ttgtattatc gagtggaaatc aaatcaadaa 180  
attgctgact ttgataagga aaaagcaacg ttggatgagg ctgacattga tgaacgaatg 240  
aaattggcac aagccttcaa tgactcttg aataatgtag tgagtggcga tccttggcgt 300  
gaagaaaatga agaaaaaagg gcgagcagag tatgcacgta tggtagaaat ccatgagcgg 360  
atggggcatg tggaaatccc cgttattgac gtggatttgc cggttatgc tggtaactgct 420  
gaagaggtat tgcagcaagg ggctggcat ctagagggaa cttctctgcc gatcggaggc 480  
aattcgcaccc atgcggtgat tacggcacat acaggtttgc caacagctaa gatgtttacg 540  
gatttgacca aacttaaagt tgggataag ttttatgtgc acaatatcaa ggaagtgtatg 600  
gccttatcaag tggatcaagt aaaggtgatt gagccgacga actttgatga tttattgatt 660  
gtaccaggc atgattatgt gaccttgctg acttgtacgc catacatgat caataccat 720  
cgtctattgg ttcgggggca tcggataccg tacgtagcag aggttggagga agaattttatt 780  
gcagcaaaca aactcagtca tctctatcgc tacctgtttt atgtggcagt tggtttgatt 840  
gtgattcttt tatggattat tcgacgcttg cgcaagaaga aaaaacaacc gaaaaaggct 900  
ttgaaggcgc tgaaggcagc aaggaaggaa gtgaagggtgg aggatggaca acagtagacg 960  
ttcacgaaaa aaaggcacaa aaaagaagaa acatccgctg atccttcttc tgattttctt 1020

agtaggattc gccgttgcga tatatccatt ggtgtctcggttattttatc gtatttagtc 1080  
aaacgagggtt attaaagagt ttgatgagac gggttcccaag atggataagg cagaacttga 1140  
ggagcggttgg cgcttggctc aagccttcaa tgcgaccttg aaaccatctg aaattcttga 1200  
tccttttaca gagcaagaga aaaagaaagg cgtctcagaa tatgccaata tgctaaaggt 1260  
ccatgagcgg attggctatg tggaaattcc tgcgattgat cagggaaattc cgatgtatgt 1320  
cggaacgagt gaggacattc ttcagaaagg ggcagggttg tttagaagggg cttagctgcc 1380  
tggtggaggt gaaaataccca atacagtatg cactgctcac agaggattgc caacggcaga 1440  
attgttcagt caattggata agatgaaaaa aggggatatac ttttatcttc acgttttaga 1500  
tcaggtgttg gcctaccaag tggatcagat agtgacggtg gagccgaatg actttgagcc 1560  
tgtcttgatt caacatgggg aagattatgc gaccttgggtt acttgtacac cgtatatgt 1620  
taacagtcat cgtctgttg tacgtggaa gcggattccg tatacggcac caattgcaga 1680  
gcggaatcga gcgggtgagag agcgtggca attctgggtt tggttattac taggagcgat 1740  
ggcggtcatc cttctttgc tgtatcgctgt gtatcgtaat cgacggatttgc tcaaaggact 1800  
agaaaagcaa ttggaggggc gtcatgtcaa ggactaaact acgagcctta ttggataact 1860  
tggtgatgtt ggtacgcgtt ttgattccata tttattgttt tggacagatg gtgttgcagt 1920  
ctcttggaca ggtgaaaggt catgctacat ttgtgaaatc catgacaact gaaatgtacc 1980  
aagaacaaca gaaccattct ctcgcctaca atcaacgctt ggcttcgcaaa aatcgcatgg 2040  
tagatccctt tttggcgag gatatgagg tcaattacca agtgcgtac gaccctgtatg 2100  
cagtctatgg ttacttgcgtt attccaagtt tggaaatcat ggagccgggtt tatttggag 2160  
cagattatca tcatttaggg atgggcttgg ctcatgtgga tggcacccg ctgcctctgg 2220  
atggtacagg gattcgctca gtgattgcgtg ggcaccgtgc agagccaaagc catgtcttt 2280  
tccgccattt ggatcagcta aaagttggag atgctttta ttatgataat ggccaggaaa 2340  
ttgtagaata tcagatgtatg gacacagaga ttatccatc gtcgaaatgg gaaaaatttt 2400  
aatcggttag ctctaaaaat atcatgaccc tgcataacccg cgtatccgatt cctacccctta 2460



Pro Val Ile Asp Val Asp Leu Pro Val Tyr Ala Gly Thr Ala Glu Glu  
115 120 125

Val Leu Gln Gln Gly Ala Gly His Leu Glu Gly Thr Ser Leu Pro Ile  
130 135 140

Gly Gly Asn Ser Thr His Ala Val Ile Thr Ala His Thr Gly Leu Pro  
145 150 155 160

Thr Ala Lys Met Phe Thr Asp Leu Thr Lys Leu Lys Val Gly Asp Lys  
165 170 175

Phe Tyr Val His Asn Ile Lys Glu Val Met Ala Tyr Gln Val Asp Gln  
180 185 190

Val Lys Val Ile Glu Pro Thr Asn Phe Asp Asp Leu Leu Ile Val Pro  
195 200 205

Gly His Asp Tyr Val Thr Leu Leu Thr Cys Thr Pro Tyr Met Ile Asn  
210 215 220

Thr His Arg Leu Leu Val Arg Gly His Arg Ile Pro Tyr Val Ala Glu  
225 230 235 240

Val Glu Glu Glu Phe Ile Ala Ala Asn Lys Leu Ser His Leu Tyr Arg  
245 250 255

Tyr Leu Phe Tyr Val Ala Val Gly Leu Ile Val Ile Leu Leu Trp Ile  
260 265 270

Ile Arg Arg Leu Arg Lys Lys Lys Gln Pro Glu Lys Ala Leu Lys  
275 280 285

Ala Leu Lys Ala Ala Arg Lys Glu Val Lys Val Glu Asp Gly Gln Gln  
290 295 300

<210> 27

<211> 915

<212> DNA

<213> *Streptococcus pneumoniae*

<400> 27

atgctgataa aatggtaaa aacaaaaaag caaaaacgaa ataatctcct attaggatg 60

gtattttca ttggaatggc ggtatggcg tatccgctgg tgtctcgctt gtattatcga 120  
 gtggaatcaa atcaacaaat tgctgacttt gataaggaaa aagcaacgtt ggatgaggct 180  
 gacattgatg aacgaatgaa attggcacaa gccttcaatg actcttgaa taatgtatg 240  
 agtggcgatc cttggtcgga agaaatgaag aaaaaaggc gagcagagta tgcacgtatg 300  
 tttagaaatcc atgagcggat ggggcatgtg gaaatccccg ttattgacgt ggatttgccg 360  
 gtttatgctg gtactgctga agaggatttg cagcaagggg ctggcatct agaggaaact 420  
 tctctgccga tcggaggcaa ttcgaccat cggtgatc cggcacatac aggttgcca 480  
 acagctaaga tggttacgga tttgacccaa cttaaagttg gggataagtt ttatgtgcac 540  
 aatatcaagg aagtgtatggc ctatcaagtg gatcaagtaa aggtgattga gccgacgaac 600  
 tttgatgatt tattgattgt accaggtcat gattatgtga ctttgctgac ttgtacgcca 660  
 tacatgatca atacccatcg tctattggtt cgggggcatc ggataaccgta ctagcagag 720  
 gttgaggaag aatttattgc agcaaacaaa ctcagtcac tctatcgcta cctgtttat 780  
 gtggcagttg gtttgattgt gattcttta tggattttc gacgcttgcg caagaagaaa 840  
 aaacaaccgg aaaaggctt gaaggcgctg aaagcagcaa ggaaggaagt gaaggtggag 900  
 gatggacaac agtag 915

<210> 28  
 <211> 2199  
 <212> DNA  
 <213> Enterococcus faecalis

<400> 28  
 actaaaatc gtttacttta tgcatttaaa taaaaagca gatcctacga aaggctttaa 60  
 aaatgaggcg aatgttgata acggtcatac cgacgaccaa acaccacaa ctgttgaagt 120  
 tgtgacaggt gggaaacgtt tcattaaagt cgatggcgat gtgacagcga cacaagcctt 180  
 ggcgggagct tccttgcg tccgtatca aaacagcgcac acagcaaatt atttgaaaat 240  
 cgatgaaaca acgaaagcag caacttgggt gaaaacaaaa gctgaagcaa ctactttac 300

aacaacggct gatggattag ttgatatac agggcttaaa tacggtaacct attattt 360  
agaaaactgta gctcctgatg attatgtctt gttaacaaat cgattgaaat ttgtggtcaa 420  
tgaacaatca tatggcacaa cagaaaacct agtttacca gaaaaagtac caaacaaca 480  
caaaggtaacc ttaccttcaa caggtggcaa aggaatctac gtttacttag gaagtggcgc 540  
agtcttgcta ctattgcag gagtctactt tgctagacgt agaaaagaaa atgcttaatt 600  
tctagcatca ccgaagaaat ttttagaaaa acaaagagcc tgggccaatc actgtcccag 660  
gctctcatgc ttatattttta aggaggaagc aatgaagtca aaaaagaaac gtcgtatcat 720  
tgatggtttt atgattcttt tactgattat tggaaataggt gcatttgcgt atcctttgt 780  
tagcgatgca ttaaataact atctggatca acaaattatc gtcattatc aagcaaaagc 840  
aagccaagaa aacacccaaag aaatggctga acttcaagaa aaaatggaaa agaaaaacca 900  
agaattagcg aaaaaaggca gcaatcctgg attagatcct tttctgaaa cgcaaaaaac 960  
aacgaaaaaa ccagacaaat cctatttga aagtcatcgc attgggtttt taaccattcc 1020  
aaaaataaaat gtccgtttac caattttga taaaacgaat gcattgctat tggaaaaagg 1080  
aagctccttg ttagaaggaa ctccttatcc tacaggtggt acgaatacac atgcggcat 1140  
ttcaggccat cgtggtctcc ctcaagccaa attatttaca gattgccag aattaaaaaa 1200  
aggcgatgaa ttttatatcg aagtcaatgg gaagacgctt gcttatcaag tagatcaa 1260  
aaaaaccgtt gaaccaactg atacaaaaga tttacacatt gagtctggcc aagatctcg 1320  
cactttatta acttgcacac cgtatatgat aaacagtcat cggttattag ttcgaggaca 1380  
tcgtatccca tatcaaccag aaaaagcagc agcggggatg aaaaaagtgg cacaacaaca 1440  
aaatttacta ttatggacat tactttaat tgcctgtcg ttaatttata gcggcttcat 1500  
tatctggtac aagcgacgga aaaagacgac cagaaaacca aagtagttag acgaaaaggc 1560  
taaacataact aaaaaaaaaga gtaaaaaaaaat agctttcaa ttttaatcc tccttatcg 1620  
gcataattga accagagaaaa cagaagtatt aacgaaataa ctaaaagagc aagccctgaa 1680  
taaaaaagcga caaaggccca atcaatcgac tggattttt cctgccaagt ttggattttt 1740

ctgtttttt tcgcgctatc ctcaagcgtg agtaaataat tcaatagtaa gaggagtagc 1800  
 aacaccgtga aatcatttgc ggtaaaaagc acatgtaaaa atagaatgac aaagacaaca 1860  
 cgggataaca ctcgattccg caaaattaaa aataacttag cacgcataat aaaccaccat 1920  
 ttcttatcag agataatgaa tctgttttg tctactctt agttatataca taaaattctt 1980  
 aataatgaaa aatgactcg agaaaataat tgaaaaaagt ttttttcct gaatcattat 2040  
 ttcgtaaat aaagaataaa cgtgttactc ttggcttatac aaatttggaa ggagtgttaa 2100  
 aaatgaaata tctggatatt attgctttaa ttttattgat tgcggaggt taaaactggt 2160  
 tattagttgg tgcatttaat tttgatttag ttgcaacaa 2199

&lt;210&gt; 29

&lt;211&gt; 284

&lt;212&gt; PRT

&lt;213&gt; Enterococcus faecalis

&lt;400&gt; 29

Met	Lys	Ser	Lys	Lys	Arg	Arg	Ile	Ile	Asp	Gly	Phe	Met	Ile	Leu
1								10					15	

Leu	Leu	Ile	Ile	Gly	Ile	Gly	Ala	Phe	Ala	Tyr	Pro	Phe	Val	Ser	Asp
								25					30		

Ala	Leu	Asn	Asn	Tyr	Leu	Asp	Gln	Gln	Ile	Ile	Ala	His	Tyr	Gln	Ala
								40				45			

Lys	Ala	Ser	Gln	Glu	Asn	Thr	Lys	Glu	Met	Ala	Glu	Leu	Gln	Glu	Lys
								55				60			

Met	Glu	Lys	Lys	Asn	Gln	Glu	Leu	Ala	Lys	Gly	Ser	Asn	Pro	Gly
65								70			75		80	

Leu	Asp	Pro	Phe	Ser	Glu	Thr	Gln	Lys	Thr	Thr	Lys	Lys	Pro	Asp	Lys
									85				90		95

Ser	Tyr	Phe	Glu	Ser	His	Thr	Ile	Gly	Val	Leu	Thr	Ile	Pro	Lys	Ile
								100			105		110		

Asn	Val	Arg	Leu	Pro	Ile	Phe	Asp	Lys	Thr	Asn	Ala	Leu	Leu	Glu	
									115			120		125	

Lys	Gly	Ser	Ser	Leu	Leu	Glu	Gly	Thr	Ser	Tyr	Pro	Thr	Gly	Gly	Thr
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

130	135	140
Asn Thr His Ala Val Ile Ser Gly His Arg Gly Leu Pro Gln Ala Lys		
145	150	155
160		
Leu Phe Thr Asp Leu Pro Glu Leu Lys Lys Gly Asp Glu Phe Tyr Ile		
165	170	175
Glu Val Asn Gly Lys Thr Leu Ala Tyr Gln Val Asp Gln Ile Lys Thr		
180	185	190
Val Glu Pro Thr Asp Thr Lys Asp Leu His Ile Glu Ser Gly Gln Asp		
195	200	205
Leu Val Thr Leu Leu Thr Cys Thr Pro Tyr Met Ile Asn Ser His Arg		
210	215	220
Leu Leu Val Arg Gly His Arg Ile Pro Tyr Gln Pro Glu Lys Ala Ala		
225	230	235
240		
Ala Gly Met Lys Lys Val Ala Gln Gln Asn Leu Leu Leu Trp Thr		
245	250	255
Leu Leu Leu Ile Ala Cys Ala Leu Ile Ile Ser Gly Phe Ile Ile Trp		
260	265	270
Tyr Lys Arg Arg Lys Lys Thr Thr Arg Lys Pro Lys		
275	280	

&lt;210&gt; 30

&lt;211&gt; 855

&lt;212&gt; DNA

&lt;213&gt; Enterococcus faecalis

&lt;400&gt; 30

atgaagtcaa aaaagaaaacg tcgtatcatt gatggtttta tgattttttt actgattatt 60

ggaatagggtg catttgcgtt tcctttgtt agcgatgcatt taaataacta tctggatcaa 120

caaattatcg ctcattatca agcaaaagca agccaagaaa acaccaaaga aatggctgaa 180

cttcaagaaa aaatggaaaaa gaaaaaccaa gaattagcga aaaaaggcag caatcctgga 240

tttagatcattt tttctgaaac gaaaaaaaaca acgaaaaaaac cagacaaatc ctatttgaa 300

agtcatatcgat ttgggtttttt aaccattcca aaaataatg tccgtttacc aatttttgat 360

aaaacgaatg cattgctatt ggaaaaagga agtccttgt tagaaggaac ctccatatcct 420  
 acaggtggta cgaatacaca tgcggtcatt tcaggccatc gtggtctccc tcaagccaaa 480  
 ttatattacag atttgccaga attaaaaaaaaa ggcgatgaat tttatatcga agtcaatggg 540  
 aagacgcttg cttatcaagt agatcaaata aaaaccgttg aaccaactga tacaaaagat 600  
 ttacacattg aigtctggcca agatctcgtc actttattaa cttgcacacc gtatatgata 660  
 aacagtcatc ggttattagt tcgaggacat cgtatcccat atcaaccaga aaaagcagca 720  
 gcggggatga aaaaagtggc acaacaacaa aatttactat tatggacatt acttttaatt 780  
 gcctgtgcgt taattattag cggcttcatt atctggtaca agcgacggaa aaagacgacc 840  
 agaaaaccaa agtag 855

<210> 31  
 <211> 2687  
 <212> DNA  
 <213> *Corynebacterium diphtheriae*

<400> 31  
 gtggtccgga gtatgacaag aacgctccgg ttcaggtaaa cggcactgggt aacggtaacg 60  
 atctcggtt cacctctgac aagaacggca acgtccactt cgagggcctg ttcgtctccg 120  
 acgaccagaa tgatccggga aagttagctg cgcagcgctg ctacgtcctc gtcgagaccg 180  
 aggccccgac gggcttcgtt actccgaaag atggggacggt cttccagtt gctgtaaaga 240  
 ttggacagac tgcttaccact acctacgacg caaagggtcga gaacgtcaag cgcgataaccc 300  
 ctgacctgcc gctgaccgggt ggcaagggtg tgctgttccct gatgattgcc ggtggtctgt 360  
 tgctgctgggt tgctgttgggt gctggttcg tctttgtacg ccgtatcaac gagtaattga 420  
 tttgtcgctt gattaaataa tcgcgttgcg ccgccccatg cagggcatca aatgccccgc 480  
 cggcggcat aaacgccccgc ggggtgcgggt ggctttccac cgcaccccca cattcttgc 540  
 cagagatttg ctgtttggcc tgcgttccaccc ggcacccccc tataatgagaa acggacgtac 600  
 ctgtcatgggt taccaccgcg tcaccgcgt ctaccggacc ggataacccca gacgcgcac 660  
 caaagcgtcg ttgggtcttt tccggactcg cattgtttgc gtgtataacg ggcgttagccg 720

gcctcatgtt ggggttgtat ccatctactg cagcgtggtt taacgcccgc gaacaggcca 780  
aactggtaga tctctatgtat tccaaaattt gaaatgcaac ccctcttagc gcggaacaat 840  
tacttgaact cgccgaccgt tataacgacc gcctgaccgt aggcgctgct ctcgatccct 900  
gggctaacgt ccccccggaa gcgggcaaag aagacggcga cggtatggcc tataaagacc 960  
agttgcgtgt tgaccgtacg gatgtcatgg ctcgtatacg tatccctct atcaagggtgg 1020  
atctaccgat ctatcacggc acgagcgata acactctaaa gaagggcgct ggccatttgg 1080  
aaggtaacctc gttaccggtg ggaggaccac gcacccattc cggtatcact gcacaccgtg 1140  
gcttagctga ggccaccatg ttcaactaattc tcaacaagggt tgggttaggg gatagattca 1200  
ccattgaggt gatgggcgaa gtccttacgt atgaagtgcg tgaaactcgt gtggtcagcc 1260  
cagaggacac tagttcctg caaactcaag acgatcgtga cttgtcaca ctcgttactt 1320  
gtactccgtt gggcatcaat acacatcgca ttctggtgac agctgagcgc attactccca 1380  
ccccgcaatc cgatatcgat gcagcacgtc aagcttccca aatcggttc cttgggtgg 1440  
cggtcatttt cgcagtggaa tttagcttta tcgccttggtt ctctggcgt tcgggttaca 1500  
tgattcctcc aaagaagaag gaagaagaca tcgaaagcga agctgatggc gatgaactct 1560  
gaaacggcgg ggaaggaacc caacgtggtc agtaccgacg ctaaacactc caccggtacc 1620  
agttccaatg cgggtaccgg tgagagctca gcgaaaaaga aagcgcagac ggcaattgct 1680  
gcgatagtca tgctttgtg cggactgtta gggctggtga ttctgttcta tccagtcgtg 1740  
tccactcaac ttaacaattt tgaacagtct aaactcgccc gacagttgg tgcagacgct 1800  
gcccaagctg accctgcccgt agttgctgct gctcttgatg ctgcccattgc ctacaacgat 1860  
tcgctagaaa atggaccct gcaggatccg tggaccggtg gagatagcac taaggatct 1920  
gcctatcagg catacgagaa actcttaggg gaatatccgg cgatggctca gatctctatc 1980  
ccggctattt ccgtgaacct tcccatattac cacgggacaa gcgacgcccac actcctcaaa 2040  
ggtgttggc acctttacgg tactgcgcta cccgttggtg gactggggac gcgttcggtt 2100  
ctaacagcgc attcaggtat ccaaaaatcg accttctttg acaatttaga aaaggtcaaa 2160

aagggtgacg ccatttatgt acgcaatatt ggtgagaccc taaaatacca agtacgcgac 2220  
 atcgaaatca tccgtccagc ggagattgac cgtatccagc caatcccaga ccgagactta 2280  
 attaccctcg tgacctgtac accctatgga atcaataccc ataggcttt ggtaactgcc 2340  
 gaacgtgtcc ctatggacc cggtgaggcg gaccgtgcatttgccggta cgaaattgtc 2400  
 tggcagtggt gcatggact agctatcggt gtgttggtgg tcatccttct cctaactggg 2460  
 tggctcatta tccgtatccc gcgagctagg aaattcgcga agaaaacagc tggagcagac 2520  
 gctgctaaat ctgttgaacc tggtgatatt gaggcgtcgc taagcgcttc agcggccgag 2580  
 gagtcccagt aatatgcaga aaccaatttc cccaaacacat gcaaacaccc aagcagtcgc 2640  
 ccattcctga aaggacgccc tactatgaag aagactcaact tgttccg 2687

&lt;210&gt; 32

&lt;211&gt; 348

&lt;212&gt; PRT

<213> *Corynebacterium diphtheriae*

&lt;400&gt; 32

Met	Ala	Met	Asn	Ser	Glu	Thr	Ala	Gly	Lys	Glu	Pro	Asn	Val	Val	Ser
1									10					15	

Thr	Asp	Ala	Lys	His	Ser	Thr	Gly	Thr	Ser	Ser	Asn	Ala	Gly	Thr	Gly
								20					30		

Glu	Ser	Ser	Ala	Lys	Lys	Ala	Gln	Thr	Ala	Ile	Ala	Ala	Ile	Val
								35					45	

Met	Leu	Leu	Cys	Gly	Leu	Leu	Gly	Leu	Val	Ile	Leu	Phe	Tyr	Pro	Val
								50				60			

Val	Ser	Thr	Gln	Leu	Asn	Asn	Tyr	Glu	Gln	Ser	Lys	Leu	Ala	Arg	Gln
								65				75		80	

Phe	Gly	Ala	Asp	Ala	Ala	Gln	Ala	Asp	Pro	Ala	Val	Val	Ala	Ala	Ala
								85					95		

Leu	Asp	Ala	Ala	His	Ala	Tyr	Asn	Asp	Ser	Leu	Glu	Asn	Gly	Pro	Leu
								100					110		

Gln	Asp	Pro	Trp	Thr	Gly	Gly	Asp	Ser	Thr	Lys	Asp	Pro	Ala	Tyr	Gln

115	120	125
Ala Tyr Glu Lys Leu Leu Gly Glu Tyr Pro Ala Met Ala Gln Ile Ser		
130	135	140
Ile Pro Ala Ile Ser Val Asn Leu Pro Ile Tyr His Gly Thr Ser Asp		
145	150	155
Ala Thr Leu Leu Lys Gly Val Gly His Leu Tyr Gly Thr Ala Leu Pro		
165	170	175
Val Gly Gly Leu Gly Thr Arg Ser Val Leu Thr Ala His Ser Gly Ile		
180	185	190
Gln Lys Ser Thr Phe Phe Asp Asn Leu Glu Lys Val Lys Lys Gly Asp		
195	200	205
Ala Ile Tyr Val Arg Asn Ile Gly Glu Thr Leu Lys Tyr Gln Val Arg		
210	215	220
Asp Ile Glu Ile Ile Arg Pro Ala Glu Ile Asp Arg Ile Gln Pro Ile		
225	230	235
Pro Asp Arg Asp Leu Ile Thr Leu Val Thr Cys Thr Pro Tyr Gly Ile		
245	250	255
Asn Thr His Arg Leu Leu Val Thr Ala Glu Arg Val Pro Met Glu Pro		
260	265	270
Gly Glu Ala Asp Arg Ala Phe Ala Gly Asp Gly Ile Val Trp Gln Trp		
275	280	285
Trp Met Lys Leu Ala Ile Gly Val Leu Val Val Ile Leu Leu Leu Thr		
290	295	300
Gly Trp Leu Ile Ile Arg Ile Leu Arg Ala Arg Lys Phe Ala Lys Lys		
305	310	315
Thr Ala Gly Ala Asp Ala Ala Lys Ser Val Glu Pro Gly Asp Ile Glu		
325	330	335
Ala Ser Leu Ser Ala Ser Ala Ala Glu Glu Ser Gln		
340	345	

<210> 33  
 <211> 1047  
 <212> DNA

<213> *Corynebacterium diphtheriae*

<400> 33

atggcgatga actctgaaac ggccccaaag gaacccaaacg tggtcagttac cgacgctaaa 60  
cactccacccg gtaccaggttc caatgcgggt accggtgaga gctcagcgaa aaagaaaagcg 120  
cagacggcaa ttgctgcgat agtcatgctt ttgtgcggac tgtagggct ggtgattctg 180  
ttctatccag tcgtgtccac tcaacttaac aattatgaac agtctaaact cggccgacag 240  
tttggtgcag acgctgccc a gctgaccct gccgtagttt ctgctgctct tgatgctgcc 300  
catgcctaca acgattcgct agaaaaatgga cccctgcagg atccgtggac cggtggagat 360  
agcactaagg atcctgccta tcaggcatac gagaaaactct tagggaaata tccggcgatg 420  
gctcagatct ctatccggc tatttccgtg aaccttccca tttaccacgg gacaagcgac 480  
gccacactcc tcaaagggtt tgggcaccc ttacggtactg cgctaccctg tggtggactg 540  
gggacgcgtt cggttctaac agcgcattca ggtatccaaa aatcgacctt ctttgacaat 600  
ttagaaaagg tcaaaaagg tgacgccatt tatgtacgca atattggtga gaccctgaaa 660  
taccaagtac gcgcacatcga aatcatccgt ccagcggaga ttgaccgtat ccagccaatc 720  
ccagaccgag acttaattac cctcgtgacc tgcacaccct atggaatcaa tacccatagg 780  
cttttggta ctgccgaacg tgcgttatg gaacccgggtt aggccggaccg tgcatttgcc 840  
ggtgacggaa ttgtctggca gtggtgatg aagctagcta tgcgtgtgtt ggtggtcatc 900  
cttctcctaa ctgggtggct cattatccgt attttgcgag ctagggaaatt cgccaaagaaa 960  
acagctggag cagacgctgc taaatctgtt gaacctgggtt atattgaggc gtcgctaagc 1020  
gcttcagccgg ccgaggagtc ccagtaa 1047

<210> 34

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
Consensus/*Streptococcus pyogenes*

&lt;220&gt;

&lt;223&gt; X in position 12 can either be a S/T.

&lt;220&gt;

&lt;223&gt; X in position 18 can either be a R/K.

&lt;400&gt; 34

Thr Leu Leu Thr Cys Thr Pro Tyr Met Ile Asn Xaa His Arg Leu Leu  
1 5 10 15

Val Xaa Gly

&lt;210&gt; 35

&lt;211&gt; 19

&lt;212&gt; PRT

<213> *Corynebacterium diphtheriae*

&lt;400&gt; 35

Thr Leu Val Thr Cys Thr Pro Tyr Gly Ile Asn Thr His Arg Leu Leu  
1 5 10 15

Val Thr Ala

&lt;210&gt; 36

&lt;211&gt; 19

&lt;212&gt; PRT

<213> *Streptococcus pyogenes*

&lt;400&gt; 36

Thr Leu Val Thr Cys Thr Pro Tyr Gly Val Asn Thr Lys Arg Leu Leu  
1 5 10 15

Val Arg Gly

&lt;210&gt; 37

&lt;211&gt; 150

&lt;212&gt; PRT

<213> *Streptococcus pyogenes*

&lt;400&gt; 37

Ile Glu Asn Asn Asp Ile Met Gly Tyr Val Glu Val Pro Ser Ile Lys

1	5	10	15												
Val	Thr	Leu	Pro	Ile	Tyr	His	Tyr	Thr	Thr	Asp	Glu	Val	Leu	Thr	Lys
		20				25					30				
Gly	Ala	Gly	His	Leu	Phe	Gly	Ser	Ala	Leu	Pro	Val	Gly	Gly	Asp	Gly
		35				40					45				
Thr	His	Thr	Val	Ile	Ser	Ala	His	Arg	Gly	Leu	Pro	Ser	Ala	Glu	Met
		50			55					60					
Phe	Thr	Asn	Leu	Asn	Leu	Val	Lys	Lys	Gly	Asp	Thr	Phe	Tyr	Phe	Arg
		65			70				75		80				
Val	Leu	Asn	Lys	Val	Leu	Ala	Tyr	Lys	Val	Asp	Gln	Ile	Leu	Thr	Val
		85				90					95				
Glu	Pro	Asp	Gln	Val	Thr	Ser	Leu	Ser	Gly	Val	Met	Gly	Lys	Asp	Tyr
		100				105					110				
Ala	Thr	Leu	Val	Thr	Cys	Thr	Pro	Tyr	Gly	Val	Asn	Thr	Lys	Arg	Leu
		115				120					125				
Leu	Val	Arg	Gly	His	Arg	Ile	Ala	Tyr	His	Tyr	Lys	Tyr	Gln	Gln	
		130			135					140					
Ala	Lys	Lys	Ala	Met	Lys										
		145		150											

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 February 2002 (14.02.2002)

PCT

(10) International Publication Number  
WO 02/012294 A3

(51) International Patent Classification<sup>7</sup>: C07K 14/315,  
A61K 39/09, C07K 16/12, C12N 5/12, A61K 39/40,  
C12N 15/12, 15/63, A61K 48/00, C12Q 1/68, G01N  
33/53, C07K 14/34

TN 38120 (US). BOHNSACK, John [US/US]; 760 South  
1200 East, Salt Lake City, UT 84102 (US).

(21) International Application Number: PCT/US01/24795

(74) Agent: LICATA, Jane, Massey; Licata & Tyrrell P.C., 66  
E. Main Street, Marlton, NJ 08053 (US).

(22) International Filing Date: 8 August 2001 (08.08.2001)

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(30) Priority Data:  
09/634,341 8 August 2000 (08.08.2000) US

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG).

(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier application:  
US 09/634,341 (CON)  
Filed on 8 August 2000 (08.08.2000)

Published:

— with international search report

(71) Applicants (for all designated States except US): ST.  
JUDE CHILDREN'S RESEARCH HOSPITAL  
[US/US]; 332 North Lauderdale Street, Memphis, TN  
38105-2794 (US). UNIVERSITY OF UTAH RE-  
SEARCH FOUNDATION [US/US]; 615 Arapeen Drive,  
Suite 10, Salt Lake City, UT 84108 (US).

(88) Date of publication of the international search report:  
10 April 2003

(72) Inventors; and

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(75) Inventors/Applicants (for US only): ADDERSON,  
Elisabeth [CA/US]; 1041 Murray Hill Lane S., Memphis,

A3

(54) Title: GROUP B STREPTOCOCCUS POLYPEPTIDES NUCLEIC ACIDS AND THERAPEUTIC COMPOSITIONS AND  
VACCINES THEREOF

WO 02/012294

(57) Abstract: This invention provides isolated nucleic acids encoding polypeptides comprising amino acid sequences of streptococcal matrix adhesion (Ema) polypeptides. The invention provides nucleic acids encoding Group B streptococcal Ema polypeptides EmaA, EmaB, EmaC, EmaD and EmaE. The present invention provides isolated polypeptides comprising amino acid sequences of Group B streptococcal polypeptides EmaA, EmaB, EmaC, EmaD and EmaE, including analogs, variants, mutants, derivatives and fragments thereof. Ema homologous polypeptides from additional bacterial species, including *S. pneumoniae*, *S. pyogenes*, *E. faecalis* and *C. diphtheriae* are also provided. Antibodies to the Ema polypeptides and immunogenic fragments thereof are also provided. The present invention relates to the identification and prevention of infections by virulent forms of streptococci. This invention provides pharmaceutical compositions, immunogenic compositions, vaccines, and diagnostic and therapeutic methods of use of the isolated polypeptides, antibodies thereto, and nucleic acids. Assays for compounds which modulate the polypeptides of the present invention for use in therapy are also provided.

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/24795

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C07K14/315	A61K39/09	C07K16/12	C12N5/12	A61K39/40
	C12N15/12	C12N15/63	A61K48/00	C12Q1/68	G01N33/53
	C07K14/34				

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K C12N C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>RICARDO MANGANELLI ET AL.: "Characterization of emb, a gene encoding the major adhesin of Streptococcus defectivus" INFECTION AND IMMUNITY, vol. 67, no. 1, January 1999 (1999-01), pages 50-56, XP002211581 abstract page 50, left-hand column, paragraph 3 -right-hand column, paragraph 2 page 51, right-hand column, paragraph 4 - paragraph 6 page 52, left-hand column, paragraph 3 -page 56, left-hand column, paragraph 3 ---</p> <p style="text-align: center;">-/-</p>	1,11-25, 35-51

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## ° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

29 August 2002

Date of mailing of the international search report

09.12.2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL-2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

MONTERO LOPEZ B.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/24795

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>SPELLERBERG B ET AL: "LMB, A PROTEIN WITH SIMILARITIES TO THE LRA1 ADHESIN FAMILY, MEDIATES ATTACHMENT OF STREPTOCOCCUS AGALACTIAE TO HUMAN LAMININ" INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 67, no. 2, February 1999 (1999-02), pages 871-878, XP000973065 ISSN: 0019-9567</p> <p>abstract</p> <p>page 871, left-hand column, paragraph 1 -right-hand column, paragraph 3</p> <p>page 874, left-hand column, paragraph 2 -right-hand column, paragraph 1</p> <p>page 875, right-hand column, paragraph 2</p> <p>page 876, left-hand column, paragraph 2 -page 877, right-hand column, paragraph 3</p> <p>---</p>	1,11-25, 35-51
X	<p>VERED OZERI ET AL.: "A two-domain mechanism for group A streptococcal adherence through protein F to the extracellular matrix" THE EMBO JOURNAL, vol. 15, no. 5, 1996, pages 989-998, XP002211582</p> <p>abstract</p> <p>page 993, left-hand column, paragraph 3 -right-hand column, paragraph 2</p> <p>page 996, right-hand column, paragraph 3 -page 997, left-hand column, paragraph 1</p> <p>---</p>	1,11-25, 35-51
A	<p>PATTI J M ET AL: "MSCRAMM-MEDIATED ADHERENCE OF MICROORGANISMS TO HOST TISSUES" ANNUAL REVIEW OF MICROBIOLOGY, ANNUAL REVIEWS INC., PALO ALTO, CA, US, vol. 48, 1994, pages 585-617, XP001037269 ISSN: 0066-4227</p> <p>the whole document</p> <p>---</p>	1,2, 11-26, 35-51
A	<p>WO 00 12132 A (TRINITY COLLEGE DUBLIN ;TEXAS A &amp; M UNIVERSITY SYST (US); INHIBITE) 9 March 2000 (2000-03-09)</p> <p>page 2, line 25 -page 3, line 13 page 9, line 19 -page 10, line 4 page 13, line 28 -page 14, line 20 page 19, line 3 -page 21, line 3 page 23, line 21 -page 39, line 19 page 40, line 7 -page 41, line 15 page 48, line 6 -page 59, line 28</p> <p>---</p> <p>-/-</p>	1,2, 11-26, 35-51

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/24795

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>RICH R L ET AL: "ACE IS A COLLAGEN-BINDING MSCRAMM FROM ENTEROCOCCUS FAECALIS"</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 38, 17 September 1999 (1999-09-17), pages 26939-26945, XP002930358 ISSN: 0021-9258 the whole document</p> <p>---</p>	1,2, 11-26, 35-51
A	<p>WO 98 38312 A (UNIV WASHINGTON)</p> <p>3 September 1998 (1998-09-03)</p> <p>the whole document</p> <p>---</p>	1,2, 11-26, 35-51
A	<p>PATTI J M ET AL: "CRITICAL RESIDUES IN THE LIGAND-BINDING SITE OF THE STAPHYLOCOCCUS AUREUS COLLAGEN-BINDING ADHESIN (MSCRAMM)"</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 270, no. 20, 19 May 1995 (1995-05-19), pages 12005-12011, XP002044191 ISSN: 0021-9258 the whole document</p> <p>-----</p>	1,2, 11-26, 35-51

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 01/24795

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  

Although claims 46-51 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.
2.  Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1, 2, 25, 26 and partially 11-24, 35-51

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1, 2, 25, 26 and partially 11-24, 35-51

Streptococcal polypeptide EmaA comprising SEQ ID NO:2, analogs, variants and fragments thereof; vaccine, and pharmaceutical compositions comprising the same; antibody and pharmaceutical composition thereof and cell line producing the antibody; nucleic acid of SEQ ID NO:1 encoding the polypeptide and variants thereof; vector and host cell comprising it and nucleic acid vaccine; use of nucleic acid and antibody in diagnosis and use of the pharmaceutical compositions for prevention and treatment of infection.

2. Claims: 3, 4, 27, 28 and partially 11-24, 35-51

Streptococcal polypeptide EmaB comprising SEQ ID NO:4, analogs, variants and fragments thereof; vaccine, and pharmaceutical compositions comprising the same; antibody and pharmaceutical composition thereof and cell line producing the antibody; nucleic acid of SEQ ID NO:3 encoding the polypeptide and variants thereof; vector and host cell comprising it and nucleic acid vaccine; use of nucleic acid and antibody in diagnosis and use of the pharmaceutical compositions for prevention and treatment of infection.

3. Claims: 5, 6, 29, 30 and partially 11-24, 35-51

Streptococcal polypeptide EmaC comprising SEQ ID NO:6, analogs, variants and fragments thereof; vaccine, and pharmaceutical compositions comprising the same; antibody and pharmaceutical composition thereof and cell line producing the antibody; nucleic acid of SEQ ID NO:5 encoding the polypeptide and variants thereof; vector and host cell comprising it and nucleic acid vaccine; use of nucleic acid and antibody in diagnosis and use of the pharmaceutical compositions for prevention and treatment of infection.

4. Claims: 7, 8, 31, 32 and partially 11-24, 35-51

Streptococcal polypeptide EmaD comprising SEQ ID NO:8, analogs, variants and fragments thereof; vaccine, and pharmaceutical compositions comprising the same; antibody and pharmaceutical composition thereof and cell line producing the antibody; nucleic acid of SEQ ID NO:7 encoding the polypeptide and variants thereof; vector and host cell comprising it and nucleic acid vaccine; use of nucleic acid and antibody in diagnosis and use of the pharmaceutical compositions for prevention and treatment of infection.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

5. Claims: 9, 10, 33, 34 and partially 11-24, 35-51

Streptococcal polypeptide EmaE comprising SEQ ID NO:10, analogs, variants and fragments thereof; vaccine, and pharmaceutical compositions comprising the same; antibody and pharmaceutical composition thereof and cell line producing the antibody; nucleic acid of SEQ ID NO:9 encoding the polypeptide and variants thereof; vector and host cell comprising it and nucleic acid vaccine; use of nucleic acid and antibody in diagnosis and use of the pharmaceutical compositions for prevention and treatment of infection.

6. Claims: 52-54

Streptococcal Ema polypeptide comprising SEQ ID NO:23 and nucleic acid encoding it

7. Claims: 55-57

Streptococcal Ema polypeptide comprising SEQ ID NO:26 and nucleic acid encoding it.

8. Claims: 58, 59

Streptococcal Ema polypeptide comprising SEQ ID NO:37 and nucleic acid encoding it.

9. Claims: 60-62

Enterococcal Ema polypeptide comprising SEQ ID NO:29 and nucleic acid encoding it.

10. Claims: 63-65

Corynebacterium Ema polypeptide and nucleic acid encoding it.

11. Claims: 66, 67 and partially 71

Polypeptide comprising SEQ ID NO:34

12. Claim : 68 and partially 71

Polypeptide comprising SEQ ID NO:35

13. Claims: 69, 70 and partially 71

Polypeptide comprising SEQ ID NO:36

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International Application No  
PCT/US 01/24795

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 0012132	A 09-03-2000	AU 5696699	A	21-03-2000
		CA 2341177	A1	09-03-2000
		EP 1121149	A1	08-08-2001
		JP 2002523474	T	30-07-2002
		NO 20010981	A	26-04-2001
		US 2002159997	A1	31-10-2002
		WO 0012132	A1	09-03-2000
<hr/>				
WO 9838312	A 03-09-1998	AU 2192497	A	18-09-1998
		CA 2247072	A1	03-09-1998
		EP 0942982	A1	22-09-1999
		JP 2001505061	T	17-04-2001
		WO 9838312	A1	03-09-1998
<hr/>				